

STIC-Biotech/ChemLib

From: Chan, Christina
Sent: Wednesday, October 01, 2003 4:35 PM
To: Schnizer, Holly; STIC-Biotech/ChemLib
Subject: RE: Request for RUSH sequence search for Appl. no. 09/444,281
Importance: High

Please rush. Thanks Chris

Chris Chan

TC 1600 New Hire Training Coordinator and SPE 1644
308-3973
CM-1, 9B19

-----Original Message-----

Fr m: Schnizer, Holly
Sent: Wednesday, October 01, 2003 4:26 PM
To: Chan, Christina
Subject: Request for RUSH sequence search for Appl. no. 09/444,281

I would like to request the following RUSH sequence search for the above appl. which is an amended due this biweek (Oct. 6).

Please search the commercial and interference databases for the peptide of SEQ ID NO:85 (ILPWKWPWWPWRR)

Thank you.

Holly Schnizer
AU 1653
CM1-9E09
305-3722
mailbox: CM1-9B01

Searcher: _____
Phone: _____
Location: _____
Date Picked Up: _____
Date Completed: _____
Searcher Prep/Review: _____
Clerical: _____
Online time: _____

TYPE OF SEARCH:
NA Sequences: _____
AA Sequences: _____
Structures: _____
Bibliographic: _____
Litigation: _____
Full text: _____
Patent Family: _____
Other: _____

VENDOR/COST (where applic.)
STN: _____
DIALOG: _____
Questel/Orbit: _____
DRLink: _____
Lexis/Nexis: _____
Sequence Sys.: _____
WWW/Internet: _____
Other (specify): _____

[Illegible text block]

[Illegible text block]

[Illegible text block]

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 09:56:42 ; Search time 77 seconds
(without alignments)
26.798 Million cell updates/sec

Title: US-09-444-281-85

Sequence: 1 ILPMKMPMPWRR 13

Scoring table: BLOSUM62
Gapop 10.0, Gapect 0.5

Searched: 1107863 seqs, 158726573 residues

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

_A_Geneseq_19Jun03:*

- 1: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1980.DAT:*
- 2: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1981.DAT:*
- 3: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1982.DAT:*
- 4: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1983.DAT:*
- 5: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1984.DAT:*
- 6: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1985.DAT:*
- 7: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1986.DAT:*
- 8: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1987.DAT:*
- 9: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1988.DAT:*
- 10: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1989.DAT:*
- 11: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1990.DAT:*
- 12: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1991.DAT:*
- 13: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1992.DAT:*
- 14: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1993.DAT:*
- 15: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1994.DAT:*
- 16: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1995.DAT:*
- 17: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1996.DAT:*
- 18: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1997.DAT:*
- 19: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1998.DAT:*
- 20: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1999.DAT:*
- 21: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2000.DAT:*
- 22: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2001.DAT:*
- 23: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2002.DAT:*
- 24: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	99	100.0	13	14	AAAR30970
2	99	100.0	13	16	AAAR78457
3	99	100.0	13	19	AAAY24608
4	99	100.0	13	19	AAW66441
5	99	100.0	13	20	AAW87609
6	99	100.0	13	21	AAW82794
7	99	100.0	13	21	AAV91740
8	99	100.0	13	21	AAV91771
9	99	100.0	13	21	AAV91772

10	99	100.0	13	21	AAV44666	Crosslink-stabilis
11	99	100.0	13	21	AAV44324	Antimicrobial pept
12	99	100.0	13	21	AAV55056	Non-amidated indol
13	99	100.0	13	21	AAV57123	Naturally occurin
14	99	100.0	13	22	ABP60382	Indolicidin peptid
15	99	100.0	13	22	ABP60383	Indolicidin peptid
16	99	100.0	13	22	AAAB1842	Antimicrobial pept
17	99	100.0	13	23	ABAB1940	Peptide fragment o
18	99	100.0	13	23	ABP59052	Peptide #1. Synth
19	99	100.0	13	23	AAO15551	L-indolicidin carr
20	99	100.0	13	23	ABAB1249	Indolicidin antiba
21	99	100.0	13	23	ABAB1261	Indolicidin antiba
22	99	100.0	13	23	ABAB07699	Bovine cathelicidi
23	99	100.0	13	23	AAU90977	Transplant media a
24	99	100.0	13	24	ABG76068	Human regulatory p
25	99	100.0	13	24	AAE34433	Cow indolicidin pe
26	99	100.0	13	24	ABU59617	Cationic cancer - t
27	99	100.0	13	24	ABR00800	Bioactive synthe
28	99	100.0	13	24	ABR00815	Bioactive synthe
29	99	100.0	14	21	AAV57118	Indolicidin peptid
30	99	100.0	14	21	AAV57143	Indolicidin peptid
31	99	100.0	15	18	AAW12879	Antimicrobial catl
32	99	100.0	15	24	ABG73946	Cell wall/cell mem
33	99	100.0	16	21	AAV57144	Indolicidin peptid
34	99	100.0	19	23	AAAB47907	C-terminus of ubiq
35	99	100.0	63	21	AAV44668	Poly-(indol (1-13)
36	99	100.0	63	21	AAV57142	Indolicidin fusion
37	99	100.0	144	23	ABR07706	Bovine peptide ant
38	99	97.0	13	16	AAAR78459	Indolicidin analog
39	96	97.0	13	22	ABP60388	Indolicidin peptid
40	96	97.0	15	18	AAW12878	Antimicrobial catl
41	95	96.0	12	21	AAV44669	Amino terminal tru
42	95	96.0	12	21	AAV57110	Indolicidin peptid
43	95	96.0	12	22	ABP60381	Indolicidin peptid
44	94	94.9	12	16	AAAR78458	Indolicidin analog
45	94	94.9	12	21	AAV57133	Indolicidin peptid

ALIGNMENTS

RESULT 1	AAAR30970	standard; peptide; 13 AA.
ID	AAAR30970;	
AC	25-MAR-2003 (updated)	
DT	12-MAY-1993 (first entry)	
DE	Broad spectrum antimicrobial indolicidin peptide.	
XX	Tryptophan rich; microbial; microbistatic; inhibition.	
KW	Bos taurus.	
OS	W09222308-A1.	
PN	23-DEC-1992.	
XX	10-JUN-1992; 92WO-US04920.	
PF	14-JUN-1991; 91US-0715271.	
XX	(REGC) UNIV CALIFORNIA.	
PA	Cullor JS, Selected ME;	
XX	WPI: 1993-017896/02.	
DR	Broad spectrum antimicrobial cpd. obtd. from bovine granulocytes -	
XX	comprises tryptophan rich peptide, pref. having low immunogenicity	
PT	and comprising proline rich peptide or carboxy terminal amide	

XX Claim 2; Page 19; 29pp; English.
 PS
 CC The sequence is that of an indolicidin peptide which shows broad
 CC spectrum antimicrobial activity and when administered to a host does
 CC not elicit an immune response. It is effective against viruses, gram
 CC positive bacteria, gram negative bacteria and fungi, including
 CC Staphylococcus aureus, Escherichia coli, Salmonella typhimurium,
 CC Listeria monocytogenes, Candida albicans and Cryptococcus neoformans.
 CC It can be used as a therapeutic agent, food preservative or
 CC disinfectant, e.g. to purify a water supply. The peptide is pref.
 CC administered at an effective amt. of 0.5-500 ug/ml final concentration.
 CC (Updated on 25-MAR-2003 to correct PN field.)
 CC
 XX SQ Sequence 13 AA;
 XX
 Query Match 100.0%; Score 99; DB 14; Length 13;
 Best Local Similarity 100.0%; Pred. No. 9.8e-07;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 ILPMKMPMPMPRR 13
 DB 1 ILPMKMPMPMPRR 13
 RESULT 2
 AAR78457
 ID AAR78457 standard; peptide; 13 AA.
 XX
 AC AAR78457;
 XX
 DT 25-MAR-1996 (first entry)
 XX
 DE Indolicidin analog #4.
 XX
 KW Indolicidin; microbicide; therapeutic agent; prophylactic;
 KW food preservative; disinfectant; medication; Gram positive bacteria;
 KW Gram negative bacteria; protozoa; yeast; fungi; viruses.
 XX
 OS Synthetic.
 XX
 PN WO9522338-A1.
 XX
 PD 24-AUG-1995.
 XX
 PF 10-FEB-1995; 95WO-US01895.
 XX
 PR 16-FEB-1994; 94US-0197205.
 XX
 PA (REGC) UNIV CALIFORNIA.
 XX
 PI SeIsted ME;
 XX
 DR WPI; 1995-302552/39.
 XX
 PT Analogues of the tryptophan-rich peptide indolicidin - exhibiting
 PT broad spectrum antimicrobial activity and selectivity without
 PT undesirable side effects
 XX
 PS Claim 6; Page 27; 37pp; English.
 XX
 CC The sequences represented by AAR78454-R78459 are indolicidin analogues.
 CC antimicrobials exhibit broad spectrum antimicrobial activity and have
 CC antimicrobial selectivity when compared to naturally occurring
 CC indolicidin. The antimicrobial activity of these analogues can be
 CC altered by incorporation of D-form, chemically altered or synthetic
 CC amino acids. These sequences can be incorporated into a pharmaceutical
 CC composition (e.g. as a liposome or non-liposome lipid complex carrier)
 CC for use in a microbicidal method. These sequences are active against
 CC Gram positive and negative bacteria, protozoa, yeast, fungi and viruses.
 CC They can be used as therapeutic agents, prophylactics, food and preservatives,
 CC disinfectants or medications. These sequences are easily
 CC synthesised in an active and effective broad spectrum antimicrobial form

CC with decreased undesirable side effects. Compared to naturally occurring
 CC indolicidin, these analogues show increased antimicrobial and decreased
 CC haemolytic activity. Peptide stability, and period of activity within
 CC the cell can be increased or decreased according to the incorporation of
 CC D- or L-form amino acids.
 XX
 SQ Sequence 13 AA;
 XX
 Query Match 100.0%; Score 99; DB 16; Length 13;
 Best Local Similarity 100.0%; Pred. No. 9.8e-07;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 ILPMKMPMPMPRR 13
 DB 1 ILPMKMPMPMPRR 13
 RESULT 3
 AAY24608
 ID AAY24608 standard; peptide; 13 AA.
 XX
 AC AAY24608;
 XX
 DT 18-AUG-1999 (first entry)
 XX
 DE Indolicidin analogue #60.
 XX
 KW Indolicidin; bacterial infection; photo-oxidised solubiliser;
 KW antimicrobial; antibiotic; antihistaminic; surface disinfectant;
 KW additive; shampoo; soap; insecticide; herbicide; preservative;
 KW food; technical material.
 XX
 OS Synthetic.
 XX
 PN WO9807745-A2.
 XX
 PD 26-FEB-1998.
 XX
 PF 21-AUG-1997; 97WO-US14779.
 XX
 PR 13-JAN-1997; 97US-0034949.
 XX
 PR 21-AUG-1996; 96US-0024754.
 XX
 PA (MICR-) MICROLOGIX BIOTECH INC.
 XX
 PI Erle D, Fraser JR, Krieger TJ, Taylor R, West MH;
 XX
 DR WPI; 1998-169090/15.
 XX
 PT New indolicidin analogues with antimicrobial activity and related
 PT nucleic acid - vectors, transformed cells and antibodies, also
 PT conjugates with polyoxalkylene glycol and fatty acid to reduce
 PT toxicity, useful therapeutically, as disinfectants etc.
 XX
 PS Example 1; Page 32; 129pp; English.
 XX
 CC AAY24549 to AAY24615 represent indolicidin analogues of formulae
 CC (I)-(VIII) containing up to 25 amino acids (aa): RZXXZXB (I), BXZXXZXB
 CC (II), BBRXXZXXB (III), BXZXXZBBN(AA)nmILBAGS (IV), BXZXXZBB(AA)nm
 CC (V), LBBnXnXZnXRK (VI), LKXZXXZXRK (VII) and BBXZXXZBBB (VIII).
 CC Where Z = F or V; X = hydrophobic residue, preferably W; B = basic aa,
 CC preferably R or K; AA = any aa; n = 0 or 1; In (II), at least 1 Z = V;
 CC in (VIII) at least 2 X = F or V. The analogues are used to treat
 CC infections caused by bacteria (Gram positive or negative, or anaerobic);
 CC fungi (yeast or moulds); parasites (protozoa, nematodes, cestodes or
 CC trematodes) or viruses. Typical of very many pathogens that can be
 CC controlled are Leishmania, Trypanosoma, Ascaris lumbricoides, Fasciola
 CC hepatica, Klebsiella pneumoniae, Bordetella pertussis, Staphylococcus
 CC aureus, Listeria, Clostridium, rotavirus and papilloma virus. Compounds
 CC derived from the analogues may be used similarly; the compounds may
 CC also be prepared from antibiotics or antihistaminic agents. The analogues
 CC may be used therapeutically or to coat medical devices; also they are
 CC useful as surface disinfectants, as additives to shampoo or soaps, as

CC Insecticides or herbicides, or as preservatives for foods and technical materials. The analogues are administered by injection, lavage, orally or topically, generally at 0.1-50 mg/kg. These analogues have a broader CC spectrum of activity than indolicidin and modification as compounds CC reduces their toxicity.

XX Sequence 13 AA:

Query Match 100.0%; Score 99; DB 19; Length 13;
Best Local Similarity 100.0%; Pred. No. 9.8e-07;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13
Db 1 ILPMKMPMPWRR 13

RESULT 4

AAW66441 ID AAW66441 standard; peptide; 13 AA.

XX AAW66441:

DT 12-JAN-1999 (first entry)

XX Cationic peptide indolicidin.

XX Indolicidin analogue; resistance; cationic peptide; antibiotic;

KW bacterial infection; tolerance; antibacterial; microorganism;

KM bacteria; fungus; parasite; virus.

XX Bos taurus.

PN WO9840401-A2.

PD 17-SEP-1998.

PF 10-MAR-1998; 98WO-CA00190.

XX 25-FEB-1998; 98US-0030619.

PR 10-MAR-1997; 97US-0040649.

PR 20-AUG-1997; 97US-0915314.

PR 26-SEP-1997; 97US-0060099.

XX (MICR-) MICROLOGIX BIOTECH INC.

PI Fraser JR, McNicol PJ, West MHP;

XX WPI; 1998-520800/44.

DR New indolicidin peptide analogues - useful for, e.g. enhancing

PT activity of antibiotic or overcoming tolerance, acquired resistance

PT or inherent resistance of microorganisms

PS Disclosure; Page 10; 105pp; English.

XX AAW66393 to AAW66469 represent native cationic peptides from the

CC present invention. The present invention describes compositions and

CC methods for treating infection, especially bacterial infections. The

CC compositions and methods use cationic peptides in combination with an

CC antibiotic agent which are then administered to a patient to enhance the

CC activity of the antibiotic agent, to overcome: (a) tolerance; (b)

CC acquired resistance; and (c) inherent resistance. The combinations of

CC antibiotics and cationic peptides can provide synergistic activity

CC against a microorganism that is tolerant, inherently resistant, or has

CC acquired resistance to an antibiotic agent. They can be used for killing

CC e.g. bacteria, fungi, parasites and viruses.

XX Sequence 13 AA:

Query Match 100.0%; Score 99; DB 19; Length 13;
Best Local Similarity 100.0%; Pred. No. 9.8e-07;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13
Db 1 ILPMKMPMPWRR 13

RESULT 5

AAW87609 ID AAW87609 standard; peptide; 13 AA.

XX AAW87609:

DT 19-MAR-1999 (first entry)

XX Antimicrobial peptide indolicidin.

KW Antimicrobial; fusion; acidic peptide; recombinant; microorganism;

KM guanerin; basic peptide; indolicidin.

XX Bos sp.

PN WO9854336-A1.

PD 03-DEC-1998.

PF 28-MAY-1998; 98WO-KR00132.

PR 09-APR-1998; 98KR-0013372.

PR 28-MAY-1997; 97KR-0021312.

XX (KOAD) KOREA ADV INST SCI & TECHNOLOGY.

PA (SAMY-) SAMYANG GENEX CORP.

PI Hong S, Kang MH, Kim JH, Kim S, Lee H, Lee JH;

XX WPI; 1999-059844/05.

DR N-PSDB; AAW83788.

XX Example 6; Page 18; 52pp; English.

CC The invention relates to mass production of antimicrobial peptides. The

CC method comprises constructing a fusion gene containing a first gene

CC encoding a negatively charged acidic peptide having at least two cysteine

CC residues, and a second gene encoding a positively charged basic

CC antimicrobial peptide. A host microorganism is transformed with a vector

CC containing the fusion gene and then cultured. The expressed antimicrobial

CC peptide is then recovered. The method is used to mass produce

CC antimicrobial peptides in recombinant microorganisms. The inhibitory

CC effect of the expressed antimicrobial peptide upon the growth of the host

CC microorganism is considerably reduced by fusing it to the acidic peptide.

CC Therefore, the use of the fusion gene provides an economic, recombinant

CC alternative of mass producing antimicrobial peptides, which overcomes the

CC disadvantages of low-productivity and poor economy, previously

CC encountered by recombinant and chemical methods. The present sequence

CC represents an antimicrobial peptide indolicidin. The encoding DNA

CC can be used along with the acidic peptide Guanerin gene in the

CC construction of the fusion gene.

XX Sequence 13 AA:

Query Match 100.0%; Score 99; DB 20; Length 13;
Best Local Similarity 100.0%; Pred. No. 9.8e-07;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13
Db 1 ILPMKMPMPWRR 13

```

RESULT 6
AAV92794
ID AAV92794 standard; peptide; 13 AA.
XX
AC AAV92794;
XX
DT 29-AUG-2000 (first entry)
XX
DE Synthetic antimicrobial peptide, Indolicidin.
XX
KW Magainin; antimicrobial; transgenic plant; protease degradation; Rev4;
KW Indolicidin; protein production; reverse peptide.
XX
OS Bos taurus.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 13
FT /note="amidated"
XX
PN WO200026344-A1.
XX
PD 11-MAY-2000.
XX
PE 29-OCT-1999; 99WO-US25561.
XX
PR 30-OCT-1998; 98US-0106373.
PR 02-NOV-1998; 98US-0106537.
XX
PA (INTE-) INTERLINK BIOTECHNOLOGIES LLC.
PA (KENT) UNIV KENTUCKY RES FOUND.
XX
PI Everett NP, Li Q, Lawrence C, Davies MH;
XX
DR WPI; 2000-365597/31.
XX
PT Polypeptides for reducing proteolytic degradation of proteins
PT administered to, or produced by a plant comprise indolicin or its
XX functional equivalents
XX
PS Example 2; Page 15; 50pp; English.
XX
CC Indolicidin is a potent antimicrobial tridecapeptide, originally
CC purified from cytoplasmic granules of bovine neutrophils. A reverse
CC peptide, Rev4 (AAV92796) of indolicidin was found to have increased
CC stability against plant protease degradation. Expression of antimicrobial
CC peptides in transgenic plants suffers a major limitation in that the
CC foreign peptides are susceptible to rapid degradation by proteases. The
CC invention concerns reducing the extent of protease degradation of a
CC protein applied to, or produced by a plant by administering indolicidin,
CC Rev4 or a functional equivalent to the plant. Transgenic plants
CC expressing indolicidin and Rev4 are useful for production of the
CC antimicrobial peptides. Compositions containing indolicidin and Rev4 are
CC also useful for production of agronomically important proteins in
CC plants.
XX
SQ Sequence 13 AA:
Query Match 100.0%; Score 99; DB 21; Length 13;
Best Local Similarity 100.0%; Pred. No. 9.8e-07;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ILPKWPMWPMRR 13
| | | | | | | | | | | | | |
Db 1 ILPKWPMWPMRR 13

RESULT 7
AAV91740
ID AAV91740 standard; Peptide; 13 AA.
XX
AC AAV91740;
XX

```

```

DT 06-JUN-2000 (first entry)
XX
DE Cationic peptide Indolicidin amino acid sequence.
XX
KW Cationic peptide; tumour; pharmaceutical composition; cancer; treatment;
KW Leukaemia; polyoxalkylene-modified; APO; lymphoma; multiple myeloma;
KW breast; lung; ovary; cervix; uterus; skin; prostate; liver; colon;
KW multidrug resistance.
XX
OS Unidentified.
XX
PN WO9965506-A2.
XX
PD 23-DEC-1999.
XX
PE 14-JUN-1999; 99WO-CA00552.
XX
PR 12-JUN-1998; 98US-0096541.
XX
PA (MICR-) MICROLOGIX BIOTECH INC.
XX
PI Friedland HD, Krieger TJ, Taylor R, Erfile D, Fraser JR, West MHP;
XX
DR WPI; 2000-223549/19.
XX
PE Novel pharmaceutical composition containing optionally activated
PT polyoxalkylene-modified cationic peptides, useful for treating tumours
XX
PT
XX
PS Disclosure; Page 11; 94pp; English.
XX
CC This sequence represents a cationic peptide amino acid sequence, which
CC can be used in the pharmaceutical composition of the invention. The
CC invention relates to a pharmaceutical composition containing at least one
CC activated polyoxalkylene (APO)-modified cationic peptide. The
CC modification of peptides with APO increases their activity against tumour
CC cells, including those with a multidrug resistant phenotype. The
CC pharmaceutical composition can be used to treat tumours, specifically
CC lymphoma, leukaemia, multiple myeloma, or tumours of breast, lung, ovary,
CC cervix, uterus, skin, prostate, liver and colon.
XX
SQ Sequence 13 AA:
Query Match 100.0%; Score 99; DB 21; Length 13;
Best Local Similarity 100.0%; Pred. No. 9.8e-07;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ILPKWPMWPMRR 13
| | | | | | | | | | | | | |
Db 1 ILPKWPMWPMRR 13

RESULT 8
AAV91771
ID AAV91771 standard; Peptide; 13 AA.
XX
AC AAV91771;
XX
DT 06-JUN-2000 (first entry)
XX
DE Amino acid sequence of cationic peptide MBI 10.
XX
KW Cationic peptide; tumour; pharmaceutical composition; cancer; treatment;
KW Leukaemia; polyoxalkylene-modified; APO; lymphoma; multiple myeloma;
KW breast; lung; ovary; cervix; uterus; skin; prostate; liver; colon;
KW multidrug resistance.
XX
OS Synthetic.
XX
PN WO9965506-A2.
XX
PD 23-DEC-1999.
XX

```

PF 14-JUN-1999; 99WO-CA00552.
 XX
 XX 12-JUN-1998; 98US-0096541.
 XX
 PA (MICR-) MICROLOGIX BIOTECH INC.
 XX
 PI Friedland HD, Krieger TJ, Taylor R, Erfle D, Fraser JR, West MHP;
 XX
 DR WPI: 2000-223549/19.
 XX
 PT Novel pharmaceutical composition containing optionally activated
 PT polyoxalkylene-modified cationic peptides, useful for treating tumours
 PS
 PS Disclosure: Page 14; 94pp; English.
 CC This sequence represents a cationic peptide amino acid sequence, which
 CC can be used in the pharmaceutical composition of the invention. The
 CC invention relates to a pharmaceutical composition containing at least one
 CC activated polyoxalkylene (APO)-modified cationic peptide. The
 CC modification of peptides with APO increases their activity against tumour
 CC cells, including those with a multidrug resistant phenotype. The
 CC pharmaceutical composition can be used to treat tumours, specifically
 CC lymphoma, leukaemia, multiple myeloma, or tumours of breast, lung, ovary,
 CC cervix, uterus, skin, prostate, liver and colon.
 XX
 SQ Sequence 13 AA:
 Query Match 100.0%; Score 99; DB 21; Length 13;
 Best Local Similarity 100.0%; Pred. No. 9.8e-07;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 ILPMKMPMPMPRR 13
 Db 1 ILPMKMPMPMPRR 13
 RESULT 9
 AAY91772
 ID AAY91772 standard; Peptide; 13 AA.
 XX
 AC AAY91772;
 XX
 DT 06-JUN-2000 (first entry)
 XX
 DE Amino acid sequence of cationic peptide MBI 10CN.
 XX
 KW Cationic peptide; tumour; pharmaceutical composition; cancer; treatment;
 KW leukaemia; polyoxalkylene-modified; APO; lymphoma; multiple myeloma;
 KW breast; lung; ovary; cervix; uterus; skin; prostate; liver; colon;
 KW multidrug resistance.
 XX
 OS Synthetic.
 XX
 PN WO9965506-A2.
 XX
 PD 23-DEC-1999.
 XX
 PF 14-JUN-1999; 99WO-CA00552.
 XX
 PR 12-JUN-1998; 98US-0096541.
 XX
 PA (MICR-) MICROLOGIX BIOTECH INC.
 XX
 PI Friedland HD, Krieger TJ, Taylor R, Erfle D, Fraser JR, West MHP;
 XX
 DR WPI: 2000-223549/19.
 XX
 PT Novel pharmaceutical composition containing optionally activated
 PT polyoxalkylene-modified cationic peptides, useful for treating tumours
 PS
 PS Disclosure: Page 14; 94pp; English.

XX
 CC This sequence represents a cationic peptide amino acid sequence, which
 CC can be used in the pharmaceutical composition of the invention. The
 CC invention relates to a pharmaceutical composition containing at least one
 CC activated polyoxalkylene (APO)-modified cationic peptide. The
 CC modification of peptides with APO increases their activity against tumour
 CC cells, including those with a multidrug resistant phenotype. The
 CC pharmaceutical composition can be used to treat tumours, specifically
 CC lymphoma, leukaemia, multiple myeloma, or tumours of breast, lung, ovary,
 CC cervix, uterus, skin, prostate, liver and colon.
 XX
 SQ Sequence 13 AA:
 Query Match 100.0%; Score 99; DB 21; Length 13;
 Best Local Similarity 100.0%; Pred. No. 9.8e-07;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 ILPMKMPMPMPRR 13
 Db 1 ILPMKMPMPMPRR 13
 RESULT 10
 AAY44666
 ID AAY44666 standard; peptide; 13 AA.
 XX
 AC AAY44666;
 XX
 DT 18-APR-2000 (first entry)
 XX
 DE Crosslink-stabilised indolicidin analog Indol 1-13(W6/9).
 XX
 KW Crosslinked indolicidin analog; X-indolicidin; Indol 1-13(W6/9);
 KW stability; bovine neutrophil; antimicrobial; antibacterial; fungicide;
 KW protozoacide; virucide; anti-HIV; human immunodeficiency virus-1;
 KW HIV-1; gram positive bacteria; gram negative; Staphylococcus aureus;
 KW Escherichia coli; Salmonella typhimurium; yeast; fungi; protozoa;
 KW Candida albicans; Cryptococcus neoformans; Giardia; Acanthamoeba.
 XX
 OS Synthetic.
 OS Bos sp.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 6..9
 FT /note="Residues at positions 6 and 9 form a
 FT di-tryptophan crosslink"
 FT 13
 FT /note="C-terminal amide"
 PN WO9965510-A1.
 XX
 PD 23-DEC-1999.
 XX
 PF 20-MAY-1999; 99WO-US11165.
 XX
 PR 18-JUN-1998; 98US-0096631.
 XX
 PA (REGC) UNIV CALIFORNIA.
 XX
 PI Selsted ME, Osapay K;
 XX
 DR WPI: 2000-147133/13.
 XX
 PT Crosslinked indolicidin analogs with antimicrobial activity against
 PT bacteria, yeast, fungi, protozoa and viruses
 XX
 PS Claim 3; Page 39; 53pp; English.
 CC The patent discloses crosslinked analogs of indolicidin (Indol 1-13)
 CC which is a naturally occurring peptide isolated from bovine neutrophils
 CC and has antimicrobial activity. The crosslinked indolicidin
 CC (X-indolicidin) analogs are stable and have antimicrobial activity
 CC against gram positive and negative bacteria (e.g. Staphylococcus aureus,

CC Escherichia coli and Salmonella typhimurium), yeasts and fungi (e.g. Candida albicans, Cryptococcus neoformans), protozoa (e.g. Giardia species and Acanthamoeba species), and viruses (e.g. HIV-1). They can be used for reducing or inhibiting the growth or survival of microorganisms in an environment e.g. a food or food product, a solution, an inanimate object comprising a surface, or a mammal. CC The present sequence is a specifically claimed X-indolicidin analog, Indol 1-13(W6/3) which contains a di-tryptophan crosslink. CC XX

Sequence 13 AA;

Query Match

100.0%; Score 99; DB 21; Length 13;

Best Local Similarity 100.0%; Pred. No. 9.8e-07; Mismatches 0; Indels 0; Gaps 0;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPWKWPWMPWRR 13

1 ILPWKWPWMPWRR 13

Db 1 ILPWKWPWMPWRR 13

RESULT 11

AAV44324

AAV44324 standard; peptide; 13 AA.

XX AAV44324;

AC 29-FEB-2000 (first entry)

XX Antimicrobial peptide, Indolicidin.

XX purf gene: glutamine pyrophosphoribosyl pyrophosphatase; purf derivative; fusion partner; antimicrobial peptide; Indolicidin; purf production; cleavage site; hydroxylamine; CNBr; DNA construct; cow; neutralise; toxicity; pharmaceutical industry; food industry.

XX Bos taurus.

XX WO9964611-A1.

XX 16-DEC-1999.

XX 08-JUN-1999; 99WO-KR00282.

XX 09-JUN-1998; 98KR-0022117.

XX 14-MAY-1999; 99KR-0017920.

XX (SAMV-) SAMYANG GENEX CORP.

XX Kim JH, Kang MH, Lee J, Park SH, Lee JW, Hong SS, Lee H;

PI WPI: 2000-097542/08.

DR N-PSDB: AA444324.

XX New DNA constructs useful for mass production of antimicrobial peptides

PT in microorganism hosts

XX Claim 1; Fig 1; 67pp; English.

XX The present amino acid sequence is an antimicrobial peptide, Indolicidin

XX derived from cow, Bos taurus. It is used along with a

XX A DNA construct that comprises, this antimicrobial peptide encoding

XX sequence and the entire, partial or derivative of purf gene, is used for

XX mass production of the antimicrobial peptide in microorganisms without

XX killing the host cells. Use of the purf gene derivative sequence, the

XX neutralises the toxicity of the antimicrobial peptides against the host

XX microorganism. The antimicrobial peptides are useful commercially in the

XX pharmaceutical and food industries.

XX Sequence 13 AA;

Query Match

100.0%; Score 99; DB 21; Length 13;

Best Local Similarity 100.0%; Pred. No. 9.8e-07;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPWKWPWMPWRR 13

1 ILPWKWPWMPWRR 13

Db 1 ILPWKWPWMPWRR 13

RESULT 12

AAV55056

AAV55056 standard; peptide; 13 AA.

XX AAV55056;

AC 23-FEB-2000 (first entry)

XX Non-amidated indolicidin peptide.

XX Indolicidin; bactericidal; sulphate-reducing bacteria; growth inhibitor; corrosion; degradation; metal; concrete; cement; dental implant; biofilm.

XX Bacillus sp.

XX WO9965553-A1.

XX 11-NOV-1999.

XX 03-MAY-1999; 99WO-US09675.

XX 06-MAY-1998; 98US-0074037.

XX 31-MAR-1999; 99US-0282277.

XX (REBC) UNIV CALIFORNIA.

XX Wood TK, Jayaraman A, Earltman JC;

XX WPI: 2000-052882/04.

XX Inhibiting growth of sulphate-reducing bacteria using other bacteria,

XX particularly for protection of metals and concrete

XX Example 4; Page 41; 84pp; English.

XX This sequence represents the non-amidated indolicidin peptide.

XX The invention relates to a method for inhibiting growth of

XX sulphate-reducing bacteria (A) on a material (B) sensitive to corrosion

XX or degradation, by applying to (B) a bacterium (C) that secretes a

XX compound (I) able to inhibit growth of (A). The method is used to protect

XX metal, concrete or cement against corrosion and degradation, but (B) can

XX also be used to protect dental implants. (B) is present in an open or

XX closed system (e.g. water cooling tower, liquid storage container, fuel

XX tank, sewer or drainage system etc.) or part of a bridge or other

XX structure. The method is more effective and less expensive than known

XX methods for inhibiting (A), and reduces the amount of toxic chemicals

XX released. Conventional biofilms of aerobic organisms tend to encourage

XX growth of (A), and addition of (C) to the biofilm prevents this. A

XX single application of (C) lasts for a long time, and (I) are produced

XX exactly where they are required and inhibit (A) without significant

XX impact on other organisms (this effect includes reducing resistance of

XX (A) to conventional biocides, which may then be used in reduced

XX amounts). If local damage to the biofilm occurs, the underlying

XX material is still protected by diffusion of (I) from neighbouring areas.

XX Sequence 13 AA;

Query Match

100.0%; Score 99; DB 21; Length 13;

Best Local Similarity 100.0%; Pred. No. 9.8e-07;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPWKWPWMPWRR 13

1 ILPWKWPWMPWRR 13

Db 1 ILPWKWPWMPWRR 13

RESULT 13
 AAY57123
 ID AAY57123 standard; peptide: 13 AA.
 XX
 AC AAY57123;
 XX
 DT 28-FEB-2000 (first entry)
 XX
 DE Naturally occurring bovine indolicidin peptide Indol 1-13.
 XX
 KW Indolicidin analogue; antimicrobial activity; helminth; bacteria; virus;
 KW treatment; inhibit growth; micro-organism; contact lens solution;
 KW transgenic plant; surgical instrument; yeast; fungi; protozoa.
 XX
 OS Bos sp.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 13
 FT /note="C-terminal amide"
 XX
 PN WO958141-A1.
 XX
 PD 18-NOV-1999.
 XX
 PF 05-MAY-1999; 99WO-US09942.
 XX
 PR 12-MAY-1998; 98US-0076227.
 XX
 PA (REGC) UNIV CALIFORNIA.
 XX
 PI Selsted ME;
 XX
 DR WPI; 2000-053028/04.
 XX
 PT New indolicidin analogues, active against bacteria, yeast, fungi,
 PT protozoa and virus, used for, e.g. treating infections -
 XX
 PS Example 1; Page 28; 62pp: English.
 XX
 CC This sequence is a naturally occurring indolicidin peptide.
 CC Peptides AAY57109-Y57138 and AAY57143-Y57144s are new indolicidin
 CC analogues, which have a homoserine residue and/or a truncated amino
 CC terminal region. The analogues have the following amino acid sequence:
 CC Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Pro-Xaa6-Xaa6-Pro-Xaa6-Xaa7-Xaa7-Xaa8
 CC where:
 CC Xaa1 = Ile, Leu, Val, Ala, Gly or absent;
 CC Xaa2 = Ile, Leu, Val, Ala, Gly or absent;
 CC Xaa3 = Pro or absent;
 CC Xaa4 = Trp, Phe or absent;
 CC Xaa5 = Arg, Lys or absent;
 CC Xaa6 = Trp or Phe;
 CC Xaa7 = Arg, Lys or absent;
 CC Xaa8 = homoserine (Hse), Met, Met-Xaa9-Met or absent, and
 CC Xaa9 = at least one amino acid;
 CC and further provided that: if Xaa2 is present, Xaa8 = Hse, Met or Met-Xaa9-Met;
 CC provided that if Xaa1 is absent, Xaa1 is absent; if Xaa3 is
 CC absent, Xaa1 and Xaa2 are absent; if Xaa4 is absent, Xaa1, Xaa2 and Xaa3
 CC are absent; and if Xaa5 is absent, Xaa1, Xaa2, Xaa3 and Xaa4 are absent.
 CC The indolicidin analogues can be used to create a fusion polypeptide
 CC consisting of the analogue linked to a peptide. The indolicidin
 CC analogues have antimicrobial activity against gram positive bacteria,
 CC gram negative bacteria, yeast, fungus, protozoa and viruses (e.g. HIV-1).
 CC They are also active against helminths. The analogues can be used for
 CC reducing or inhibiting growth or survival of a microorganism. They can be
 CC used for treating infections. They can also be included in a liquid such
 CC as water or an aqueous solution, e.g. contact lens solution. The
 CC analogues have potential uses in food products, and in objects such as
 CC the surface of an instrument used to prepare food or to perform surgery.
 CC Transgenic plants or animals useful in the food industry can be produced
 CC by introducing a nucleic acid molecule encoding an indolicidin analogue
 CC into the germline cells of such organisms.
 XX
 SQ Sequence 13 AA;

Query Match 100.0%; Score 99; DB 21; Length 13;
 Best Local Similarity 100.0%; Pred. No. 9.8e-07;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 ILPMKMPMPMPRR 13
 |||||
 Db 1 ILPMKMPMPMPRR 13
 RESULT 14
 ABP60382
 ID ABP60382 standard; peptide: 13 AA.
 XX
 AC ABP60382;
 XX
 DT 28-MAR-2003 (first entry)
 XX
 DE Indolicidin peptide SEQ ID NO 1.
 XX
 KW Indolicidin; ophthalmic; disinfection; contact lens; antimicrobial;
 KW Pseudomonas aeruginosa; Staphylococcus aureus; Serratia marcescens;
 KW Candida albicans; Fusarium solani.
 XX
 OS Unidentified.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 13
 FT /note="C-terminal CONH2"
 XX
 PN WO200071175-A1.
 XX
 PD 30-NOV-2000.
 XX
 PF 23-MAY-2000; 2000WO-US14608.
 XX
 PR 25-MAY-1999; 99US-0318195.
 XX
 PA (LARG-) LARGE SCALE BIOLOGY CORP.
 XX
 PA (STRI-) SRI INT.
 XX
 PA (REGC) UNIV CALIFORNIA.
 XX
 PA (WESL-) WESLEY-JESSEN CORP.
 XX
 PA (TUSE/) TUSE D.
 XX
 PA (MORT/) MORTELMANS K.
 XX
 PA (HOKA/) HOKAMA L A.
 XX
 PA (SELS/) SELSTED M E.
 XX
 PA (CHAP/) CHAPOY L L.
 XX
 PA (QUINN/) QUINN M H.
 XX
 PI Tuse D, Mortelmans K, Hokama LA, Selsted ME, Chapoy LL, Quinn MH;
 PI WPI; 2001-080322/09.
 XX
 DR Ophthalmic composition for storing, cleaning, or disinfecting contact
 XX lens, comprises indolicidin, and buffer having specified halide ion
 XX concentration or Good's buffer -
 PT
 PT Claim 15; Page 68; 91pp: English.
 XX
 PS The invention relates to an ophthalmic composition (I) for storing,
 CC cleaning, or disinfecting a contact lens, comprising an indolicidin
 CC antimicrobial peptide and a buffer having a halide ion concentration less
 CC than 0.85 weight%, based on the total weight of (I) or Good's buffer. (I)
 CC is a multipurpose solution for care of a contact lens and is suitable for
 CC contact lens disinfection, storage, cleaning, conditioning, rehydrating,
 CC moistening and lubricating. (I) is useful for disinfecting the contact
 CC lens or contact lens storage vessel such as contact lens vital, contact
 CC lens case or a contact lens shipping package by contacting the lens or
 CC vessel with a disinfecting solution comprising (I). (I) is useful for
 CC packaging a contact lens involving sealing the lens in a container with
 CC (I), where the contact lens is not autoclaved. (I) reduces the number of
 CC Pseudomonas aeruginosa, Staphylococcus aureus and Serratia marcescens
 CC organisms by 3.0 logs or more within 4 hours and the number of Candida

CC albicans and Fusarium solani by 1.0 log or more within 18 hours. (1) is
 CC self-preserving and requires no additional preservatives or
 CC disinfectants. Since indolicidin are safe for topical application to the
 CC eye, (1) enables immediate application of the contact lens to the eye
 CC without the need for neutralisation, deactivation or washing any of the
 CC components of (1). The present sequence is that of an indolicidin peptide
 CC of the invention.

XX Sequence 13 AA;
 SQ

Query Match 100.0%; Score 99; DB 22; Length 13;
 Best Local Similarity 100.0%; Pred. No. 9.8e-07;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKWPMPWRR 13
 |||
 Db 1 ILPMKWPMPWRR 13

RESULT 15
 ABP60383 standard; peptide; 13 AA.
 XX ID
 AC ABP60383;
 DT 28-MAR-2003 (first entry)
 XX
 DE Indolicidin peptide SEQ ID NO 2.
 XX
 KW Indolicidin; ophthalmic; disinfection; contact lens; antimicrobial;
 KW Pseudomonas aeruginosa; Staphylococcus aureus; Serratia marcescens;
 KW Candida albicans; Fusarium solani.
 XX
 OS Unidentified.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 13 /note="C-terminal OH"
 FT
 PN WO200071175-A1.
 XX
 PD 30-NOV-2000.
 XX
 PF 23-MAY-2000; 2000WO-US14608.
 XX
 PR 25-MAY-1999; 99US-0318195.
 XX
 PA (LARG-) LARGE SCALE BIOLOGY CORP.
 PA (STRI) SRI INT.
 PA (REGC) UNIV CALIFORNIA.
 PA (WEST-) WESLEY-JESSEN CORP.
 PA (TUSE-) TUSE D.
 PA (MORT/) MORTELMANS K.
 PA (HOKA/) HOKAMA L A.
 PA (SELS/) SELSTED M E.
 PA (CHAP/) CHAPOY L L.
 PA (QUINN/) QUINN M H.
 XX
 PI Tuse D, Morielmans K, Hokama LA, Selsted ME, Chapoy LL, Quinn MH;
 XX
 DR WPI: 2001-080322/09.
 XX
 PT Ophthalmic composition for storing, cleaning, or disinfecting contact
 PT lens, comprises indolicidin, and buffer having specified halide ion
 PT concentration or Good's buffer
 XX
 PS Disclosure: Page 16; 91pp; English.
 XX
 CC The invention relates to an ophthalmic composition (I) for storing,
 CC cleaning, or disinfecting a contact lens, comprising an indolicidin
 CC antimicrobial peptide and a buffer having a halide ion concentration less
 CC than 0.85 weight%, based on the total weight of (I) or Good's buffer. (I)
 CC is a multipurpose solution for care of a contact lens and is suitable for

CC contact lens disinfection, storage, cleaning, conditioning, rehydrating,
 CC mistensing and lubricating. (1) is useful for disinfecting the contact
 CC lens or contact lens storage vessel such as contact lens vial, contact
 CC lens case or a contact lens shipping package by contacting the lens or
 CC vessel with a disinfecting solution comprising (1). (1) is useful for
 CC packaging a contact lens involving sealing the lens in a container with
 CC (1), where the contact lens is not autoclaved. (1) reduces the number of
 CC Pseudomonas aeruginosa, Staphylococcus aureus and Serratia marcescens
 CC organisms by 3.0 logs or more within 4 hours and the number of Candida
 CC albicans and Fusarium solani by 1.0 log or more within 18 hours. (1) is
 CC self-preserving and requires no additional preservatives or
 CC disinfectants. Since indolicidin are safe for topical application to the
 CC eye, (1) enables immediate application of the contact lens to the eye
 CC without the need for neutralisation, deactivation or washing any of the
 CC components of (1). The present sequence is that of an indolicidin peptide
 CC of the invention.

XX Sequence 13 AA;
 SQ

Query Match 100.0%; Score 99; DB 22; Length 13;
 Best Local Similarity 100.0%; Pred. No. 9.8e-07;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKWPMPWRR 13
 |||
 Db 1 ILPMKWPMPWRR 13

Search completed: October 2, 2003, 10:01:28
 Job time : 78 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 09:59:37 ; Search time 41 seconds
(without alignments)
30.493 Million cell updates/sec

Title: US-09-444-281-85

Perfect score: 99

Sequence: 1 ILPMKMPWMPWRR 13

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283308 seqs, 96168682 residues

Total number of hits satisfying chosen parameters: 283308

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

1: p1r1:*
2: p1r2:*
3: p1r3:*
4: p1r4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	99	100.0	144	1 UC1222	indolicidin precursor
2	54	54.5	1173	1 VG1HHC	E2 glycoprotein pr
3	53.5	54.0	299	2 T12505	hypothetical prote
4	53	53.5	327	2 E72851	AcOfl-13 protein -
5	53.5	53.5	331	2 T41758	AcMPPV orf13 - Bom
6	51	51.5	55	2 E90626	ATP synthase F0 ch
7	51	51.5	689	2 AC1927	hypothetical prote
8	51	51.5	1038	2 T38935	bone morphogenetic
9	50.5	51.0	970	2 T28234	ORF MSV076 probabl
10	50	50.5	83	2 B73392	hypothetical prote
11	50	50.5	337	2 G95922	probable glycosylt
12	50.5	49.8	1	1 J70751	ferredoxin-NADP re
13	49.5	50.0	296	2 T03562	conserved hypothet
14	49	49.5	60	2 A56547	sex-peptide precu
15	49	49.5	425	2 E84631	probable serine ca
16	49	49.5	467	2 E89605	protein F18G5.2 [1
17	48.5	49.0	111	2 T29295	hypothetical prote
18	48	48.5	55	2 T11105	H+-transporting tw
19	48	48.5	265	2 AH0755	conserved hypothet
20	48	48.5	400	2 AF2107	hypothetical prote
21	47	47.5	55	1 PAXL8	H+-transporting tw
22	47	47.5	55	2 S68132	H+-transporting tw
23	47	47.5	55	2 S08424	H+-transporting tw
24	47	47.5	55	2 E90618	ATP synthase F0 ch
25	47	47.5	55	2 T11538	H+-transporting tw
26	47	47.5	55	2 T11184	H+-transporting tw
27	47	47.5	55	2 T11291	H+-transporting tw
28	47	47.5	55	2 T09861	H+-transporting tw
29	47	47.5	55	2 T09951	H+-transporting tw

30	47	47.5	55	2 T11768	H+-transporting tw
31	47	47.5	55	2 T11304	H+-transporting tw
32	47	47.5	248	2 S23449	NADH oxidase (H2O2
33	47	47.5	253	2 G70715	hypothetical prote
34	47	47.5	297	2 D87260	integral membrane
35	47	47.5	456	2 T18963	hypothetical prote
36	47	47.5	496	2 A54770	N-acetylglucosamin
37	47	47.5	534	1 S75101	hypothetical prote
38	47	47.5	728	2 T51071	related to tria pr
39	47	47.5	1112	2 S70522	cyclic nucleotide
40	46.5	47.0	1299	2 AB2244	hypothetical prote
41	46	46.5	54	1 S04619	H+-transporting tw
42	46	46.5	55	2 T11171	H+-transporting tw
43	46	46.5	55	2 T12413	H+-transporting tw
44	46	46.5	55	2 E58892	H+-transporting tw
45	46	46.5	55	2 E90612	ATP synthase F0 ch

ALIGNMENTS

RESULT 1

JC1222
indolicidin precursor - bovine

N:Alternate names: antimicrobial peptide

C:Species: Bos primigenius taurus (cattle)

C:Date: 10-Sep-1999 #sequence:revision 10-Sep-1999 #text_change 10-Sep-1999

C:Accession: JC1222; A42387; S25664

Biochem. Biophys. Res. Commun. 187, 467-472, 1992

A:Title: CDNA cloning of the neutrophil bactericidal indolicidin.

A:Reference number: JC1222; MUID:92392368; PMID:1520337

A:Accession: JC1222

A:Molecule type: mRNA

A:Residues: 1-144 <SAL>

A:Cross-references: EMBL:X67340; NID:g462; PIDN:CAA47755.1; PID:g463

A:Experimental source: bone marrow

R:Selected, M.E.; Novotny, M.J.; Morris, W.L.; Tang, Y.Q.; Smith, W.; Cullor, J.S.

J. Biol. Chem. 267, 4292-4295, 1992

A:Title: Indolicidin, a novel bactericidal tridecapeptide amide from neutrophils.

A:Reference number: A42387; MUID:92165771; PMID:1537821

A:Accession: A42387

A:Molecule type: protein

A:Residues: 131-143 <SRL>

A:Experimental source: neutrophils

A:Note: sequence extracted from NCBI backbone (NCBI:83840)

C:Superfamily: cathelin; cystatin homology

C:Keywords: amidated carboxyl end

F:1-29/Domain: signal sequence #status predicted <Sig>

F:30-130/Domain: propeptide #status predicted <Pro>

F:131-143/Product: indolicidin #status experimental <Mat>

F:143/Modified site: amidated carboxyl end (Arg) (amide in mature form from following

Query Match 100.0%; Score 99; DB 1; Length 144;

Best local Similarity 100.0%; Pred. No. 7.4e-06;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPWMPWRR 13
|||||

DB 131 ILPMKMPWMPWRR 143

RESULT 2

VG1HHC
E2 glycoprotein precursor - human coronavirus (strain 229E)

N:Alternate names: peplomer glycoprotein; S glycoprotein; spike glycoprotein

C:Species: human coronavirus

A:Note: host Homo sapiens (man)

C:Date: 31-Dec-1991 #sequence:revision 31-Dec-1991 #text_change 16-Jun-2000

C:Accession: A34766; S05460

R:Raabe, T.; Schelle-Pinz, B.; Siddell, S.G.

J. Gen. Virol. 71, 1065-1073, 1990

A:Title: Nucleotide sequence of the gene encoding the spike glycoprotein of human corona
A:Reference number: A34766; MUID:90264837; PMID:2345367
A:Accession: A34766
A:Molecule type: mRNA
A:Residues: 1-1173 <RAA>
A:Cross-references: EMBL:X16816; NID:958926; PIDN:CAA34723.1; PID:958927
A:Experimental source: strain 229E
R:Rabe, T.; Siddell, S.
Nucleic Acids Res. 17, 6387, 1989
A:Title: Nucleotide sequence of the human coronavirus HCV 229E mRNA 4 and mRNA 5 unique
A:Reference number: A34038; MUID:89366667; PMID:2701946
A:Accession: S05460
A:Status: translation not shown
A:Molecule type: mRNA
A:Residues: 1159-1173 <RA2>
A:Cross-references: EMBL:X16554; NID:958921; PIDN:CAA33680.1; PID:91334827
C:Superfamily: coronavirus E2 glycoprotein
C:Keywords: glycoprotein; transmembrane protein
F:1-15/Domain: signal sequence #status predicted <SIG>
F:16-1173/Product: E2 glycoprotein #status predicted <MAT>
F:1116-1138/Domain: transmembrane #status predicted <TMN>
F:23,62,98,147,171,176,220,243,326,333,440,464,518,538,542,568,581,587,663,671,930,1015,

Query Match 54.5%; Score 54; DB 1; Length 1173;
Best Local Similarity 85.7%; Pred. No. 21;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 5 KPWMPW 11
||| |
Db 1113 KPWMPW 1119

RESULT 3
T12505
hypohepatic protein DKFZP434C192.1 - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 23-Jul-1999 #sequence_revision 23-Jul-1999 #text_change 23-Jul-1999
C:Accession: T12505
R:Ansorge, W.; Witkner, U.; Mewes, H.W.; Gassenhuber, J.; Wiemann, S.
submitted to the Protein Sequence Database, June 1999
A:Reference number: Z17527
A:Accession: T12505
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-299 <ANS>
A:Cross-references: EMBL:AL096753
A:Experimental source: adult testis; clone DKFZP434C192
C:Genetics:
A:Note: DKFZP434C192.1

Query Match 54.0%; Score 53.5; DB 2; Length 299;
Best Local Similarity 57.1%; Pred. No. 6.4;
Matches 8; Conservative 0; Mismatches 3; Indels 3; Gaps 1;

OY 3 PW--KMPWPMRR 13
|| |
Db 30 PWSASPMWPMR 43

RESULT 4
E72851
AcOrf-13 protein - Autographa californica nuclear polyhedrosis virus
C:Species: Autographa californica nuclear polyhedrosis virus, AcMNPV
A:Note: dsDNA virus
C:Date: 12-Nov-1999 #sequence_revision 12-Nov-1999 #text_change 12-Nov-1999
C:Accession: E72851
R:Rayes, M.D.; Howard, S.C.; Kuzio, J.; Lopez-Ferber, M.; Possee, R.D.
Virology 202, 586-605, 1994
A:Title: The complete DNA sequence of Autographa californica nuclear polyhedrosis virus.
A:Reference number: A72850; MUID:94303173; PMID:8030224
A:Accession: E72851
A:Status: preliminary
A:Molecule type: DNA

A:Residues: 1-327 <AYR>
A:Cross-references: GB:L22858; NID:9510708; PIDN:AAA6643.1; PID:9559082
C:Genetics:
A:Gene: AcOrf-13

Query Match 53.5%; Score 53; DB 2; Length 327;
Best Local Similarity 54.5%; Pred. No. 8;
Matches 6; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

OY 1 ILPKWPMW 11
: | | | |
Db 1 MLSQLMNMW 11

RESULT 5
T41758
AcMNPV orf13 - Bombyx mori nuclear polyhedrosis virus (isolate T3)
C:Species: Bombyx mori nuclear polyhedrosis virus, BmSNPV
A:Variety: isolate T3
C:Date: 03-Dec-1999 #sequence_revision 03-Dec-1999 #text_change 21-Jul-2000
C:Accession: T41758
R:Gomi, S.; Majima, K.; Maeda, S.
J. Gen. Virol. 80, 1323-1337, 1999
A:Title: Sequence analysis of the genome of Bombyx mori nucleopolyhedrovirus.
A:Reference number: Z22020; MUID:99281911; PMID:10355780
A:Accession: T41758
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-331 <RAM>
A:Cross-references: EMBL:L33180; NID:93745835; PIDN:AAC63687.1; PID:93745840
A:Experimental source: isolate T3
C:Genetics:
A:Note: Orf_5

Query Match 53.5%; Score 53; DB 2; Length 331;
Best Local Similarity 54.5%; Pred. No. 8.1;
Matches 6; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

OY 1 ILPKWPMW 11
: | | | |
Db 1 MLSQLMNMW 11

RESULT 6
E90626
ATP synthase F0 chain 8 [imported] - Eudromia elegans mitochondrion
C:Species: mitochondrion Eudromia elegans
C:Date: 15-Jun-2001 #sequence_revision 15-Jun-2001 #text_change 17-May-2002
C:Accession: E90626
R:Hadrath, O.; Baker, A.J.
Proc. R. Soc. Lond. B Biol. Sci. 268, 939-945, 2001
A:Title: Complete mitochondrial DNA genome sequences of extinct birds: rattle phylog
A:Reference number: A99613; MUID:21263106; PMID:11370967
A:Accession: E90626
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-55 <KUR>
A:Cross-references: GB:NC_002772; NID:914141818; PIDN:NP_115277.1; GSPDB:GN00163
C:Genetics:
A:Gene: ATP8
A:Genome: mitochondrion
A:Genetic code: SSCI
C:Superfamily: H+-transporting ATP synthase protein 8
C:Keywords: mitochondrion

Query Match 51.5%; Score 51; DB 2; Length 55;
Best Local Similarity 85.7%; Pred. No. 2.5;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2 LPKMPW 8
|| |
Db 48 LPKMPW 54

RESULT 7
AC1927
hypothetical protein all0966 [imported] - Nostoc sp. (strain PCC 7120)
C:Species: Nostoc sp. PCC 7120
A:Note: Nostoc sp. strain PCC 7120 is a synonym of Anabaena sp. strain PCC 7120
C:Date: 14-Dec-2001 #sequence_revision 14-Dec-2001 #text_change 09-Dec-2002
C:Accession: AC1927
R:Kanakko, T.; Nakamura, Y.; Wolk, C.P.; Kuritz, T.; Sasamoto, S.; Watanabe, A.; Iriguchi, S.; Nakazaki, N.; Shimpo, S.; Sugimoto, M.; Takazawa, M.; Yamada, M.; Yasuda, M.; Tabata, S.
DNA Res. 8, 205-213, 2001
A:Title: Complete Genomic Sequence of the Filamentous Nitrogen-fixing Cyanobacterium Anabaena PCC 7120
A:Reference number: AB1807; MUID:21595285; PMID:11759840
A:Accession: AC1927
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-689 <KUR>
A:Cross-references: GB:BA000019; PIDN:BAW2923.1; PID:g17130312; GSPDB:GN00179
A:Experimental source: strain PCC 7120
C:Genetics:
A:Gene: all0966

Query Match
Best Local Similarity 51.5%; Score 51; DB 2; Length 689;
Matches 5; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 4 WKPMWPMW 12
| | | | |
Db 141 WMMGWPMW 149

RESULT 8
I38935
bone morphogenetic protein receptor II precursor - human
N:Alternate names: activin receptor-like kinase type II; bone morphogenetic protein 4 receptor
M:Contains: protein kinase (EC 2.7.1.37)
C:Species: Homo sapiens (man)
C:Date: 16-Feb-1996 #sequence_revision 16-Feb-1996 #text_change 24-Sep-1999
C:Accession: I38935; I55438; I37209
R:Kawabata, M.; Chytil, A.; Moses, H.L.
J. Biol. Chem. 270, 5625-5630, 1995
A:Title: Cloning of a novel type II serine/threonine kinase receptor through interaction
A:Reference number: A55947; MUID:95197572; PMID:7890683
A:Accession: I38935
A:Molecule type: mRNA
A:Residues: 1-1038 <KAW>
A:Cross-references: EMBL:U20165; NID:g704361; PIDN:AAC50105.1; PID:g704362
R:Nohno, T.; Ishikawa, T.; Saito, T.; Hosokawa, K.; Noji, S.; Wolinski, D.H.; Rosenbaum, J. Biol. Chem. 270, 22522-22526, 1995
A:Title: Identification of a human type II receptor for bone morphogenetic protein-4 the
A:Reference number: I55438; MUID:95403457; PMID:7673243
A:Accession: I55438
A:Status: nucleic acid sequence not shown; translation not shown; translated from GB/EMF
A:Molecule type: mRNA
A:Residues: 1-1038 <NOH>
A:Cross-references: GB:D50516; NID:807712; PIDN:BA09094.1; PID:807713
R:Rosenzweig, B.L.; Imamura, T.; Okadome, T.; Cox, G.N.; Yamashita, H.; ten Dijke, P.; H. Proc. Natl. Acad. Sci. U.S.A. 92, 7632-7636, 1995
A:Title: Cloning and characterization of a human type II receptor for bone morphogenetic
A:Reference number: I37209; MUID:95372334; PMID:7644468
A:Accession: I37209
A:Status: nucleic acid sequence not shown
A:Molecule type: mRNA
A:Residues: 1-827, 'R', 829-1038 <ROS>
A:Cross-references: EMBL:Z48923; NID:g1009409; PIDN:CA08759.1; PID:g1009410
C:Genetics:
A:Gene: GDB:BMPP2; BRK-3; T-ALK; BMPR3; BMPR-II
A:Cross-references: GDB:642243; OMIM:600799
A:Map position: 20pter-20qter
C:Superfamily: unassigned Ser/Thr or Tyr-specific protein kinases; protein kinase homolog
C:Keywords: ATP; glycoprotein; phosphotransferase; receptor; transmembrane protein
F:1-26/Domain: signal sequence #status predicted <SIG>
F:27-1038/Product: bone morphogenetic protein receptor II #status predicted <MAT>

F:27-150/Domain: extracellular #status predicted <EXT>
F:151-170/Domain: transmembrane #status predicted <TRM>
F:201-508/Domain: protein kinase homology <KIN>
F:209-217/Region: protein kinase ATP-binding motif
F:55,110,126/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match
Best Local Similarity 51.5%; Score 51; DB 2; Length 1038;
Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 3 PKMKPMW 11
| | | | |
Db 8 PMKPMWLPW 16

RESULT 9
T28234
ORF MSV076 probable spheroidin - Melanoplus sanguinipes entomopoxvirus
C:Species: Melanoplus sanguinipes entomopoxvirus
C:Date: 21-Jan-2000 #sequence_revision 21-Jan-2000 #text_change 21-Jul-2000
C:Accession: T28234
R:Afonso, C.L.; Tulman, E.R.; Lu, Z.; Oma, E.; Kutish, G.F.; Rock, D.L.
J. Virol. 73, 533-552, 1999
A:Title: The genome of Melanoplus sanguinipes entomopoxvirus.
A:Reference number: Z20484; MUID:99102612; PMID:9847359
A:Accession: T28234
A:Status: preliminary; translated from GB/EMBL/DDBJ
A:Molecule type: DNA
A:Residues: 1-970 <AF0>
A:Cross-references: EMBL:AF063866; NID:g4049647; PIDN:AAC97813.1; PID:g4049853
C:Genetics:
A:Note: MSV076

Query Match
Best Local Similarity 51.0%; Score 50.5; DB 2; Length 970;
Matches 8; Conservative 3; Mismatches 2; Indels 1; Gaps 1;

QY 1 ILPMKPMW-PMWR 13
| | | | |
Db 838 ILPMKPMWPMWR 851

RESULT 10
B72392
hypothetical protein - Thermotoga maritima (strain MSB8)
C:Species: Thermotoga maritima
C:Date: 11-Jun-1999 #sequence_revision 11-Jun-1999 #text_change 21-Jul-2000.
C:Accession: B72392
R:Nelson, K.E.; Clayton, R.A.; Gill, S.R.; Gwin, M.L.; Dodson, R.J.; Haft, D.H.; Hilt
Garrett, M.M.; Stewart, A.M.; Cotton, M.D.; Pratt, M.S.; Phillips, C.A.; Richardson, C.M.
Nature 399, 323-329, 1999
A:Title: Evidence for lateral gene transfer between Archaea and Bacteria from genome
A:Reference number: A72200; MUID:99287316; PMID:10360571
A:Accession: B72392
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-83 <ARN>
A:Cross-references: GB:AE001713; GB:AE000512; NID:g4980809; PIDN:AAD35403.1; PID:g498
A:Experimental source: strain MSB8
C:Genetics:
A:Gene: TM0315

Query Match
Best Local Similarity 50.5%; Score 50; DB 2; Length 83;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 4 WKPMWPMW 11
| | | | |
Db 7 WMMGWPMW 14

RESULT 11

G95922
 probable glycosyltransferase protein Smb21068 [imported] - Sinorhizobium meliloti (strain
 C:Species: Sinorhizobium meliloti
 C:Date: 24-Aug-2001 #sequence.revision 24-Aug-2001 #text.change 30-Sep-2001
 C:Accession: G95922
 R:Finan, T.M.; Weidner, S.; Wong, K.; Buhmester, J.; Chain, P.; Vorholter, F.J.; Hernat
 Proc. Natl. Acad. Sci. U.S.A. 98, 9889-9894, 2001
 A:Title: The complete sequence of the 1,683-kb PSymb megaplasmid from the N2-fixing endo
 A:Reference number: A95842; MUID:21396508; PMID:11481431
 A:Accession: G95922
 A:Status: preliminary
 A:Molecule type: DNA
 A:Residues: 1-337 <KOR>
 A:Cross-references: GB:AL591985; PIDN:CAC49047.1; PID:915140532; GSPDB:GN00167
 A:Experimental source: strain 1021, megaplasmid PSymb
 R:Callbert, F.; Finan, T.M.; Long, S.R.; Puhler, A.; Abola, P.; Ampe, F.; Barloy-Hubier,
 P.; Chain, P.; Cowie, A.; Davis, K.W.; Dreano, S.; Federspiel, N.A.; Fisher, R.F.;
 L.; Hyman, R.W.; Jones, T.
 Science 293, 668-672, 2001
 A:Authors: Kahn, D.; Kahn, M.L.; Kalman, S.; Keating, D.H.; Kiss, E.; Komp, C.; Lelaure,
 hebbault, P.; Vandenbol, M.; Vorholter, F.J.; Weidner, S.; Wells, D.H.; Wong, K.; Yeh, K.
 A:Title: The composite genome of the legume symbiont Sinorhizobium meliloti.
 A:Reference number: A96039; MUID:21368234; PMID:11474104
 A:Contents: annotation
 C:Genetics:
 A:Gene: Smb21068
 A:Genome: plasmid

Query Match	50.5%;	Score 50;	DB 2;	Length 337;
Best Local Similarity	66.7%;	Pred. No. 19;		
Matches	6;	Conservative	0;	Mismatches
			3;	Indels
			0;	Gaps
			0;	

OY 3 PRCWRMPW 11
 11 11111
 Db 262 PRCWRMPW 270

RESULT 12
 J070751
 ferredoxin-NADP reductase (EC 1.18.1.2), long form precursor - bovine
 N:Alternate names: adrenodoxin reductase
 C:Species: Bos primigenius taurus (cattle)
 C:Date: 14-Jul-1994 #sequence.revision 18-Oct-1996 #text.change 03-Jun-2002
 C:Accession: J070751; J07079; J03090; S03558; P50003; A29604; S52100
 R:Takata, Y.; Sagara, Y.; Kono, A.; Sekimizu, K.; Horiuchi, T.
 Biol. Pharm. Bull. 16, 1200-1206, 1993
 A:Title: Gene structure of bovine adrenodoxin reductase.
 A:Reference number: J070751; MUID:94177140; PMID:8130767
 A:Accession: J070751
 A:Molecule type: DNA
 A:Residues: 1-498 <YAK>
 A:Cross-references: GB:D83475; NID:91199916; PIDN:BA011921.1; PID:94521308
 A:Experimental source: adrenal cortex
 A:Note: The authors translated the codon GNC for residue 205 as Gly
 R:Sagara, Y.; Takata, Y.; Miyata, T.; Hara, T.; Horiuchi, T.
 J. Biochem. 102, 1333-1336, 1987
 A:Title: Cloning and sequence analysis of adrenodoxin reductase cDNA from bovine adrenal
 A:Reference number: J07079; MUID:88198050; PMID:3448086
 A:Accession: J07079
 A:Molecule type: mRNA
 A:Residues: 1-204,211-498 <SAG>
 A:Cross-references: GB:D00211; NID:9217433; PIDN:BA00150.1; PID:9217434
 A:Note: the deduced sequence is partially confirmed by amino acid sequencing of 15 isol
 R:Sagara, Y.
 submitted to DBJ, September 1989
 A:Reference number: J50390
 A:Contents: revision, insertion of residues 205-210
 A:Accession: J50390
 A:Molecule type: mRNA
 A:Residues: 56-498 <SAG>
 R:Hannuoglu, I.; Gultinger, T.
 Eur. J. Biochem. 180, 479-484, 1989
 A:Title: cDNA sequence of adrenodoxin reductase. Identification of NADP-binding sites in

A:Reference number: S03558; MUID:89170752; PMID:2924777
 A:Accession: S03558
 A:Molecule type: mRNA
 A:Residues: 155-204,211-498 <HAN>
 A:Cross-references: EMBL:X13736; NID:965; PIDN:CAA32002.1; PID:9833776
 A:Note: 40S-Ser was also found
 R:Hamamoto, I.; Kurokouchi, K.; Tanaka, S.; Ichikawa, Y.
 Biochim. Biophys. Acta 953, 207-213, 1988.
 A:Title: Adrenoferradoxin-binding peptide of NADPH-adrenoferradoxin reductase.
 A:Reference number: P50003; MUID:88184054; PMID:3355838
 A:Accession: P50003
 A:Molecule type: protein
 A:Residues: 33-41,'S',43-62;260-283,'TW',496-498 <HAN>
 A:Note: A cyanogen bromide peptide binds to adrenoferradoxin
 R:Nonaka, Y.; Murakami, H.; Yabasaki, Y.; Kuramitsu, S.; Kagamiyama, H.; Yamano, T.;
 Biochem. Biophys. Res. Commun. 145, 1239-1247, 1987
 A:Title: Molecular cloning and sequence analysis of full-length cDNA for mRNA of adre
 A:Reference number: A29604; MUID:87270696; PMID:3038094
 A:Accession: A29604
 A:Molecule type: mRNA
 A:Residues: 1-76,'R',78-80,'VWLAFTTPSRML',95-123,'RVYRLT',129-204,211-273,'R',275-3
 A:Cross-references: GB:M17029; NID:9162628; PIDN:AAA30362.1; PID:9162629
 A:Experimental source: adrenal cortex
 R:Watburt, R.J.; Seybert, D.W.
 Biochim. Biophys. Acta 1246, 39-46, 1995
 A:Title: Structural and functional characterization of bovine adrenodoxin reductase b
 A:Reference number: S52100; MUID:95110846; PMID:7811729
 A:Accession: S52100
 A:Status: preliminary
 A:Molecule type: protein
 A:Residues: 'X',34-41,'X',43-48,'X',50-51;304-306,'X',308-309,'X',311-326 <MAR>
 C:Comment: Ferradoxin-NADP reductase is localized in the matrix of adrenal cortex mi
 erredoxin-NADP reductase, adrenodoxin and two forms of cytochrome P-450.
 C:Genetics:
 A:introns: 27/1; 59/3; 91/3; 132/3; 170/3; 204/3; 246/3; 275/1; 341/3; 399/1; 456/1
 C:Function:
 A:Description: catalyzes the reversible reduction of NADP+ by reduced ferredoxin or r
 C:Superfamily: human ferredoxin-NADP+ reductase
 C:Keywords: alternative splicing; flavoprotein; mitochondrion; monomer; NADP; oxidore
 F:1-32/Domains: transit peptide (mitochondrion) #status predicted <S16>
 F:33-498/Product: ferredoxin-NADP+ reductase, long form #status predicted <MAT>
 F:33-204,211-498/Product: ferredoxin-NADP+ reductase, short form #status experimental
 F:40-70/Region: beta-alpha-beta FAD nucleotide-binding fold
 F:180-190/Region: NADP binding #status predicted
 F:281/Binding site: substrate (lys) #status experimental

Query Match	50.5%;	Score 50;	DB 1;	Length 498;
Best Local Similarity	66.7%;	Pred. No. 28;		
Matches	6;	Conservative	0;	Mismatches
			3;	Indels
			0;	Gaps
			0;	

OY 3 PRCWRMPW 11
 11 11111
 Db 3 PRCWRMPW 11

RESULT 13
 T03562
 conserved hypothetical protein - Rhodobacter capsulatus
 C:Species: Rhodobacter capsulatus
 C:Date: 24-Mar-1999 #sequence.revision 24-Mar-1999 #text.change 02-Aug-2002
 C:Accession: T03562
 R:Vilek, C.; Paces, V.; Maltsev, N.; Paces, J.; Haselkorn, R.; Fousteln, M.
 Proc. Natl. Acad. Sci. U.S.A. 94, 9384-9388, 1997
 A:Title: Sequence of a 189-kb segment of the chromosome of Rhodobacter capsulatus SB1
 A:Reference number: Z14953; MUID:97404404; PMID:9256491
 A:Accession: T03562
 A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: DNA
 A:Residues: 1-296 <VILC>
 A:Cross-references: EMBL:AF010496; NID:93128256; PIDN:AA016215.1; PID:93128363
 C:Genetics:
 A:Map position: 1
 C:Superfamily: hypothetical protein yded

Query Match 50.0%; Score 49.5; DB 2; Length 296;
 Best Local Similarity 50.0%; Pred. No. 20;
 Matches 9; Conservative 3; Mismatches 1; Indels 5; Gaps 2;

OY 1 ILPKWMPW---WP-WRR 13
 :||: ||| ||: ||
 Db 52 LLPFWPWLRLRDMPLYRR 69

RESULT 14

A56547
 sex-peptide precursor - Drosophila suzukii
 N:Alternate names: male accessory gland peptide
 C:Species: Drosophila suzukii
 C:Date: 21-Jul-1995 #sequence_revision 21-Jul-1995 #text_change 21-Jul-2000
 C:Accession: A56547; B56547
 R:Schmidt, T.; Choiflat, Y.; Schneider, M.; Hunziker, P.; Fuyama, Y.; Kubli, E.
 Insect Biochem. Mol. Biol. 23, 571-579, 1993
 A:Title: Drosophila suzukii contains a peptide homologous to the Drosophila melanogaster
 A:Reference number: A56547; MUID:93357785; PMID:8353518
 A:Accession: A56547
 A:Molecule type: DNA
 A:Residues: 1-60 <SCH>
 A:Cross-references: GB:S64573; NID:9409350; PIDN:AAB27872.2; PID:97548732
 A:Note: sequence modified after extraction from NCBI backbone
 A:Note: authors translated the codon TGC for residue 12 as Trp
 A:Note: sequence extracted from NCBI backbone (NCBIN:136396)
 A:Accession: B56547
 A:Molecule type: protein
 A:Residues: 20-60 <SC2>
 A:Note: sequence modified after extraction from NCBI backbone
 C:Genetics:
 A:Gene: FLYBase:DsuZ/SP
 A:Cross-references: FLYBase:FBgn0012991
 A:Introns: 44/1
 C:Keywords: neuropeptide
 F:1-19/Domain: signal sequence #status predicted <SIG>
 F:20-60/Product: sex-peptide #status experimental <MAT>

Query Match 49.5%; Score 49; DB 2; Length 60;
 Best Local Similarity 50.0%; Pred. No. 4.8;
 Matches 7; Conservative 1; Mismatches 2; Indels 4; Gaps 1;

OY 4 WKMPW---WPPRR 13
 |:||| ||| |
 Db 20 WEPWPKKKPPWR 33

RESULT 15

E84631
 probable serine carboxypeptidase II [imported] - Arabidopsis thaliana
 C:Species: Arabidopsis thaliana (mouse-ear cress)
 C:Date: 02-Feb-2001 #sequence_revision 02-Feb-2001 #text_change 16-Feb-2001
 C:Accession: E84631
 R:Lin, X.; Kaul, S.; Rounsley, S.D.; Spea, T.P.; Benito, M.I.; Town, C.D.; Fujii, C.Y.;
 M.; Koo, H.; Moffat, K.S.; Cronin, L.A.; Shen, M.; Vanaken, S.E.; Umayam, L.; Tallon, L.;
 eus, D.; Nierman, W.C.; White, O.; Eisen, J.A.; Salzberg, S.L.; Fraser, C.M.; Venter, J.
 Nature 402, 761-768, 1999
 A:Title: Sequence and analysis of chromosome 2 of the plant Arabidopsis thaliana.
 A:Reference number: A84420; MUID:20083487; PMID:10617197
 A:Accession: E84631
 A:Status: preliminary
 A:Molecule type: DNA
 A:Residues: 1-425 <STO>
 A:Cross-references: GB:AE002093; NID:g3738328; PIDN:AAC63669.1; GSPDB:GN00139
 C:Genetics:
 A:Gene: AL2924010
 A:Map position: 2
 C:Superfamily: serine carboxypeptidase

Query Match 49.5%; Score 49; DB 2; Length 425;
 Best Local Similarity 70.0%; Pred. No. 32;

Matches 7; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 OY 2 LPKWPMPW 11
 ||| ||: ||
 Db 363 LPVKTPWYPM 372

Search completed: October 2, 2003, 10:04:46
 Job time : 42 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 09:57:07 ; Search time 25 Seconds

(without alignments)
24.454 Million cell updates/sec

Title: US-09-444-281-85

Sequence: 1 ILPMKMPMPMPMR 13

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 127863 seqs, 47026705 residues

Total number of hits satisfying chosen parameters: 127863

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database : SwissProt_41.*

Prod. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	99	100.0	144	INOC_BOVIN	P33046 bos taurus
2	54	54.5	1173	VGL2_CVH22	P15423 human coron
3	53	53.5	327	Y013_NPVAC	P41423 autographa
4	51	51.5	1038	BMR2_HUMAN	Q13873 homo sapien
5	50	50.5	55	ATP8_CORN	Q9td16 corythaxol
6	50	50.5	492	ADRO_BOVIN	P08165 bos taurus
7	48	48.5	55	ATP8_PELSU	Q79674 pelomedusa
8	47.5	48.0	279	ELO1_HUMAN	Q91155 mus musculu
9	47.5	48.0	279	ELO1_MOUSE	Q91155 mus musculu
10	47	47.5	55	ATP8_GADMO	P15596 gadus morhu
11	47	47.5	55	ATP8_ONCXY	P48179 oncorhynch
12	47	47.5	55	ATP8_PRODO	Q33416 protocerus
13	47	47.5	55	ATP8_SALAL	Q9xn27 salvelinus
14	47	47.5	55	ATP8_SALFO	Q9xn35 salvelinus
15	47	47.5	55	ATP8_SCYCA	Q79403 scylliorhin
16	47	47.5	55	ATP8_SOUAC	Q92505 squallus aca
17	47	47.5	55	ATP8_VIRAL	Q9m311 viroo altit
18	47	47.5	55	ATP8_XENLA	P03631 xenopus lae
19	47	47.5	253	Y945_MYCTU	P71564 mycobacteri
20	47	47.5	1112	CN3B_HUMAN	Q13370 homo sapien
21	46	46.5	54	ATP8_CHICK	P14093 gallus gall
22	46	46.5	55	ATP8_ANAPL	P50655 anas platyr
23	46	46.5	55	ATP8_ATYAM	Q9x255 aythya amer
24	46	46.5	55	ATP8_CHAPE	Q9ctb9 chaetura pe
25	46	46.5	55	ATP8_COLPA	Q9mtd7 columbaea p
26	46	46.5	55	ATP8_CORCR	Q9ctb17 corythaeola
27	46	46.5	55	ATP8_COTJA	P50682 coturnix co
28	46	46.5	55	ATP8_IATCH	Q03168 latimeria c
29	46	46.5	55	ATP8_LOXNO	Q9m4j1 loxigilla n
30	46	46.5	55	ATP8_MOSHO	Q9ctb18 musophaga v
31	46	46.5	55	ATP8_OPIHO	Q9ctb15 opisthocomu
32	46	46.5	55	ATP8_RHEAM	Q79396 rhea americ
33	46	46.5	55	ATP8_STRCA	Q21401 struthio ca

ALIGNMENTS

RESULT 1	ID	INOC_BOVIN	STANDARD:	PRT:	144 AA.
AC	P33046;				
DT	01-OCT-1993 (Rel. 27, Created)				
DT	01-OCT-1993 (Rel. 27, Last sequence update)				
DT	15-SEP-2003 (Rel. 42, Last annotation update)				
DE	Indolicidin precursor.				
OS	Bos taurus (Bovine).				
OC	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;				
OC	Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;				
OC	Bovidae; Bovinae; Bos.				
OX	NCBI_Taxid:9913;				
RN	[1]				
RP	SEQUENCE FROM N.A.				
RC	TISSUE-Bone marrow;				
RA	MEDLINE-92392368; PubMed-1520337;				
RA	del Sal G., Storici P., Schneider C., Romeo D., Zanetti M.;				
RT	"CDNA cloning of the neutrophil bactericidal peptide indolicidin.";				
RL	Biochem. Biophys. Res. Commun. 187:467-472(1992).				
RN	[2]				
RP	SEQUENCE OF 131-143.				
RC	TISSUE-Neutrophils;				
RA	MEDLINE-92165771; PubMed-1537821;				
RA	Selsted M.E., Novotny M.J., Morris W.L., Tang Y.-Q., Smith W.;				
RT	Cullor J.S.;				
RL	"Indolicidin, a novel bactericidal tridecapeptide amide from				
RL	neutrophils.";				
RL	J. Biol. Chem. 267:4292-4295(1992).				
CC	- FUNCTION: POTENT MICROBICIDAL ACTIVITY, ACTIVE AGAINST				
CC	STAPHYLOCOCCUS AUREUS AND ESCHERICHIA COLI.				
CC	- TISSUE SPECIFICITY: LARGE GRANULES OF NEUTROPHILS.				
CC	- PTM: ELASTASE MIGHT BE RESPONSIBLE FOR ITS MATURATION.				
CC	- SIMILARITY: BELONGS TO THE CATHELICIDIN FAMILY.				
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration				
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation -				
CC	the European Bioinformatics Institute. There are no restrictions on its				
CC	use by non-profit institutions as long as its content is in no way				
CC	modified and this statement is not removed. Usage by and for commercial				
CC	entities requires a license agreement (See http://www.isb-sib.ch/announce/				
CC	or send an email to license@sib-sib.ch).				
CC	EMBL; X67340; CAA47755.1; -				
DR	PIR; J01222; J01222.				
DR	PDB; 1G89; 17-JAN-01.				
DR	PDB; 1G8C; 17-JAN-01.				
DR	PDB; 1HRI; 31-DEC-02.				
DR	InterPro: IPR001894; Cathelicidin.				
DR	Pfam: PF00666; Cathelicidin; 1.				
DR	ProDom: PD001838; Cathelicidin; 1.				
DR	PROSITE: PS00946; CATHELICIDINS_1; 1.				
DR	PROSITE: PS00947; CATHELICIDINS_2; 1.				
KW	Antibiotic; Amidation; Signal; Pyrrolidone carboxylic acid;				
FT	3D-structure. 1 29 POTENTIAL.				

```

FT PROPEP 30 130 INDOLICIDIN.
FT PEPTIDE 131 143 PYRROLIDONE CARBOXYLIC ACID (BY
FT MOD_RES 30 30 SIMILARITY).
FT DISULFID 85 96 BY SIMILARITY.
FT DISULFID 107 124 BY SIMILARITY.
FT MOD_RES 143 143 AMINATION (G-144 PROVIDE AMIDE GROUP).
SQ SEQUENCE 144 AA: 16479 MW: 83163555C09911 CMC64.

Query Match 100.0%; Score 99; DB 1; Length 144;
Best Local Similarity 100.0%; Pred. No. 5.2e-06;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKWPMPWMPMR 13
Db 131 ILPMKWPMPWMPMR 143

RESULT 2
VGL2_CVH2 STANDARD: PRT: 1173 AA.
AC P15423; P89344; P89343; Q66174; Q990M1; Q990M2; Q990M3;
AC Q990M4;
DT 01-APR-1990 (Rel. 14, Created)
DT 01-APR-1990 (Rel. 14, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE E2 glycoprotein precursor (Spike glycoprotein) (Peplomer protein).
GN S.
OS Human coronavirus (strain 229E) (HCoV-229E).
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Nidovirales;
OC Coronaviridae; Coronavirus.
OC NCBI_TaxID=11137;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE-90264837; PubMed-2345367;
RA Raabe T., Schelle-prinz B., Siddell S.G.;
RT "Nucleotide sequence of the gene encoding the spike glycoprotein of
RT human coronavirus HCoV 229E."
RL J. Gen. Virol. 71:1065-1073(1990).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE-21262210; PubMed-11369870;
RA Thiel V., Herold J., Schelle B., Siddell S.G.;
RT "Infectious RNA transcribed in vitro from a cDNA copy of the human
RT coronavirus genome cloned in vaccinia virus."
RL J. Gen. Virol. 82:1273-1281(2001).
RN [3]
RP SEQUENCE OF 98-1113 FROM N.A., AND VARIANTS.
RC STRAIN=Isolate RW stock, Isolate P100E, Isolate P11A, and
RC Isolate P11B;
RA Bonavia A., Holmes K.V.;
RT "Viral and cellular changes in a human cell line persistently infected
RT with human coronavirus HCoV-229E."
RL Submitted (FEB-2001) to the EMBL/GenBank/DBJ databases.
RN [4]
RP SEQUENCE OF 98-1113 FROM N.A., AND VARIANTS.
RC STRAIN=Isolate ATCC VR-74, Isolate A162, and Isolate LRI 281;
RX MEDLINE-99086140; PubMed-9870539;
RA Hays J.P., Myint S.H.;
RT "PCR sequencing of the spike genes of geographically and
RT chronologically distinct human coronaviruses 229E."
RL J. Virol. Methods 75:179-193(1998).
RN [5]
RP SEQUENCE OF 1159-1173 FROM N.A.
RX MEDLINE-8936667; PubMed-2701946;
RA Raabe T., Siddell S.;
RT "Nucleotide sequence of the human coronavirus HCV 229E mRNA 4 and mRNA
RT 5 unique regions."
RL Nucleic Acids Res. 17:6387-6387(1989).
RN [6]
RP INTERACTION WITH ANPEP.
RX MEDLINE-2440020; PubMed-1255191;
RA Bonavia A., Zelus B.D., Wentworth D.E., Talbot P.J., Holmes K.V.;

```

```

RT "Identification of a receptor-binding domain of the spike glycoprotein
RT of human coronavirus HCoV-229E."
RL J. Virol. 77:2530-2538(2003).
RN [7]
RP INTERACTION WITH ANPEP.
RX MEDLINE-22521439; PubMed-12634402;
RA Breslin J.J., Mork I., Smith M.K., Vogel L.K., Hemmla E.M.,
RA Bonavia A., Talbot P.J., Sjoestrom H., Noren O., Holmes K.V.;
RT "Human coronavirus 229E: receptor binding domain and neutralization by
RT soluble receptor at 37 degrees C."
RL J. Virol. 77:4435-4438(2003).
RN [8]
RP REVIEW.
RX MEDLINE-21109095; PubMed-11162792;
RA Gallagher T.M., Buchmeier M.J.;
RT "Coronavirus spike proteins in viral entry and pathogenesis."
RL Virology 279:371-374(2001).
CC -I- FUNCTION: Structural protein that makes spikes at the surface of
CC the virus. Determines enteropathogenicity and virulence of the
CC virus. Initiates infection by specifically recognizing and binding
CC the human aminopeptidase ANPEP receptor. Its association with
CC ANPEP may lead to its conformational change that triggers fusion
CC between viral and host cellular membrane.
CC -I- SUBUNIT: Homotrimer. During virus morphogenesis, it is found in a
CC complex with M and HE proteins (By similarity). Interacts with
CC ANPEP.
CC -I- SUBCELLULAR LOCATION: Type I membrane protein.
CC -I- DOMAIN: The spike S1 domain displays the specificity for the host
CC receptor.
CC -I- DOMAIN: The leucine zipper-like heptad repeats may mediate the
CC fusion of viral and cellular membranes.
CC -I- POLYMORPHISM: The strong variation between the different
CC strains may affect the virulence of the virus.
CC -I- MISCELLANEOUS: In contrast to serogroup 2, E2 glycoprotein protein
CC from serogroup 1 is not cleaved.
CC -I- SIMILARITY: Contains 1 spike S1 domain.
CC -I- SIMILARITY: Contains 1 spike S2 domain.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: X16816; CAA34723.1; -
CC EMBL: AF304460; AAG48392.1; -
CC EMBL: AF344186; AAK32188.1; -
CC EMBL: AF344187; AAK32189.1; -
CC EMBL: AF344188; AAK32190.1; -
CC EMBL: AF344189; AAK32191.1; -
CC EMBL: Y09923; CAA71056.1; -
CC EMBL: Y10051; CAA71146.1; -
CC EMBL: Y10052; CAA71147.1; -
CC EMBL: X15654; CAA33680.1; -
CC PIR: A34766; VGIRHC.
CC InterPro: IPR002551; Corona_S1.
CC Pfam: PF01600; Corona_S1.
CC Pfam: PF01601; Corona_S2.
CC Virulence: Glycoprotein; Envelope protein; Transmembrane; Signal;
CC Coiled coil.
CC KW SIGNAL 1 15
CC CHAIN 16 1173
CC DOMAIN 16 1115
CC TRANSMEM 116 1135
CC DOMAIN 1136 1173
CC DOMAIN 32 536
CC DOMAIN 417 547
CC DOMAIN 537 1171
CC DOMAIN 1054 1103
CC DOMAIN 1067 1102
CC E2 GLYCOPROTEIN.
CC EXTRACELLULAR (POTENTIAL).
CC POTENTIAL.
CC CYTOPLASMIC (POTENTIAL).
CC SPIKE S1.
CC INTERACTION WITH ANPEP.
CC SPIKE S2.
CC COILED COIL (POTENTIAL).
CC LEUCINE ZIPPER-LIKE HEPTAD REPEATS.

```

FT	DOMAIN	1136	1157	CYS-RICH
FT	CARBOHYD	223	62	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	62	98	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	147	147	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	171	171	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	176	176	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	220	220	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	226	226	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	243	243	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	326	326	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	333	333	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	440	440	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	464	464	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	518	518	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	538	538	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	542	542	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	568	568	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	581	581	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	587	587	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	663	663	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	671	671	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	930	930	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	1015	1015	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	1020	1020	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	1037	1037	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	1049	1049	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	1061	1061	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	1066	1066	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	1076	1076	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	1082	1082	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	1096	1096	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	VARIANT	98	98	N -> S (in isolate LRI 281).
FT	VARIANT	120	120	N -> I (in isolate LRI 281).
FT	VARIANT	127	128	LR -> IS (in isolate A162).
FT	VARIANT	176	176	N -> T (in isolate P100E).
FT	VARIANT	210	210	T -> S (in isolate A162).
FT	VARIANT	223	223	T -> N (in isolate A162).
FT	VARIANT	228	229	DF -> V (in isolate A162).
FT	VARIANT	230	230	C -> L (in isolate LRI 281).
FT	VARIANT	230	230	C -> F (in isolates RW Stock, P11A, P11B P100E and ATCC VR-74).
FT	VARIANT	248	248	S -> A (in isolate A162).
FT	VARIANT	270	270	D -> Y (in isolate P100E).
FT	VARIANT	295	295	V -> A (in isolate LRI 281).
FT	VARIANT	300	300	T -> M (in isolate P100E).
FT	VARIANT	307	307	D -> N (in isolate A162).
FT	VARIANT	310	311	PO -> LR (in isolate A162).
FT	VARIANT	314	324	GGGCFNCYPRAG -> VGRGYNCRPRAY (in isolate A162).
FT	VARIANT	336	336	K -> N (in isolate LRI 281).
FT	VARIANT	349	358	KYAVAVANG -> GPVCKPFD (in isolate A162)
FT	VARIANT	401	401	V -> M (in isolate A162).
FT	VARIANT	404	411	MAASKYRT -> LANINSMN (in isolate A162).
FT	VARIANT	414	414	S -> T (in isolate P100E).
FT	VARIANT	424	424	G -> V (in isolate A162).
FT	VARIANT	430	430	Q -> K (in isolate A162).
FT	VARIANT	441	441	V -> A (in isolate LRI 281).
FT	VARIANT	444	444	D -> N (in isolate A162).
FT	VARIANT	462	462	V -> I (in isolate A162).
FT	VARIANT	481	481	L -> V (in isolate A162).
FT	VARIANT	488	488	K -> N (in isolate A162).
FT	VARIANT	530	530	K -> I (in isolate A162).
FT	VARIANT	537	577	L -> M (in isolate A162).
FT	VARIANT	578	578	I -> T (in isolate A162).
FT	VARIANT	590	590	V -> G (in isolate P11B).
FT	VARIANT	642	642	T -> I (in isolate P100E).
FT	VARIANT	681	681	R -> M (in isolate A162).
FT	VARIANT	700	700	T -> R (in isolate A162).
FT	VARIANT	711	711	L -> I (in isolates RW Stock, P11A, P11B and P100E).
FT	VARIANT	714	714	D -> N (in isolate LRI 281).
FT	VARIANT	765	765	K -> N (in isolates RW Stock, P11A, P11B and P100E).
FT	VARIANT	765	765	V -> A (in isolate A162).

```

FT VARIANT 775 775 A -> S (in isolate A162).

Query Match 54.5%; Score 54; DB 1; Length 1173;
Best Local Similarity 85.7%; Pred. No. 9.9;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 5 KWPMPWP 11
|||||
Db 1113 KWPMPWP 1119

RESULT 3
ID Y013_NPVAC STANDARD; PRT; 327 AA.
AC P41423;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 01-NOV-1997 (Rel. 35, Last annotation update)
DE Hypothetical 38.7 Kda protein in PK1-LEF1 intergenic region.
OS Autographa californica nuclear polyhedrosis virus (AcMNPV).
OC Viruses; dsDNA viruses, no RNA stage; Baculoviridae;
OC Nucleopolyhedrovirus.
OX NCBI_TaxID=46015;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C6;
RX MEDLINE=943031173; PubMed=8030224;
RA Ayres M.D., Howard S.C., Kuzio J., Lopez-Ferber M., Possee R.D.;
RT "The complete DNA sequence of Autographa californica nuclear
polyhedrosis virus."
RL Virology 202;586-605(1994).
RN [2]
RP SEQUENCE OF 1-209 FROM N.A.
RC STRAIN=LI;
RX MEDLINE=93267802; PubMed=8497062;
RA Passarelli A.L., Miller L.K.;
RT "Identification and characterization of lef-1, a baculovirus gene
involved in late and very late gene expression."
RL J. Virol. 67:3481-3488(1993).
CC -1 SIMILARITY: TO CORRESPONDING ORF IN OPMNPV.
-----
CC CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sdb.ch/announce/
CC or send an email to license@sdb.ch).
CC -----
DR EMBL; L22858; AAA66643.1; -
DR EMBL; L09723; AAA46706.1; -
DR PIR; E72851; E72851.
KW Hypothetical protein.
SQ SEQUENCE 327 AA; 38660 MW; 4D494C1D62285171 CRC64;

Query Match 53.5%; Score 53; DB 1; Length 327;
Best Local Similarity 54.5%; Pred. No. 4.2;
Matches 6; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

OY 1 ILPMKWPMPWP 11
|||||
Db 1 MLSPMLNWMW 11

RESULT 4
ID BMR2_HUMAN STANDARD; PRT; 1038 AA.
AC Q13873; Q16569;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Bone morphogenetic protein receptor type II precursor (EC 2.7.1.37)
( BMP type II receptor) (BMPR-II).

```

GN BMPR2 OR PPH1.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Substantia nigra;
 RX MEDLINE=95372334; PubMed=7644468;
 RA Rosenzweig B.L., Imanura T., Okadome T., Cox G.N., Yamashita H.,
 RA ten Dijke P., Heidin C., Miyazono K.;
 RT "Cloning and characterization of a human type II receptor for bone
 RT morphogenetic proteins.";
 RL Proc. Natl. Acad. Sci. U.S.A. 92:7632-7636(1995).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Skin fibroblast;
 RX MEDLINE=95403457; PubMed=7673243;
 RA Nohno T., Ishikawa T., Saito T., Hosokawa K., Noji S., Wosling D.H.,
 RA Rosenbaum J.S.;
 RT "Identification of a human type II receptor for bone morphogenetic
 RT protein-4 that forms differential heteromeric complexes with bone
 RT morphogenetic protein type I receptors.";
 RL J. Biol. Chem. 270:22522-22526(1995).
 RN [3]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=95197572; PubMed=7890683;
 RA Kawabata M., Chytil A., Moses H.L.;
 RT "Cloning of a novel type II serine/threonine kinase receptor through
 RT interaction with the type I transforming growth factor-beta
 RT receptor.";
 RL J. Biol. Chem. 270:5625-5630(1995).
 RN [4]
 RP VARIANTS PPH1 GLN-491 AND TRP-491.
 RX MEDLINE=20395844; PubMed=10903931;
 RA Deng Z., Morse J.H., Slager S.L., Cuervo N., Moore K.J., Venetos G.,
 RA Kalachikov S., Cayanis E., Fischer S.G., Barst R.D., Hodge S.E.,
 RA Knowles J.A.;
 RT "Familial primary pulmonary hypertension (gene PPH1) is caused by
 RT mutations in the bone morphogenetic protein receptor-II gene.";
 RL Am. J. Hum. Genet. 67:737-744(2000).
 RN [5]
 RP VARIANTS PPH1 TYR-60; TYR-117 AND ARG-483.
 RX MEDLINE=20473811; PubMed=11015450;
 RA Thomson J.R., Machado R.D., Pauculo M.W., Morgan N.V., Humbert M.,
 RA Elliott G.C., Ward K., Yacoub M., Mikhail G., Rogers P., Newman J.H.,
 RA Wheeler L., Higenbottam T., Gibbs J.S.R., Egan J., Crozier A.,
 RA Pascock A., Allcock R., Corris P., Loyd J.E., Trembath R.C.;
 RA Nichols W.C.;
 RT "Sporadic primary pulmonary hypertension is associated with germline
 RT mutations of the gene encoding BMPR-II, a receptor member of the
 RT TGF-beta family.";
 RL J. Med. Genet. 37:741-745(2000).
 RN [6]
 RP VARIANTS PPH1 TRP-118; TYR-347 AND GLY-485.
 RX MEDLINE=20428187; PubMed=10973234;
 RA Lane K.B., Machado R.D., Pauculo M.W., Thomson J.R.,
 RA Phillips J.A. IIR, Loyd J.E., Nichols W.C., Trembath R.C., Aldred M.,
 RA Brannon C.A., Conneally P.M., Foroud T., Fretwell N., Gaddipati R.,
 RA Koller D., Loyd E.J., Morgan N.V., Newman J.H., Prince M.A.,
 RA Villarino Gueell C., Wheeler L.;
 RT "Heterozygous germline mutations in BMPR2, encoding a TGF-beta
 RT receptor, cause familial primary pulmonary hypertension.";
 RL Nat. Genet. 26:81-84(2000).
 RN [7]
 RP VARIANTS PPH1 ARG-123; SER-123; ARG-420 AND THR-512, VARIANT ASP-224,
 RP AND CHARACTERIZATION OF VARIANT PPH1 GLY-485.
 RX MEDLINE=21063176; PubMed=11115378;
 RA Machado R.D., Pauculo M.W., Thomson J.R., Lane K.B., Morgan N.V.,
 RA Wheeler L., Phillips J.A. IIR, Newman J.H., Williams D., Galie N.,
 RA Manes A., McNeill K., Yacoub M., Mikhail G., Rogers P., Corris P.,
 RA Humbert M., Donnai D., Martensson G., Tranebjaerg L., Loyd J.E.,
 RA Trembath R.C., Nichols W.C.;

RT "BMPR2 haploinsufficiency as the inherited molecular mechanism for
 RT primary pulmonary hypertension.";
 RL Am. J. Hum. Genet. 68:92-102(2001).
 CC -1- FUNCTION: BINDS TO BMP-7, BMP-2 AND, LESS EFFICIENTLY, BMP-4.
 CC BINDING IS WEAK BUT ENHANCED BY THE PRESENCE OF TYPE I RECEPTORS
 CC FOR BMPs.
 CC -1- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
 CC -1- SUBUNIT: HETERODIMERIZE WITH TYPE-I RECEPTORS.
 CC -1- SUBCELLULAR LOCATION: Type I membrane protein.
 CC -1- TISSUE SPECIFICITY: HIGHLY EXPRESSED IN HEART AND LIVER.
 CC -1- DISEASE: Defects in BMPR2 are the cause of primary pulmonary
 CC hypertension (PPH1) [MIM:178600]; a rare autosomal dominant
 CC disorder characterized by plexiform lesions of proliferating
 CC endothelial cells in pulmonary arterioles. The lesions lead to
 CC elevated pulmonary arterial pressure, right ventricular failure,
 CC and death. The disease can occur from infancy throughout life and
 CC it has a mean age at onset of 36 years. Penetrance is reduced.
 CC Although familial PPH1 is rare, cases secondary to known
 CC etiologies are more common and include those associated with the
 CC appetite-suppressant drugs.
 CC -1- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.
 CC TGFb RECEPTOR SUBFAMILY.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
 CC or send an email to license@sib-sib.ch).
 CC -----
 CC EMBL: Z48923; CAA88759.1; -;
 CC EMBL: D50516; BAA09094.1; -;
 CC EMBL: U20165; AAC50105.1; -;
 CC PIR: I38935; I38935
 CC GeneW: HGNC:1078; BMPR2.
 CC MIM: 600799; -;
 CC MIM: 178600; -;
 CC GO: GO:0005887; C: Integral to plasma membrane; TAS.
 CC GO: GO:0005515; F: protein binding activity; TAS.
 CC GO: GO:0007178; P: transmembrane receptor protein serine/threo. . . ; TAS.
 CC InterPro: IPR000472; Activin_rec.
 CC InterPro: IPR000719; Prot_Kinase.
 CC InterPro: IPR002290; Ser_thr_pKinase.
 CC Pfam: PF01064; Activin_rec1.
 CC Pfam: PF00069; pKinase; 1.
 CC ProDom: PD000001; Prot_kinase; 1.
 CC PROSITE: PS00107; PROTEIN_KINASE_ATP; 1.
 CC PROSITE: PS00108; PROTEIN_KINASE_ST; FALSE_NEG.
 CC PROSITE: PS50011; PROTEIN_KINASE_DOM; 1.
 CC KEGG: Receptor; Transferase; Serine/threonine-protein kinase; ATP-binding;
 CC Transmembrane; Glycoprotein; Signal; Polymorphism; Disease mutation.
 CC SIGNAL 1 26
 CC CHAIN 27 1038
 CC -----
 CC BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE
 CC II.
 CC EXTRACELLULAR (POTENTIAL).
 CC POTENTIAL.
 CC CYTOPLASMIC (POTENTIAL).
 CC PROTEIN KINASE.
 CC ATP (BY SIMILARITY).
 CC ATP (BY SIMILARITY).
 CC BY SIMILARITY.
 CC POLY-SER.
 CC POLY-THR.
 CC POLY-ASN.
 CC N-LINKED (GLCNAc. . .) (POTENTIAL).
 CC N-LINKED (GLCNAc. . .) (POTENTIAL).
 CC N-LINKED (GLCNAc. . .) (POTENTIAL).
 CC C->Y (in PPH1).
 CC /FTId=VAR_013670.
 CC C->Y (in PPH1).
 CC /FTId=VAR_013671.
 CC C->W (in PPH1).
 CC -----
 CC VARIANT 118 118

```

FT  VARIANT 123 123 /FTID=VAR_013672.
FT  VARIANT 123 123 C -> R (in PPH1).
FT  VARIANT 123 123 /FTID=VAR_013673.
FT  VARIANT 224 224 C -> S (in PPH1).
FT  VARIANT 224 224 /FTID=VAR_013674.
FT  VARIANT 347 347 E -> D.
FT  VARIANT 347 347 /FTID=VAR_013675.
FT  VARIANT 420 420 C -> Y (in PPH1).
FT  VARIANT 420 420 /FTID=VAR_013676.
FT  VARIANT 483 483 C -> R (in PPH1).
FT  VARIANT 483 483 /FTID=VAR_013677.
FT  VARIANT 485 485 C -> R (in PPH1).
FT  VARIANT 485 485 /FTID=VAR_013678.
FT  VARIANT 491 491 D -> G (in PPH1; complete loss of
FT  VARIANT 491 491 function).
FT  VARIANT 491 491 /FTID=VAR_013679.
FT  VARIANT 491 491 R -> Q (in PPH1; sporadic).
FT  VARIANT 491 491 /FTID=VAR_013680.
FT  VARIANT 512 512 R -> W (in PPH1).
FT  VARIANT 512 512 /FTID=VAR_013681.
FT  VARIANT 519 519 K -> T (in PPH1).
FT  VARIANT 519 519 /FTID=VAR_013682.
FT  VARIANT 519 519 N -> R (in PPH1).
FT  VARIANT 519 519 /FTID=VAR_013683.
FT  VARIANT 828 828 G -> R (in REF. 1).
FT  VARIANT 828 828 /FTID=VAR_013684.
FT  VARIANT 1038 AA; 115201 MM; 1389923CE574B913 CRC64.

```

```

Query Match 51.5%; Score 51; DB 1; Length 1038;
Best Local Similarity 66.7%; Pred. No. 21;
Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

```

```

Oy 3 PPKMPMPW 11
Db 8 PPKMPMPW 16

```

```

RESULT 5
ATP8 CORN STANDARD; PRT; 55 AA.
AC Q9TB16;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE ATP synthase protein 8 (EC 3.6.3.14) (ATPase subunit 8) (A6L).
GN MTP8 OR ATP8.
OS Corythaeoides concolor (Grey go-away-bird).
OG Mitochondrion.
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Aves; Neognathae; Musophagiformes; Musophagidae;
OC Corythaeoides.
OX NCBI_TaxID=103956;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=99416451; PubMed=10486983;
RA Hughes J.M., Baker A.J.;
RT "Phylogenetic relationships of the enigmatic hoatzin (Opisthocomus
RT hoatzin) resolved using mitochondrial and nuclear gene sequences.";
RL Mol. Biol. Evol. 16:1300-1307(1999).
CC -1- FUNCTION: THIS IS ONE OF THE CHAINS OF THE NONENZYMATIC COMPONENT
CC (CF0) SUBUNIT OF THE MITOCHONDRIAL ATPASE COMPLEX.
CC -1- CATALYTIC ACTIVITY: ATP + H(2)O + H(+) (in) = ADP + phosphate +
CC H(+) (out).
CC -1- SUBCELLULAR LOCATION: Membrane-bound.
CC -1- SIMILARITY: BELONGS TO THE ATPASE PROTEIN 8 FAMILY.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).

```

```

DR EMBL: AF168039; AAD56467.1; -.
DR InterPro: IPR001421; ATPase_mlt.
DR Pfam: PF00895; ATP-synt_8; 1.
KW Hydrogen ion transport; CF(0); Mitochondrion; Transmembrane.
SQ SEQUENCE 55 AA; 6485 MW; 973552DB0E918AD CRC64;

```

```

Query Match 50.5%; Score 50; DB 1; Length 55;
Best Local Similarity 75.7%; Pred. No. 2;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Oy 2 LPPKMPW 8
Db 48 LPPKMPW 54

```

```

RESULT 6
ADRO BOVIN STANDARD; PRT; 492 AA.
AC P08165; Q95KN8;
DT 01-AUG-1988 (Rel. 08, Created)
DT 15-JUL-1998 (Rel. 36, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE NADPH:adrenodoxin oxidoreductase, mitochondrial precursor
DE (EC 1.18.1.2) (Adrenodoxin reductase) (AR) (ferredoxin-NADP(+)
DE reductase).
GN PDXR OR ADXR.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Bovinae; Bos.
OX NCBI_TaxID=9913;
RN [1]
RP SEQUENCE FROM N.A., AND ALTERNATIVE SPLICING.
RX MEDLINE=94177140; PubMed=8130787;
RA Takata Y., Sagara Y., Kono A., Sekimizu K., Horuchi T.;
RT "Gene structure of bovine adrenodoxin reductase.";
RL Biol. Pharm. Bull. 16:1200-1206(1993).
RN [2]
RP SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.
RX MEDLINE=88198050; PubMed=3448086;
RA Sagara Y., Takata Y., Miyata T., Hara T., Horuchi T.;
RT "Cloning and sequence analysis of adrenodoxin reductase cDNA from
RT bovine adrenal cortex.";
RL J. Biochem. 102:1333-1336(1987).
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE=87270696; PubMed=3038094;
RA Nonaka Y., Murakami H., Yabusaki Y., Kuramitsu S., Kagamiyama H.,
RA Yamano T., Okamoto M.;
RT "Molecular cloning and sequence analysis of full-length cDNA for mRNA
RT of adrenodoxin oxidoreductase from bovine adrenal cortex.";
RL Biochem. Biophys. Res. Commun. 145:1239-1247(1987).
RN [4]
RP SEQUENCE FROM N.A.
RX MEDLINE=89170752; PubMed=2924777;
RA Hanukoglu I., Gutfinger T.;
RT "cDNA sequence of adrenodoxin reductase. Identification of NADP-
RT binding sites in oxidoreductases.";
RL Eur. J. Biochem. 180:479-484(1989).
RN [5]
RP SEQUENCE OF N-TERMINUS, AND PARTIAL SEQUENCE.
RX MEDLINE=88082777; PubMed=3691502;
RA Hanukoglu I., Gutfinger T., Hanu M., Shively J.E.;
RT "Isolation of a cDNA for adrenodoxin reductase (ferredoxin-NADP+
RT reductase). Implications for mitochondrial cytochrome P-450 systems.";
RL Eur. J. Biochem. 169:449-455(1987).
RN [6]
RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 33-492.
RX TISSUE=Adrenal gland;
RX MEDLINE=9929392; PubMed=10369776;
RA Ziegler G.A., Vornheim C., Hanukoglu I., Schulz G.E.;

```

RT "The structure of adrenodoxin reductase of mitochondrial P450 systems:
RT election transfer for steroid biosynthesis.";
RL J. Mol. Biol. 289:981-990(1999).
[7]
RP X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS).
RX MEDLINE-20455764; PubMed-10998235;
RA Ziegler G.A., Schulz G.E.;
RT "Crystal structures of adrenodoxin reductase in complex with NADP+ and
RT NADPH suggesting a mechanism for the electron transfer of an enzyme
RT family";
RL Biochemistry 39:10986-10995(2000).
[8]
RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF COMPLEX WITH ADRENODOXIN.
RX MEDLINE-21264735; PubMed-11053423;
RA Mueller J.J., Lapko A., Bourenkov G., Ruckpaul K., Heinemann U.;
RT "Adrenodoxin reductase-adrenodoxin complex structure suggests electron
RT transfer path in steroid biosynthesis";
RL J. Biol. Chem. 276:2786-2789(2001).
CC -I- FUNCTION: SERVES AS THE FIRST ELECTRON TRANSFER PROTEIN IN ALL THE
CC MITOCHONDRIAL P450 SYSTEMS, INCLUDING CHOLESTEROL SIDE CHAIN
CC CLEAVAGE IN ALL STEROIDOGENIC TISSUES, STEROID 11-BETA
CC HYDROXYLATION IN THE ADRENAL CORTEX, 25-OH-VITAMIN D3-24
CC HYDROXYLATION IN THE KIDNEY, AND STEROL C-27 HYDROXYLATION IN THE
CC LIVER.
CC -I- CATALYTIC ACTIVITY: Reduced adrenodoxin + NADP(+) = oxidized
CC adrenodoxin + NADPH.
CC -I- COFACTOR: FAD.
CC -I- PATHWAY: CHOLESTEROL SIDE-CHAIN-CLEAVAGE SYSTEM.
CC -I- SUBUNIT: Monomer.
CC -I- SUBCELLULAR LOCATION: Mitochondrial matrix.
CC -I- ALTERNATIVE PRODUCTS:
CC Event-Alternative splicing; Named isoforms=2;
CC Name-Short;
CC IsoId=P08165-1; Sequence=Displayed;
CC Name=Long;
CC IsoId=P08165-2; Sequence=VSP_003415;
CC Note=Represents 10-20% of all adrenodoxin reductase mRNAs and
CC seems to be inactive;
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
CC
DR EMBL; D83475; BA011921.1; -;
DR EMBL; D83472; BA011921.1; JOINED.
DR EMBL; D83473; BA011921.1; JOINED.
DR EMBL; D83474; BA011921.1; JOINED.
DR EMBL; M17029; AAA30362.1; -;
DR EMBL; D00211; BAA00150.1; -;
DR EMBL; X13736; CAA32002.1; -;
DR PIR; JT0751; JT0751.
DR PDB; 1CJC; 12-APR-99.
DR PDB; 1E1L; 24-SEP-00.
DR PDB; 1E1K; 24-SEP-00.
DR PDB; 1E1M; 24-SEP-00.
DR PDB; 1E6E; 09-AUG-01.
DR PDB; 1E6F; 09-AUG-01.
DR InterPro: IPR000759; Adnrx_reductase.
DR PRINTS: PR00419; ADXRDTASE.
KW Electron transport; Oxidoreductase; Flavoprotein; NADP; FAD;
KW Mitochondrion; Transist peptide; Alternative splicing; 3D-structure.
KW TRANSIT 1 32 MITOCHONDRION
FT CHAIN 33 492 NADPH:ADRENODOXIN OXIDOREDUCTASE.
FT VARSPLIC 204 204 E -> EVLLLCQ (in isoform long).
FT /Frid=VSP_003415.
FT G -> R (IN REF. 3).
FT FGVAPEDEPKVKNVI -> VWLALITPSRMML (IN REF. 3).
FT QDAYH -> RYRIIL (IN REF. 3).
FT CONFLICT 124 128

FT CONFLICT 268
FT CONFLICT 317
FT CONFLICT 323
FT CONFLICT 333
FT CONFLICT 352
FT STRAND 40
FT STRAND 44
FT STRAND 48
FT STRAND 60
FT STRAND 65
FT STRAND 69
FT STRAND 77
FT STRAND 78
FT STRAND 81
FT STRAND 82
FT STRAND 85
FT STRAND 86
FT STRAND 88
FT STRAND 92
FT STRAND 93
FT STRAND 101
FT STRAND 102
FT STRAND 104
FT STRAND 105
FT STRAND 106
FT STRAND 110
FT STRAND 114
FT STRAND 115
FT STRAND 117
FT STRAND 118
FT STRAND 120
FT STRAND 126
FT STRAND 129
FT STRAND 132
FT STRAND 138
FT STRAND 139
FT STRAND 145
FT STRAND 148
FT STRAND 150
FT STRAND 151
FT STRAND 152
FT STRAND 154
FT STRAND 162
FT STRAND 163
FT STRAND 164
FT STRAND 166
FT STRAND 169
FT STRAND 170
FT STRAND 176
FT STRAND 183
FT STRAND 187
FT STRAND 197
FT STRAND 200
FT STRAND 203
FT STRAND 204
FT STRAND 205
FT STRAND 210
FT STRAND 217
FT STRAND 218
FT STRAND 223
FT STRAND 227
FT STRAND 232
FT STRAND 234
FT STRAND 246
FT STRAND 247
FT STRAND 249
FT STRAND 250
FT STRAND 251
FT STRAND 254
FT STRAND 257
FT STRAND 260
FT STRAND 262
FT STRAND 266
FT STRAND 269
FT STRAND 272
FT STRAND 286
FT STRAND 291
FT STRAND 298
FT STRAND 299
FT STRAND 302
FT STRAND 307
FT STRAND 310
FT STRAND 317
FT STRAND 320
FT STRAND 324
FT STRAND 335
FT STRAND 338
FT STRAND 340
FT STRAND 342
FT STRAND 343
FT STRAND 353
FT STRAND 359
FT STRAND 363
FT STRAND 364
FT STRAND 371
FT STRAND 375
FT STRAND 379
FT STRAND 380
FT STRAND 383
FT STRAND 384
FT STRAND 385
FT STRAND 386
FT STRAND 387
FT STRAND 388
FT STRAND 389
FT STRAND 390
FT STRAND 392
FT STRAND 393
FT STRAND 394
FT STRAND 396
FT STRAND 398
FT STRAND 399
FT STRAND 402
FT STRAND 404
FT STRAND 405
FT STRAND 428

K -> R (IN REF. 3).
PS -> RL (IN REF. 3).
RAGRIAYTR -> ARRSAMOSPE (IN REF. 3).
TRAVPTGVEDL -> HPSAMWCGGP (IN REF. 3).

Query Match 50.5%; Score 50; DB 1; Length 492;

Best Local Similarity 66.7%; Pred. No. 14;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3 PPKWMPWP 11
1 1 1 1 1
Db 3 PPKWMPWP 11

RESULT 7

ATP8_PELSU STANDARD; PRT; 55 AA.
AC 079674;
DT 15-JUL-1999 (Rel. 38, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last sequence update)
DE 28-FEB-2003 (Rel. 41, Last annotation update)
GN ATP synthase protein 8 (EC 3.6.3.14) (ATPase subunit 8) (A6L).
OS Pelomedusa subrufa (African side-necked turtle).
OC Mitochondrion.
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Testudines; Pleurodira; Pelomedusidae; Pelomedusa.
OX NCBI_TaxID=44522;
RN [1]
RP SEQUENCE FROM N.A.
RA Zaroya R.;
RL Submitted (DEC-1997) to the EMBL/Genbank/DBJ databases.
CC -1- FUNCTION: THIS IS ONE OF THE CHAINS OF THE NONENZYMATIC COMPONENT
(CF(0) SUBUNIT) OF THE MITOCHONDRIAL ATPase COMPLEX.
CC -1- CATALYTIC ACTIVITY: ATP + H(2)O + H(+)(in) = ADP + phosphate +
H(+)(out).
CC -1- SIMILARITY: BELONGS TO THE ATPase PROTEIN 8 FAMILY.
CC -----

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----

CC EMBL: AF039066; AAD05054.1; -;
CC DR PIR: T11105; T11105.
CC DR InterPro: IPR001421; ATPase8_mit.
CC DR Pfam: PF00895; ATP-synt_8; 1.
CC KM Hydrogen ion transport; CF(0); Mitochondrion; Transmembrane.
CC FT TRANSMEM 4 24 POTENTIAL.
CC SQ SEQUENCE 55 AA; 6536 MW; D8D4BC8F8651A001 CRC64;

Query Match 48.5%; Score 48; DB 1; Length 55;
Best Local Similarity 71.4%; Pred. No. 3.5;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2 LFWKMPW 8
: 1 1 1 1 1
Db 48 MPWTMPW 54

RESULT 8

ELO1_HUMAN STANDARD; PRT; 279 AA.
AC Q9BW60; Q9NVN9; Q9Y396;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DE 15-SEP-2003 (Rel. 42, Last annotation update)
DE Elongation of very long chain fatty acids protein 1 (CGI-88).
GN ELOVL1 OR SSC1.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.

RA MEDLINE=20272150; PubMed=10810093;
RA Lai C.-H., Chou C.-Y., Chang L.-Y., Liu C.-S., Lin W.-C.;
RT "Identification of novel human genes evolutionarily conserved in
RT Caenorhabditis elegans by comparative proteomics";
RL Genome Res. 10:703-713(2000).
RN [2]

RP SEQUENCE FROM N.A.
RA Isogai T., Ota T., Hayashi K., Sugiyama T., Otsuki T., Suzuki Y.,
RA Nishikawa T., Nagai K., Sugano S., Aotsuka S., Yoshikawa Y.,
RA Matsunawa H., Ishii S., Kawai Y., Saito K., Yamamoto J., Wakamatsu A.,
RA Nakamura Y., Nagahari K., Masuko Y., Sasaki N.;
RT "NEO human cDNA sequencing project";
RL Submitted (FEB-2000) to the EMBL/Genbank/DBJ databases.
RN [3]

RP SEQUENCE FROM N.A.
RC TISSUE=Kidney;
RX MEDLINE=22388257; PubMed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Scheffer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Wax S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McKernan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hultk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Rodriguez R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butlerfield Y.S.N., Krzywinski M.T., Skalska U., Smalls D.E.,
RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length
RT human and mouse cDNA sequences";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).

CC -1- FUNCTION: Could be implicated in tissue-specific synthesis of very
CC long chain fatty acids and sphingolipids. May catalyze one or both
CC of the reduction reaction in fatty acid elongation, i.e.,
CC conversion of beta-ketoacyl CoA to beta-hydroxyacyl CoA or
CC reduction of trans-2-enoyl CoA to the saturated acyl CoA
CC derivative (By similarity).
CC -1- SUBCELLULAR LOCATION: Integral membrane protein. Endoplasmic
CC reticulum (Potential).
CC -1- SIMILARITY: BELONGS TO THE ELO FAMILY.
CC -1- CAUTION: Ref.1 sequence differs from that shown due to a
CC frameshift in position 189.
CC -----

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----

CC EMBL: AF151846; AAD34083.1; ALF_FRAME.
CC DR EMBL: AK001653; BAA91813.1; -;
CC DR EMBL: BC000618; AAH00618.1; -;
CC DR Genew: HGNC:14418; ELOVL1.
CC DR InterPro: IPR002076; GNS1_SUR4.
CC DR Pfam: PF01151; ELO_1.
CC DR PROSITE: PS01188; ELO_1.

CC Fatty acid biosynthesis; Transmembrane; Endoplasmic reticulum.
CC KW TRANSMEM 23 43 POTENTIAL.
CC FT TRANSMEM 61 81 POTENTIAL.
CC FT TRANSMEM 176 196 POTENTIAL.
CC FT TRANSMEM 201 221 POTENTIAL.
CC FT TRANSMEM 231 251 POTENTIAL.
CC FT TRANSMEM 275 277 POTENTIAL.

CC SITE 275 277 ENDOPLASTIC RETICULUM RETRIEVAL MOTIF
CC (POTENTIAL).
CC FT CONFLICT 68 68 S -> P (IN REF. 2).
CC FT

SQ SEQUENCE 279 AA: 32663 MW: B168EE4C7EAF92A6 CRC64;
 Query Match 48.0%; Score 47.5; DB 1; Length 279;
 Best Local Similarity 66.7%; Pred. No. 17;
 Matches 6; Conservative 1; Mismatches 1; Indels 1; Gaps 1;

QY 1 ILPMKMPMW 9
 Db 147 VLPMSW-WW 154

RESULT 9
 ELO1 MOUSE STANDARD: PRT: 279 AA.
 ID 09JUL5: 09D1B2: 28-FEB-2003 (Rel. 41, Created)
 AC 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE Elongation of very long chain fatty acids protein 1.
 GN ELOVL1 OR SSCI.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN-BALB/C; TISSUE=Liver;
 RX MEDLINE=20253178; PubMed=10791983;
 RA Twilix P., Westberg R., Silve S., Asadi A., Jakobsson A., Cannon B.,
 RT "Role of a new mammalian gene family in the biosynthesis of very long
 chain fatty acids and sphingolipids";
 RL J. Cell Biol. 149:707-718(2000).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Breast tumor;
 RX MEDLINE=2238257; PubMed=12477932;
 RA Strusberg R.L., Collins F.S., Wagner L., Shennan C.M., Schuler G.D.,
 RA Klausner R.D., Collins F.S., Wagner L., Shennan C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Scheffer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carinci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
 RA Bosk S.A., McKernan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulik S.W.,
 RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahy J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smallus D.E.,
 RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.,
 RT "Generation and initial analysis of more than 15,000 full-length
 human and mouse cDNA sequences";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [3]
 RP SEQUENCE OF 78-279 FROM N.A.
 RC STRAIN=C57BL/6J; TISSUE=Embryo;
 RX MEDLINE=21085660; PubMed=11217851;
 RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
 RA Arakawa T., Hara A., Fukunishi Y., Kono H., Adachi J., Fukuda S.,
 RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamana K.I.,
 RA Saito T., Okazaki Y., Gojibori T., Bono H., Kasukawa T., Saito R.,
 RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
 RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochia H.,
 RA Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,
 RA Schiml L.M., Staudt F., Suzuki R., Tomita M., Wagner L., Washio T.,
 RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Basho I.,
 RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
 RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
 RA Gustinich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,

RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
 RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
 RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
 RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whitaker C., Wilming L.,
 RA Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawai H., Kohitsuki S.,
 RA Hayashizaki Y.;
 RA "Functional annotation of a full-length mouse cDNA collection";
 RL Nature 409:685-690(2001).
 RT
 CC -1- FUNCTION: Could be implicated in tissue-specific synthesis of very
 long chain fatty acids and sphingolipids. May catalyze one or both
 of the reduction reaction in fatty acid elongation, i.e.,
 conversion of beta-ketoacyl CoA to beta-hydroxyacyl CoA or
 reduction of trans-2-enoyl CoA to the saturated acyl CoA
 derivative.
 CC -1- SUBCELLULAR LOCATION: Integral membrane protein. Endoplasmic
 reticulum (potential).
 CC -1- TISSUE SPECIFICITY: Expressed in a broad variety of tissues.
 CC Highly expressed in stomach, lung, kidney, skin and intestine.
 CC Moderately expressed in white adipose tissue, liver, spleen,
 CC brain, brown adipose tissue, heart and muscle. Weakly expressed in
 CC testis.
 CC
 CC -1- SIMILARITY: BELONGS TO THE ELO FAMILY.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL Outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL; AF170907; AAF72572.1; -;
 CC EMBL; BC006735; AAH06735.1; -;
 CC EMBL; AK003743; BAB22975.1; -;
 CC MGD; MGI:1858959; Elov11.
 CC InterPro; IPR002076; GMS1_SUR4.
 CC Pfam; PF01151; ELO; 1.
 CC PROSITE; PS01188; ELO; 1.
 CC Fatty acid biosynthesis; Transmembrane; Endoplasmic reticulum.
 CC TRANSMEM 23 43
 CC TRANSMEM 61 81 POTENTIAL.
 CC TRANSMEM 176 196 POTENTIAL.
 CC TRANSMEM 203 223 POTENTIAL.
 CC TRANSMEM 231 251 POTENTIAL.
 CC SITE 275 277 ENDOPLASMIC RETICULUM RETRIEVAL MOTIF
 CC (POTENTIAL).
 CC YE -> MR (IN REF. 3).
 FT CONFLICT 78 79
 SQ SEQUENCE 279 AA: 32678 MW: CA5A1CF5FD52F76 CRC64;
 Query Match 48.0%; Score 47.5; DB 1; Length 279;
 Best Local Similarity 66.7%; Pred. No. 17;
 Matches 6; Conservative 1; Mismatches 1; Indels 1; Gaps 1;

QY 1 ILPMKMPMW 9
 Db 147 VLPMSW-WW 154

RESULT 10
 ATP8_GADMO STANDARD: PRT: 55 AA.
 ID ATP8_GADMO
 AC P15996: 01-APR-1990 (Rel. 14, Created)
 DT 01-APR-1990 (Rel. 14, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE ATP synthase protein 8 (EC 3.6.3.14) (ATPase subunit 8) (A6L).
 GN MTATP8 OR ATP8
 CN Gadus morhua (Atlantic cod).
 OS Gadus morhua (Atlantic cod).
 OC Mitochondrion.
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
 OC Acanthomorpha; Paracanthopterygii; Gadiformes; Gadidae; Gadus.
 OX NCBI_TaxID=8049;

RM [1]
RP SEQUENCE FROM N.A.
RC STRAIN-Norwegian coastal 1; TISSUE=Liver;
RX MEDLINE=90174958; PubMed=2308841;
RA Johansen S., Gaddal P.H., Johansen T.;
RT "Organization of the mitochondrial genome of Atlantic cod, *Gadus morhua*.";
RL Nucleic Acids Res. 18:411-419(1990).
RM [2]
RP SEQUENCE FROM N.A.
RC STRAIN-Norwegian coastal 1;
RX MEDLINE=96414925; PubMed=8817926;
RA Johansen S., Bakke I.;
RT "The complete mitochondrial DNA sequence of Atlantic cod (*Gadus morhua*): relevance to taxonomic studies among codfishes.";
RL Mol. Mar. Biol. Biotechnol. 5:203-214(1996).
CC -1- FUNCTION: THIS IS ONE OF THE CHAINS OF THE NONENZYMATIC COMPONENT (CF(0)) SUBUNIT OF THE MITOCHONDRIAL ATPASE COMPLEX.
CC -1- CATALYTIC ACTIVITY: ATP + H(2)O + H(+) (In) = ADP + phosphate + H(+) (Out).
CC -1- SUBCELLULAR LOCATION: Membrane-bound.
CC -1- SIMILARITY: BELONGS TO THE ATPASE PROTEIN 8 FAMILY.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).
CC -----
DR EMBL: X17659; CA35655.1; -
DR EMBL: X99772; CA68110.1; -
DR PIR: S08424; S08424.
DR InterPro: IPR001421; ATPase8_mit.
DR Pfam: PF00895; ATP-synt_8; 1.
DR Hydrogen ion transport; CF(0); Mitochondrion; Transmembrane.
KW TRANSMEM 4
FT TRANSMEM 24
SQ SEQUENCE 55 AA; 6481 MW; E85C81E63DB48B15 CRC64;
Query Match 47.5%; Score 47; DB 1; Length 55;
Best Local Similarity 83.3%; Pred. No. 4.7;
Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3 PMKMPW 8
DB 49 PMNMPW 54
RESULT 11
ATP8_ONCMY
ID ATP8_ONCMY STANDARD; PRT; 55 AA.
AC P48179;
DT 01-FEB-1996 (Rel. 33, Created)
DT 01-FEB-1996 (Rel. 33, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE ATP synthase protein 8 (EC 3.6.3.14) (ATPase subunit 8) (A6L).
GN MWT8B OR ATP8.
OS Oncorhynchus mykiss (Rainbow trout) (*Salmo gairdneri*), and
OS Salmo salar (Atlantic salmon).
OC Mitochondrion.
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei;
OC Protacanthopterygii; Salmoniformes; Salmonidae; Oncorhynchus.
OX NCBI_TaxID=8030;
RN [1]
RP SEQUENCE FROM N.A.
RC SPECIES=O.mykiss; TISSUE=Liver;
RX MEDLINE=96139027; PubMed=8587139;
RA Zardoya R., Garrido-Pertier A., Bautista J.M.;
RT "The complete nucleotide sequence of the mitochondrial DNA genome of the rainbow trout, *Oncorhynchus mykiss*.";
RL J. Mol. Evol. 41:942-951(1995).

RM [2]
RP SEQUENCE FROM N.A.
RC SPECIES=S.salar; TISSUE=Liver;
RX MEDLINE=20018174; PubMed=10548724;
RA Hurst C.D., Bartlett S.E., Davidson W.S., Bruce I.J.;
RT "The complete mitochondrial DNA sequence of the Atlantic salmon, *Salmo salar*.";
RL Gene 239:237-242(1999).
RM [3]
RP SEQUENCE FROM N.A.
RC SPECIES=S.salar;
RA Arason U., Johnsen E., Rasmussen A.S.;
RT "The complete mitochondrial genome sequence of a teleost, *Salmo salar*, and comparisons with other salmoniformes.";
RL Submitted (MAR-1999) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: THIS IS ONE OF THE CHAINS OF THE NONENZYMATIC COMPONENT (CF(0)) SUBUNIT OF THE MITOCHONDRIAL ATPASE COMPLEX.
CC -1- CATALYTIC ACTIVITY: ATP + H(2)O + H(+) (In) = ADP + phosphate + H(+) (Out).
CC -1- SUBCELLULAR LOCATION: Membrane-bound.
CC -1- SIMILARITY: BELONGS TO THE ATPASE PROTEIN 8 FAMILY.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).
CC -----
DR EMBL: L29771; AAB03351.1; -
DR EMBL: U12143; AAD04737.1; -
DR PIR: AF133701; AAF61382.1; -
DR PIR: T09861; T09861.
DR PIR: T09951; T09951.
DR InterPro: IPR001421; ATPase8_mit.
DR Pfam: PF00895; ATP-synt_8; 1.
DR Hydrogen ion transport; CF(0); Mitochondrion; Transmembrane.
KW TRANSMEM 4
FT TRANSMEM 24
SQ SEQUENCE 55 AA; 6413 MW; D02920C3E346925F CRC64;
Query Match 47.5%; Score 47; DB 1; Length 55;
Best Local Similarity 83.3%; Pred. No. 4.7;
Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3 PMKMPW 8
DB 49 PMNMPW 54
RESULT 12
ATP8_PRODO
ID ATP8_PRODO STANDARD; PRT; 55 AA.
AC Q35416;
DT 15-JUL-1999 (Rel. 38, Created)
DT 15-JUL-1999 (Rel. 38, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE ATP synthase protein 8 (EC 3.6.3.14) (ATPase subunit 8) (A6L).
GN MWT8B OR ATP8.
OS *Protopterus dolloi* (Lungfish).
OC Mitochondrion.
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Dniptoi; Lepidosireniiformes; Protopteridae; Protopterus.
OX NCBI_TaxID=27779;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Egg;
RX MEDLINE=96271539; PubMed=8846902;
RA Zardoya R., Meyer A.;
RT "The complete nucleotide sequence of the mitochondrial genome of the lungfish (*Protopterus dolloi*) supports its phylogenetic position as a close relative of land vertebrates.";
RL Genetics 142:1249-1263(1996).

```

CC -!- FUNCTION: THIS IS ONE OF THE CHAINS OF THE NONENZYMATIC COMPONENT
CC (CF(0) SUBUNIT) OF THE MITOCHONDRIAL ATPASE COMPLEX.
CC -!- CATALYTIC ACTIVITY: ATP + H(2)O + H(+)(in) = ADP + phosphate +
CC H(+)(out).
CC -!- SUBCELLULAR LOCATION: Membrane-bound.
CC -!- SIMILARITY: BELONGS TO THE ATPASE PROTEIN 8 FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: LA2813; AAC38025.1; -.
CC DR PIR: S68132; S68132.
CC DR InterPro: IPR001421; ATPase8_mit.
CC DR Pfam: PF00895; ATP-synt_8; 1.
CC KW Hydrogen ion transport; CF(0); Mitochondrion; Transmembrane.
CC SQ SEQUENCE 55 AA; 6523 MW; 95343043B5B2DC53 CRC64;
CC
CC Query Match 47.5%; Score 47; DB 1; Length 55;
CC Best Local Similarity 83.3%; Pred. No. 4.7;
CC Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
CC
CC QY 3 PMKMPW 8
CC Db 49 PMNMPW 54
CC
CC RESULT 13
CC ATP8_SALAL STANDARD; PRT; 55 AA.
CC ID ATP8_SALAL
CC AC Q9XN27;
CC DT 16-OCT-2001 (Rel. 40, Created)
CC DT 16-OCT-2001 (Rel. 40, Last sequence update)
CC DT 28-FEB-2003 (Rel. 41, Last annotation update)
CC DE ATP synthase protein 8 (EC 3.6.3.14) (ATPase subunit 8) (A6L).
CC GN MTAtp8 OR ATP8 OR ATPASE8.
CC OS Salvelinus alpinus (Arctic char).
CC OG Mitochondrion.
CC OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
CC OC Actinopterygii; Neopterygii; Teleostei; Euteleostei;
CC OC Protacanthopterygii; Salmoniformes; Salmonidae; Salvelinus.
CC OX NCBI_TaxID=8036;
CC RN [1]
CC RP SEQUENCE FROM N.A.
CC RA Dolron S., Blier P.U., Bernatchez L.;
CC RT "A comparative analysis of complete sequence of mitochondrial genome
CC RT between brook char (Salvelinus fontinalis) and arctic char (S.
CC RT alpinus).";
CC RL Submitted (MAY-1999) to the EMBL/GenBank/DBJ databases.
CC CC -!- FUNCTION: THIS IS ONE OF THE CHAINS OF THE NONENZYMATIC COMPONENT
CC CC (CF(0) SUBUNIT) OF THE MITOCHONDRIAL ATPASE COMPLEX.
CC CC -!- CATALYTIC ACTIVITY: ATP + H(2)O + H(+)(in) = ADP + phosphate +
CC CC H(+)(out).
CC CC -!- SUBCELLULAR LOCATION: Membrane-bound.
CC CC -!- SIMILARITY: BELONGS TO THE ATPASE PROTEIN 8 FAMILY.
CC CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: AF154851; AAD41389.1; -.
CC DR InterPro: IPR001421; ATPase8_mit.
CC DR Pfam: PF00895; ATP-synt_8; 1.
CC KW Hydrogen ion transport; CF(0); Mitochondrion; Transmembrane.
CC SQ SEQUENCE 55 AA; 6455 MW; 71E430C2E346924A CRC64;

```

```

CC Query Match 47.5%; Score 47; DB 1; Length 55;
CC Best Local Similarity 83.3%; Pred. No. 4.7;
CC Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
CC
CC QY 3 PMKMPW 8
CC Db 49 PMNMPW 54
CC
CC RESULT 14
CC ATP8_SALFO STANDARD; PRT; 55 AA.
CC ID ATP8_SALFO
CC AC Q9XN35;
CC DT 16-OCT-2001 (Rel. 40, Created)
CC DT 16-OCT-2001 (Rel. 40, Last sequence update)
CC DT 28-FEB-2003 (Rel. 41, Last annotation update)
CC DE ATP synthase protein 8 (EC 3.6.3.14) (ATPase subunit 8) (A6L).
CC GN MTAtp8 OR ATP8 OR ATPASE8.
CC OS Salvelinus fontinalis (Brook trout) (Brook char).
CC OG Mitochondrion.
CC OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
CC OC Actinopterygii; Neopterygii; Teleostei; Euteleostei;
CC OC Protacanthopterygii; Salmoniformes; Salmonidae; Salvelinus.
CC OX NCBI_TaxID=8038;
CC RN [1]
CC RP SEQUENCE FROM N.A.
CC RA Dolron S., Blier P.U., Bernatchez L.;
CC RT "A comparative analysis of complete sequence of mitochondrial genome
CC RT between brook char (Salvelinus fontinalis) and arctic char (S.
CC RT alpinus).";
CC RL Submitted (MAY-1999) to the EMBL/GenBank/DBJ databases.
CC CC -!- FUNCTION: THIS IS ONE OF THE CHAINS OF THE NONENZYMATIC COMPONENT
CC CC (CF(0) SUBUNIT) OF THE MITOCHONDRIAL ATPASE COMPLEX.
CC CC -!- CATALYTIC ACTIVITY: ATP + H(2)O + H(+)(in) = ADP + phosphate +
CC CC H(+)(out).
CC CC -!- SUBCELLULAR LOCATION: Membrane-bound.
CC CC -!- SIMILARITY: BELONGS TO THE ATPASE PROTEIN 8 FAMILY.
CC CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: AF154850; AAD41376.1; -.
CC DR InterPro: IPR001421; ATPase8_mit.
CC DR Pfam: PF00895; ATP-synt_8; 1.
CC KW Hydrogen ion transport; CF(0); Mitochondrion; Transmembrane.
CC SQ SEQUENCE 55 AA; 6443 MW; D02930C2E346925F CRC64;
CC
CC Query Match 47.5%; Score 47; DB 1; Length 55;
CC Best Local Similarity 83.3%; Pred. No. 4.7;
CC Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
CC
CC QY 3 PMKMPW 8
CC Db 49 PMNMPW 54
CC
CC RESULT 15
CC ATP8_SCYCA STANDARD; PRT; 55 AA.
CC ID ATP8_SCYCA
CC AC Q79405;
CC DT 15-DEC-1998 (Rel. 37, Created)
CC DT 15-DEC-1998 (Rel. 37, Last sequence update)
CC DT 28-FEB-2003 (Rel. 41, Last annotation update)
CC DE ATP synthase protein 8 (EC 3.6.3.14) (ATPase subunit 8) (A6L).
CC GN MTAtp8 OR ATP8 OR ATPASE8.
CC OS Scyllorhinus canicula (Spotted dogfish) (Spotted catshark).
CC OG Mitochondrion.

```

CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Chondrichthyes;
 CC Elasmobranchii; Galeomorphi; Galeoidea; Carcharhiniformes;
 CC Scyliorhinidae; Scyliorhinus.
 OX NCBI_TaxID=7830;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Muscle;
 RX MEDLINE=98393590; PubMed=9725850;
 RA Delarbre C., Spruyt N., Delmarre C., Gallut C., Barriel V.,
 RA Janvier P., Laudet V., Gachelin G.;
 RT "The complete nucleotide sequence of the mitochondrial DNA of the
 dogfish, Scyliorhinus canicula.";
 RL Genetics 150:331-344(1998).
 CC -!- FUNCTION: THIS IS ONE OF THE CHAINS OF THE NONENZYMATIC COMPONENT
 CC (CF(0) SUBUNIT) OF THE MITOCHONDRIAL ATPASE COMPLEX.
 CC -!- CATALYTIC ACTIVITY: ATP + H(2)O + H(+) (in) = ADP + phosphate +
 CC H(+) (out).
 CC -!- SUBCELLULAR LOCATION: Membrane-bound.
 CC -!- SIMILARITY: BELONGS TO THE ATPASE PROTEIN 8 FAMILY.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@sib-sib.ch).
 CC -----
 DR EMBL: Y16067; CAA76023.1; -.
 DR PIR: T11304; T11304.
 DR InterPro: IPR001421; ATPase8_mlt.
 DR Pfam: PF00895; ATP-synt_8; 1.
 KM Hydrogen ion transport; CF(0); Mitochondrion; Transmembrane.
 FT TRANSMEM 4 24 POTENTIAL.
 SQ SEQUENCE 55 AA; 6607 MW; 075956C2A3DF05B9 CRC64;

Query Match 47.5%; Score 47; DB 1; Length 55;
 Best local Similarity 83.3%; Pred. No. 4.7;
 Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 3 PKKMPW 8
 |||||
 Db 49 PNMMPW 54

Search completed: October 2, 2003, 10:02:01
 Job time : 25 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 09:59:17 : Search time 105 Seconds
(without alignments)
31.949 Million cell updates/sec

Title: US-09-444-281-85
Perfect score: 99
Sequence: 1 ILPMKPMWPMWR 13

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 830525 seqs, 258052604 residues

Total number of hits satisfying chosen parameters: 830525

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

SPTREMBL_23:*
1: sp_archaea:*
2: sp_bacteria:*
3: sp_fungi:*
4: sp_human:*
5: sp_invertebrate:*
6: sp_mammal:*
7: sp_mhc:*
8: sp_organelle:*
9: sp_phage:*
10: sp_plant:*
11: sp_rodent:*
12: sp_virus:*
13: sp_vertebrate:*
14: sp_unclassified:*
15: sp_rvirts:*
16: sp_bacteriap:*
17: sp_archaeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	59.6	780	16	08PE93	08PE93 xanthomonas
2	57.6	723	12	09DUC4	09DUC4 tt virus.
3	55.6	49	12	09DTR0	09DTR0 tt virus.
4	55.6	152	2	08RPF4	08RPF4 desulfatob
5	55.6	208	16	08PBI7	08PBI7 xanthomonas
6	55.6	342	4	096BE4	096BE4 homo sapien
7	55.6	748	12	09DTR1	09DTR1 tt virus.
8	55.6	750	12	09DTR1	09DTR1 tt virus.
9	54.5	1173	12	09DTR1	09DTR1 human coron
10	54.5	1173	12	09DTR1	09DTR1 human coron
11	54.5	1173	12	09DTR1	09DTR1 human coron
12	54.5	1173	12	09DTR1	09DTR1 human coron
13	54.5	1383	12	084712	084712 porcine epi
14	54.5	1383	12	084712	084712 porcine epi
15	54.5	1383	12	084712	084712 porcine epi
16	54.5	1386	12	08Q98	08Q98 porcine epi

17	53.5	54.0	299	4	09Y4N1	09Y4N1 homo sapien
18	53	53.5	216	5	09W476	09W476 drosophila
19	53	53.5	257	17	08TW99	08TW99 methanopyru
20	53	53.5	328	12	08B9N6	08B9N6 rachiplusia
21	53	53.5	331	12	092380	092380 bombyx mori
22	53	53.5	600	5	08IGB8	08IGB8 drosophila
23	53	53.5	1245	3	09Y7V5	09Y7V5 trichoderma
24	52.5	53.0	640	2	0934J3	0934J3 prevotella
25	52.5	52.5	102	16	08P4Z9	08P4Z9 xanthomonas
26	52.5	52.5	105	16	08P4Z9	08P4Z9 xanthomonas
27	52.5	52.5	351	16	08DUN5	08DUN5 synechococc
28	51.5	51.5	55	8	09B6T0	09B6T0 eudromia el
29	51.5	51.5	298	17	08ZU59	08ZU59 pyrobaculum
30	51.5	51.5	530	4	013161	013161 homo sapien
31	51.5	51.5	689	16	08Y85	08Y85 anabena sp
32	50.5	51.0	214	5	09N9T4	09N9T4 leishmania
33	50.5	51.0	970	12	09YW19	09YW19 melanoplus
34	50.5	51.0	988	12	091HP7	091HP7 oedeleus as
35	50.5	50.5	55	8	08SEB4	08SEB4 elenia fal
36	50.5	50.5	83	16	09WYF1	09WYF1 thermotoga
37	50.5	50.5	327	16	09AUN3	09AUN3 oryza sativ
38	50.5	50.5	337	16	092Y02	092Y02 rhizobium m
39	50.5	50.5	466	4	075035	075035 homo sapien
40	50.5	50.5	746	12	09JH31	09JH31 tt virus.
41	49.5	50.0	157	5	09Y0E8	09Y0E8 drosophila
42	49.5	50.0	198	10	08G2X7	08G2X7 oryza sativ
43	49.5	50.0	296	2	068125	068125 rhodospirillum rubrum
44	49.5	50.0	310	11	08CB00	08CB00 mus musculus
45	49.5	50.0	806	10	09FGM0	09FGM0 arabidopsis

ALIGNMENTS

RESULT 1
08PE93
ID 08PE93
AC 08PE93
DT 01-OCT-2002 (TREMREL. 22, Created)
DT 01-OCT-2002 (TREMREL. 22, Last sequence update)
DE Hypothetical protein XCC0088.
XCC0088.
OS Xanthomonas campestris (pv. campestris).
OC Bacteria; Proteobacteria; Gammaproteobacteria; Xanthomonadales;
OC Xanthomonadaceae; Xanthomonas.
OX NCBI_TaxID=340;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC 33913 / NCPPB 528;
RX MEDLINE=22022145; PubMed=12024217;
RA da Silva A.C.R., Ferro J.A., Reinach F.C., Farah C.S., Furlan L.R.,
RA Quaggio R.B., Monteiro-Vitorello C.B., Van Sluys M.A., Almeida N.F.,
RA Alves L.M.C., do Amaral A.M., Bertolini M.C., Camargo L.E.A.,
RA Camarotte G., Camarotte F., Cardozo J., Chamargo F., Ciapina L.P.,
RA Ciccarelli R.M.B., Coutinho L.V., Cursino-Santos J.R., El-Dorri H.,
RA Faria J.B., Ferreira A.J.S., Ferreira R.C.C., Ferro M.I.T.,
RA Fornighieri E.F., Franco M.C., Greggio C.C., Gruber A.,
RA Katsuyama A.M., Kishi L.T., Leite R.P., Lemos E.G.M., Lemos M.V.F.,
RA Locali E.C., Machado M.A., Madeira A.M.B.N., Martinez-Rossi N.M.,
RA Martins E.C., Meidants J., Menck C.F.M., Miyaki C.Y., Moon D.H.,
RA Moreira L.M., Novo M.T.M., Okura V.K., Oliveira M.C., Oliveira V.R.,
RA Pereira H.A., Rossi A., Sena J.A.D., Silva C., de Souza R.F.,
RA Spinoia L.A.F., Takita M.A., Tamura R.E., Teixeira E.C., Tezza R.I.D.,
RA Trindade dos Santos M., Truffi D., Tsai S.M., White F.F.,
RA Setubal J.C., Kitajima J.P.;
RT "Comparison of the genomes of two Xanthomonas pathogens with differing
RT host specificities";
RL Nature 417:459-463(2002).
DR EMBL: AE012102; AAC39407.1;
KW Hypothetical protein; Complete proteome.
SQ SEQUENCE 780 AA; 85074 MW; 12867434D1852549 CRC64;

Query Match 59.6%; Score 59; DB 16; Length 780;
 Best Local Similarity 75.0%; Pred. No. 13;
 Matches 6; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 4 WKPMW 11
 1 1 1 1 1 1
 148 WPMWPMW 155

RESULT 2

O9DUC4 PRELIMINARY; PRT; 723 AA.
 ID O9DUC4;
 AC O9DUC4;
 DT 01-MAR-2001 (TREMBLrel. 16, Created)
 DT 01-MAR-2001 (TREMBLrel. 16, Last sequence update)
 DT 01-MAR-2003 (TREMBLrel. 23, Last annotation update)
 DE ORF1.
 OS TT virus.
 OC Viruses; ssDNA viruses; unclassified ssDNA viruses.
 OX NCBI_TaxID=68887;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=MF-TTV9;
 RA Okamoto H.;
 RL Submitted (APR-2000) to the EMBL/GenBank/DBJ databases.
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=MF-TTV9;
 RX MEDLINE=20534983; PubMed=11080484;
 RA Okamoto H., Nishizawa T., Tawara A., Peng Y., Takahashi M.,
 RA Kishimoto J., Tanaka T., Miyakawa Y., Mayumi M.;
 RT "Species-specific TT viruses in humans and nonhuman primates and their
 RT phylogenetic relatedness";
 RL Virology 277:368-378(2000).
 DR EMBL: AB041959; BAB19313.1; -.
 DR InterPro: IPR001563; Serine_carboxypept.
 DR InterPro: IPR004219; Tyrosine_Unk.
 DR Pfam: PF02856; TT_ORF1; 1
 DR PROSITE: PS00131; CARBOXYPEPT_SER_SER; 1
 DR PROSITE: 723 AA; 85393 MW; 232D003096766344 CRC64;
 SO SEQUENCE

Query Match 57.6%; Score 57; DB 12; Length 73;
 Best Local Similarity 100.0%; Pred. No. 22;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 7 PMWPMR 13
 1 1 1 1 1 1 1
 2 PMWPMR 8

RESULT 3

O9D80 PRELIMINARY; PRT; 49 AA.
 ID O9D80;
 AC O9D80;
 DT 01-MAR-2001 (TREMBLrel. 16, Created)
 DT 01-MAR-2001 (TREMBLrel. 16, Last sequence update)
 DT 01-OCT-2002 (TREMBLrel. 22, Last annotation update)
 DE ORF1 (Fragment).
 OS TT virus.
 OC Viruses; ssDNA viruses; unclassified ssDNA viruses.
 OX NCBI_TaxID=68887;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=TYM9;
 RX MEDLINE=20568739; PubMed=11118348;
 RA Okamoto H., Nishizawa T., Tawara A., Takahashi M., Kishimoto J.,
 RA Sai T., Sugai Y.;
 RT "TT virus mRNAs detected in the bone marrow cells from an infected
 RT individual";
 RL Biochem. Biophys. Res. Commun. 279:700-707(2000).
 DR EMBL: AB050449; BAB19930.1; -.
 FT NON_TER 49
 RA SEQUENCE 49 AA; 7225 MW; 1DA6F8F1AB69AA43 CRC64;
 SO SEQUENCE

Query Match 55.6%; Score 55; DB 12; Length 49;
 Best Local Similarity 44.4%; Pred. No. 3; 6;
 Matches 8; Conservative 1; Mismatches 3; Indels 6; Gaps 1;

OY 2 LPKMPM-----WPMR 13
 : 1 1 1 1 1 1
 1 MAWTWWRORRRRWRWPMR 18

RESULT 4

O8RPF4 PRELIMINARY; PRT; 152 AA.
 ID O8RPF4;
 AC O8RPF4;
 DT 01-JUN-2002 (TREMBLrel. 21, Created)
 DT 01-JUN-2002 (TREMBLrel. 21, Last sequence update)
 DT 01-MAR-2003 (TREMBLrel. 23, Last annotation update)
 DE Hypothetical 16.9 kDa protein.
 OS Desulfotobacterium hafnense.
 OC Bacteria; Firmicutes; Clostridia; Clostridiales; Peptococcaceae;
 OC Desulfotobacterium.
 OX NCBI_TaxID=49338;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=DCB-2;
 RA Davis J.K., Tiedje J.M.;
 RT "Sequence and transcriptional analysis of reductive dehalogenase genes
 RT of Desulfotobacterium";
 RL Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL: AF403185; AAL87800.1; -.
 DR InterPro: IPR006311; Tat.
 DR TIGRFAMs: TIGR01409; Tat_signal_seq; 1.
 KW Hypothetical protein.
 SO SEQUENCE 152 AA; 16876 MW; 2F5A00F01E70A379 CRC64;

Query Match 55.6%; Score 55; DB 2; Length 152;
 Best Local Similarity 85.7%; Pred. No. 9; 7;
 Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 3 PMKPMW 9
 1 1 1 1 1 1
 146 PMKPMW 152

RESULT 5

O8PB17 PRELIMINARY; PRT; 208 AA.
 ID O8PB17;
 AC O8PB17;
 DT 01-OCT-2002 (TREMBLrel. 22, Created)
 DT 01-OCT-2002 (TREMBLrel. 22, Last sequence update)
 DT 01-OCT-2002 (TREMBLrel. 22, Last annotation update)
 DE Hypothetical protein XCC1132.
 GN XCC1132.
 OS Xanthomonas campestris (pv. campestris).
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Xanthomonadales;
 OC Xanthomonadaceae; Xanthomonas.
 OX NCBI_TaxID=340;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=ATCC 33913 / NCPPB 528;
 RX MEDLINE=22022145; PubMed=12024217;
 RA da Silva A.C.R., Ferro J.A., Reinach F.C., Farah C.S., Furlan L.R.,
 RA Quaggio R.B., Monteiro-Vitorello C.B., Van Sluys M.A., Almeida N.F.,
 RA Alves L.M.C., do Amaral A.M., Bertolini M.C., Camargo L.E.A.,
 RA Camarotte G., Cannavan F., Cardoso J., Chanbergo F., Clapina L.P.,
 RA Ciccarelli R.M.B., Coutinho L.L., Cursino-Santos J.R., El-Dorri H.,
 RA Faria J.B., Ferreira A.J.S., Ferreira R.C.C., Ferro M.I.T.,
 RA Fornighieri E.F., Franco M.C., Greggio C.C., Gruber A.,
 RA Katsuyama A.M., Kishi I.T., Leite R.P., Lemos E.G.M., Lemos M.V.F.,
 RA Locati E.C., Machado M.A., Madeira A.M.B.N., Martinez-Rossi N.M.,
 RA Martins E.C., Meidanis J., Menck C.F.M., Miyaki C.Y., Moon D.H.,
 RA Moreira L.M., Novo M.T.M., Okura V.K., Oliveira M.C., Oliveira V.R.,
 RA Pereira H.A., Rossi A., Sena J.A.D., Silva C., de Souza R.F.,

RA Spinoia L.A.F., Takita M.A., Tamura R.E., Teixeira E.C., Tezza R.I.D.,
 RA Trindade dos Santos M., Truffi D., Tsai S.M., White F.F.,
 RA Setubal J.C., Kitajima J.P.;
 RT "Comparison of the genomes of two Xanthomonas pathogens with differing
 RT host specificities."
 RL Nature 417:459-463(2002).
 DR EMBL: AE012212; AAM40431.1;
 DR InterPro: IPR003709; Vany.
 DR Pfam: PF02557; Vany; 1.
 KW Hypothetical protein; Complete proteome.
 SQ SEQUENCE 208 AA; 22940 MW; 10B180F6EAF7B014 CRC64;

Query Match 55.6%; Score 55; DB 16; Length 208;
 Best Local Similarity 75.0%; Pred. No. 13;
 Matches 6; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 3 PPKWMPW 10
 DB 200 PWHMRWMP 207

RESULT 6
 Q96BE4 PRELIMINARY; PRT; 342 AA.
 AC Q96BE4;
 DT 01-DEC-2001 (TREMBLrel. 19, Created)
 DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)
 DT 01-OCT-2002 (TREMBLrel. 22, Last annotation update)
 DE Hypothetical protein.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Skin, and amelanotic;
 RA Strausberg R.;
 RL Submitted (OCT-2001) to the EMBL/Genbank/DBJ databases.
 DR EMBL: BC015687; AAL15687.1;
 KW Hypothetical protein.
 SQ SEQUENCE 342 AA; 37741 MW; 3147596F8D7DF849 CRC64;

Query Match 55.6%; Score 55; DB 4; Length 342;
 Best Local Similarity 63.6%; Pred. No. 19;
 Matches 7; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

OY 1 LPPKMPW 11
 DB 296 LLPGMPGMPW 306

RESULT 7
 Q9DT81 PRELIMINARY; PRT; 748 AA.
 AC Q9DT81;
 DT 01-MAR-2001 (TREMBLrel. 16, Created)
 DT 01-MAR-2001 (TREMBLrel. 16, Last sequence update)
 DT 01-OCT-2002 (TREMBLrel. 22, Last annotation update)
 DE ORF1.
 OS TT virus.
 OC Viruses; ssDNA viruses; unclassified ssDNA viruses.
 OX NCBI_TaxID=68887;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=TYM8;
 RX MEDLINE=205568739; PubMed=11118348;
 RA Okamoto H., Nishizawa T., Tawara A., Takahashi M., Kishimoto J.,
 RT Sai T., Sugai Y.;
 RT "TT virus mRNAs detected in the bone marrow cells from an infected
 RT individual."
 RL Biochem. Biophys. Res. Commun. 279:700-707(2000).
 DR EMBL: AB050448; BAB19928.1;
 DR InterPro: IPR004219; TVVirus_Unk.

DR Pfam: PF02956; TT_ORF1; 1.
 SQ SEQUENCE 748 AA; 88552 MW; D65C8B2CA5CE26F CRC64;

Query Match 55.6%; Score 55; DB 12; Length 748;
 Best Local Similarity 44.4%; Pred. No. 38;
 Matches 8; Conservative 1; Mismatches 3; Indels 6; Gaps 1;

OY 2 LPKMPW-----WPMR 13
 DB 1 MAWMMQRRRRRPMWR 18

RESULT 8
 Q91D04 PRELIMINARY; PRT; 750 AA.
 AC Q91D04;
 DT 01-DEC-2001 (TREMBLrel. 19, Created)
 DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)
 DT 01-OCT-2002 (TREMBLrel. 22, Last annotation update)
 DE ORF1.
 OS TT virus.
 OC Viruses; ssDNA viruses; unclassified ssDNA viruses.
 OX NCBI_TaxID=68887;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=21488921; PubMed=11601907;
 RA Okamoto H., Nishizawa T., Takahashi M., Asabe S., Tsuda F.,
 RA Yoshikawa A.;
 RT "Heterogeneous distribution of TT virus of distinct genotypes in
 RT multiple tissues from infected humans."
 RL Virology 288:358-368(2001).
 DR EMBL: AB060592; BAB69900.1;
 DR InterPro: IPR004219; TVVirus_Unk.
 DR Pfam: PF02956; TT_ORF1; 1.
 SQ SEQUENCE 750 AA; 89223 MW; 616EC86DC3469091 CRC64;

Query Match 55.6%; Score 55; DB 12; Length 750;
 Best Local Similarity 44.4%; Pred. No. 38;
 Matches 8; Conservative 1; Mismatches 3; Indels 6; Gaps 1;

OY 2 LPKMPW-----WPMR 13
 DB 1 MAWMMQRRRRRPMWR 18

RESULT 9
 Q990M4 PRELIMINARY; PRT; 1173 AA.
 AC Q990M4;
 DT 01-JUN-2001 (TREMBLrel. 17, Created)
 DT 01-JUN-2001 (TREMBLrel. 17, Last sequence update)
 DT 01-OCT-2002 (TREMBLrel. 22, Last annotation update)
 DE Spike glycoprotein.
 OS Human coronavirus (strain 229E).
 OC Viruses; ssRNA positive-strand viruses, no DNA stage; Nidovirales;
 OC Coronaviridae; Coronavirus.
 OX NCBI_TaxID=11137;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=229E;
 RA Bonavia A., Holmes K.V.;
 RT "Viral and cellular changes in a human cell line persistently infected
 RT with human coronavirus HCoV-229E."
 RL Submitted (FEB-2001) to the EMBL/Genbank/DBJ databases.
 DR EMBL: AF344186; AAK32188.1;
 DR InterPro: IPR002551; Corona_S1.
 DR InterPro: IPR002552; Corona_S2.
 DR Pfam: PF01600; Corona_S1; 1.
 DR Pfam: PF01601; Corona_S2; 1.
 SQ SEQUENCE 1173 AA; 128669 MW; ABC6E0A75EBBD8A4 CRC64;

Query Match 54.5%; Score 54; DB 12; Length 1173;

Best Local Similarity 85.7%; Pred. No. 74;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 5 KMPWMPW 11
|||||
Db 1113 KMPWMPW 1119

RESULT 10

0990M1 PRELIMINARY; PRT: 1173 AA.
AC 0990M1;
DT 01-JUN-2001 (TREMBlrel. 17, Created)
DT 01-JUN-2001 (TREMBlrel. 17, Last sequence update)
DT 01-OCT-2002 (TREMBlrel. 22, Last annotation update)
DE Spike glycoprotein.
GN S.
OS Human coronavirus (strain 229E).
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Nidovirales;
OC Coronaviridae; Coronavirus.
OX NCBI_TaxID=11137;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=229E;
RA Bonavia A., Holmes K.V.;
RT "Viral and cellular changes in a human cell line persistently infected with human coronavirus HCoV-229E";
RL Submitted (FEB-2001) to the EMBL/Genbank/DBJ databases.
DR EMBL: AF344188; AAK32190.1; -;
DR InterPro: IPR002551; Corona_S1.
DR InterPro: IPR002552; Corona_S2.
DR Pfam: PF01600; Corona_S1; 1.
DR Pfam: PF01601; Corona_S2; 1.
SQ SEQUENCE 1173 AA; 128760 MW; B73A165A6270152A CRC64;

Query Match 54.5%; Score 54; DB 12; Length 1173;
Best Local Similarity 85.7%; Pred. No. 74;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 5 KMPWMPW 11
|||||
Db 1113 KMPWMPW 1119

RESULT 11

0990M3 PRELIMINARY; PRT: 1173 AA.
AC 0990M3;
DT 01-JUN-2001 (TREMBlrel. 17, Created)
DT 01-JUN-2001 (TREMBlrel. 17, Last sequence update)
DT 01-OCT-2002 (TREMBlrel. 22, Last annotation update)
DE Spike glycoprotein.
GN S.
OS Human coronavirus (strain 229E).
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Nidovirales;
OC Coronaviridae; Coronavirus.
OX NCBI_TaxID=11137;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=229E;
RA Bonavia A., Holmes K.V.;
RT "Viral and cellular changes in a human cell line persistently infected with human coronavirus HCoV-229E";
RL Submitted (FEB-2001) to the EMBL/Genbank/DBJ databases.
DR EMBL: AF344187; AAK32189.1; -;
DR InterPro: IPR002551; Corona_S1.
DR InterPro: IPR002552; Corona_S2.
DR Pfam: PF01600; Corona_S1; 1.
DR Pfam: PF01601; Corona_S2; 1.
SQ SEQUENCE 1173 AA; 128683 MW; 9E2368160082A81A CRC64;

Query Match 54.5%; Score 54; DB 12; Length 1173;
Best Local Similarity 85.7%; Pred. No. 74;

Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 5 KMPWMPW 11
|||||
Db 1113 KMPWMPW 1119

RESULT 12

0990M2 PRELIMINARY; PRT: 1173 AA.
AC 0990M2;
DT 01-JUN-2001 (TREMBlrel. 17, Created)
DT 01-JUN-2001 (TREMBlrel. 17, Last sequence update)
DT 01-OCT-2002 (TREMBlrel. 22, Last annotation update)
DE Spike glycoprotein.
GN S.
OS Human coronavirus (strain 229E).
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Nidovirales;
OC Coronaviridae; Coronavirus.
OX NCBI_TaxID=11137;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=229E;
RA Bonavia A., Holmes K.V.;
RT "Viral and cellular changes in a human cell line persistently infected with human coronavirus HCoV-229E";
RL Submitted (FEB-2001) to the EMBL/Genbank/DBJ databases.
DR EMBL: AF344188; AAK32190.1; -;
DR InterPro: IPR002551; Corona_S1.
DR InterPro: IPR002552; Corona_S2.
DR Pfam: PF01600; Corona_S1; 1.
DR Pfam: PF01601; Corona_S2; 1.
SQ SEQUENCE 1173 AA; 128653 MW; 8B658FCBBD1842DA CRC64;

Query Match 54.5%; Score 54; DB 12; Length 1173;
Best Local Similarity 85.7%; Pred. No. 74;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 5 KMPWMPW 11
|||||
Db 1113 KMPWMPW 1119

RESULT 13

084712 PRELIMINARY; PRT: 1383 AA.
AC 084712;
DT 01-NOV-1996 (TREMBlrel. 01, Created)
DT 01-NOV-1996 (TREMBlrel. 01, Last sequence update)
DT 01-OCT-2002 (TREMBlrel. 22, Last annotation update)
DE Spike protein.
OS Porcine epidemic diarrhea virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Nidovirales;
OC Coronaviridae; Coronavirus.
OX NCBI_TaxID=28295;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Brl/87;
RX MEDLINE=94231173; PubMed=8176382;
RA Duarte M., Laude H.;
RT "Sequence of the spike protein of the porcine epidemic diarrhoea virus";
RL J. Gen. Virol. 75:1195-1200(1994).
[2]
RP SEQUENCE FROM N.A.
RC STRAIN=Brl/87;
RX MEDLINE=93389433; PubMed=8397280;
RA Bridgen A., Duarte M., Tobler K., Laude H., Ackermann M.;
RT "Sequence determination of the nucleocapsid protein gene of the porcine epidemic diarrhoea virus confirms that this virus is a coronavirus related to human coronavirus 229E and porcine transmissible gastroenteritis virus";
RT J. Gen. Virol. 74:1795-1804(1993).

RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN-CV777;
RX MEDLINE-94120721; PubMed-8291230;
RA Duarte M., Tobler K., Bridgen A., Rasschaert D., Ackermann M.,
Laude H.;
RT "Sequence analysis of the porcine epidemic diarrhea virus genome
between the nucleocapsid and spike protein genes reveals a polymo."
RL Virology 198:466-476(1994).
DR EMBL: Z25483; CAAB0971.1; -
DR InterPro: IPR002551; Corona_S1.
DR InterPro: IPR002552; Corona_S2.
DR Pfam: PF01600; Corona_S1; 1.
DR Pfam: PF01601; Corona_S2; 1.
FT CONFLICT 422 422 Y -> N (TN REF. 1)
SQ SEQUENCE 1383 AA; 151405 MW; 741C845DD3BDC4D CRC64;

Query Match
Best Local Similarity 54.5%; Score 54; DB 12; Length 1383;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5 KMPMPW 11
DB 1322 KMPMPW 1328

RESULT 14
O91AV1 PRELIMINARY; PRT; 1383 AA.
ID O91AV1;
AC O91AV1;
DT 01-DEC-2001 (TREMBLrel. 19, Created)
DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)
DT 01-OCT-2002 (TREMBLrel. 22, Last annotation update)
DE Spike protein.
OS Porcine epidemic diarrhea virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Nidovirales;
OC Coronaviridae; Coronavirus.
OX NCBI_TaxID=28295;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-CV777;
RX MEDLINE-93389433; PubMed-8397280;
RA Bridgen A., Duarte M., Tobler K., Laude H., Ackermann M.;
RT "Sequence determination of the nucleocapsid protein gene of the
porcine epidemic diarrhea virus confirms that this virus is a
coronavirus related to human coronavirus 229E and porcine
transmissible gastroenteritis virus."
RL J. Gen. Virol. 74:1795-1804(1993).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN-CV777;
RX MEDLINE-94120721; PubMed-8291230;
RA Duarte M., Tobler K., Bridgen A., Rasschaert D., Ackermann M.,
Laude H.;
RT "Sequence analysis of the porcine epidemic diarrhea virus genome
between the nucleocapsid and spike protein genes reveals a polymorphic
ORF."
RL Virology 198:466-476(1994).
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN-CV777;
RX MEDLINE-96112302; PubMed-8830538;
RA Tobler K., Ackermann M.;
RT "PEDV leader sequence and junction sites."
RL Adv. Exp. Med. Biol. 380:541-542(1995).
RN [4]
RP SEQUENCE FROM N.A.
RC STRAIN-CV777;
RX MEDLINE-98455678; PubMed-9782358;
RA Bridgen A., Koehrhans R., Tobler K., Carvajal A., Ackermann M.;
RT "Further analysis of the genome of porcine epidemic diarrhea virus."
RL Adv. Exp. Med. Biol. 440:781-786(1998).
RN [5]

RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN-CV777;
RA Koehrhans R., Bridgen A., Ackermann M., Tobler K.;
RT "The complete genome sequence of porcine epidemic diarrhea
coronavirus."
RL Submitted (FEB-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL: AF353511; AAK38656.1; -
DR InterPro: IPR002551; Corona_S1.
DR InterPro: IPR002552; Corona_S2.
DR Pfam: PF01600; Corona_S1; 1.
DR Pfam: PF01601; Corona_S2; 1.
SQ SEQUENCE 1383 AA; 151352 MW; 022E5E5E5435876D CRC64;

Query Match
Best Local Similarity 54.5%; Score 54; DB 12; Length 1383;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5 KMPMPW 11
DB 1322 KMPMPW 1328

RESULT 15
O8B482 PRELIMINARY; PRT; 1383 AA.
ID O8B482;
AC O8B482;
DT 01-MAR-2003 (TREMBLrel. 23, Created)
DT 01-MAR-2003 (TREMBLrel. 23, Last sequence update)
DT 01-MAR-2003 (TREMBLrel. 23, Last annotation update)
DE Spike protein.
OS Porcine epidemic diarrhea virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Nidovirales;
OC Coronaviridae; Coronavirus.
OX NCBI_TaxID=28295;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-Chinju99;
RA Yeo S.-G., Krell P., Nagy E.;
RT "Cloning and nucleotide sequence analysis of spike gene of porcine
epidemic diarrhea virus detected in Korea."
RL Submitted (OCT-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL: AY167585; AAN86621.1; -
SQ SEQUENCE 1383 AA; 151582 MW; B5BA4D7EE5371A54 CRC64;

Query Match
Best Local Similarity 54.5%; Score 54; DB 12; Length 1383;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5 KMPMPW 11
DB 1322 KMPMPW 1328

Search completed: October 2, 2003, 10:03:57
Job time : 107 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 10:00:07 : Search time 25 seconds

(without alignments)
22.002 Million cell updates/sec

Title: US-09-444-281-85

Perfect score: 99

Sequence: 1 ILPWKMPMPWRR 13

Scoring table:

BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 328717 seqs, 42310858 residues

Total number of hits satisfying chosen parameters: 328717

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database :

Issued_Patents_AA:
1: /cgn2_6/ptodata/1/1aa/5A.COMB.pep:*
2: /cgn2_6/ptodata/1/1aa/5B.COMB.pep:*
3: /cgn2_6/ptodata/1/1aa/6A.COMB.pep:*
4: /cgn2_6/ptodata/1/1aa/6B.COMB.pep:*
5: /cgn2_6/ptodata/1/1aa/PCRTOS.COMB.pep:*
6: /cgn2_6/ptodata/1/1aa/Backfilest1.pep:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	99	100.0	13	1	US-07-715-271-1
2	99	100.0	13	1	US-08-197-205-1
3	99	100.0	13	1	US-08-197-205-5
4	99	100.0	13	3	US-09-230-180-30
5	99	100.0	13	3	US-08-702-054B-16
6	99	100.0	13	3	US-09-076-227-1
7	99	100.0	13	4	US-09-099-631A-1
8	99	100.0	13	4	US-09-318-195A-2
9	99	100.0	13	4	US-09-030-619-98
10	99	100.0	13	4	US-09-030-619-204
11	99	100.0	13	4	US-09-416-481A-1
12	99	100.0	13	4	US-09-416-481A-24
13	99	100.0	13	4	US-09-416-481A-36
14	99	100.0	13	4	US-09-416-481A-25
15	99	100.0	13	4	US-09-416-481A-6
16	99	100.0	13	4	US-09-416-481A-37
17	99	100.0	13	4	US-09-076-227-35
18	99	100.0	13	4	US-09-416-481A-35
19	99	100.0	13	4	US-09-099-631A-12
20	99	100.0	13	4	US-09-416-481A-39
21	99	100.0	13	1	US-08-197-205-7
22	99	100.0	13	3	US-08-702-054B-6
23	99	100.0	13	3	US-08-702-054B-6
24	99	100.0	13	3	US-08-702-054B-6
25	99	100.0	13	3	US-08-702-054B-6
26	99	100.0	13	3	US-08-702-054B-6
27	99	100.0	13	3	US-08-702-054B-6

28	95	96.0	12	4	US-09-076-227-2	Sequence 2, Appl
29	95	96.0	12	4	US-09-099-631A-5	Sequence 5, Appl
30	95	96.0	12	4	US-09-416-481A-2	Sequence 2, Appl
31	94	94.9	12	1	US-08-197-205-6	Sequence 6, Appl
32	94	94.9	12	4	US-09-076-227-25	Sequence 25, Appl
33	94	94.9	12	4	US-09-318-195A-6	Sequence 6, Appl
34	94	94.9	12	4	US-09-416-481A-25	Sequence 25, Appl
35	94	94.9	13	1	US-08-197-205-2	Sequence 2, Appl
36	94	94.9	13	4	US-09-318-195A-1	Sequence 1, Appl
37	94	94.9	13	4	US-09-318-195A-3	Sequence 3, Appl
38	94	94.9	13	4	US-09-318-195A-7	Sequence 7, Appl
39	93	93.9	13	1	US-08-197-205-3	Sequence 3, Appl
40	93	93.9	15	3	US-08-702-054B-8	Sequence 8, Appl
41	91	91.9	11	3	US-08-702-054B-9	Sequence 9, Appl
42	91	91.9	11	4	US-09-076-227-3	Sequence 3, Appl
43	91	91.9	11	4	US-09-099-631A-6	Sequence 6, Appl
44	91	91.9	11	4	US-09-416-481A-3	Sequence 3, Appl
45	91	91.9	12	1	US-08-197-205-4	Sequence 4, Appl

ALIGNMENTS

RESULT 1
US-07-715-271-1
; Sequence 1, Application US/07715271
; Patent No. 5324716
; GENERAL INFORMATION:
; APPLICANT: Selsted, Michael E.
; APPLICANT: Cullor, James S.
; TITLE OF INVENTION: BROAD SPECTRUM ANTIMICROBIAL COMPOUNDS
; TITLE OF INVENTION: AND METHODS OF USE
; NUMBER OF SEQUENCES: 1
; CORRESPONDENCE ADDRESS:
; ADDRESS: PRETTY, SCHROEDER, BRUEGGEMANN & CLARK
; STREET: 444 So. Flower Street, Suite 2000
; CITY: Los Angeles
; STATE: California
; COUNTRY: United States
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07715, 271
; FILING DATE: 19910614
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P31 8963
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-535-9001
; TELEFAX: 619-535-8949
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-07-715-271-1

Query Match 100.0%; Score 99; DB 1; Length 13;

Best local Similarity 100.0%; Pred. No. 1; le-07;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPWKMPMPWRR 13
|||||
DB 1 ILPWKMPMPWRR 13

RESULT 2
US-08-197-205-1
; Sequence 1, Application US/08197205
; Patent No. 5547939
; GENERAL INFORMATION:
; APPLICANT: Selsted, Michael E.
; TITLE OF INVENTION: Broad Spectrum Antimicrobial Compounds
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Campbell and Flores
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: USA
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/197,205
; FILING DATE: 16-FEB-1994
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-UC 9881
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 535-9001
; TELEFAX: (619) 535-8949
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; US-08-197-205-1

Query Match 100.0%; Score 99; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.1e-07;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPWKPMPWRR 13
Db 1 ILPWKPMPWRR 13

RESULT 3
US-08-197-205-5
; Sequence 5, Application US/08197205
; Patent No. 5547939
; GENERAL INFORMATION:
; APPLICANT: Selsted, Michael E.
; TITLE OF INVENTION: Broad Spectrum Antimicrobial Compounds
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Campbell and Flores
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: USA
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/197,205
; FILING DATE: 16-FEB-1994
; CLASSIFICATION: 514

ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-UC 9881
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 535-9001
; TELEFAX: (619) 535-8949
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; US-08-197-205-5

Query Match 100.0%; Score 99; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.1e-07;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPWKPMPWRR 13
Db 1 ILPWKPMPWRR 13

RESULT 4
US-08-915-314-29
; Sequence 29, Application US/08915314
; Patent No. 6180604
; GENERAL INFORMATION:
; APPLICANT: Fraser, Janet R.
; APPLICANT: West, Michael H.P.
; APPLICANT: Krieger, Timothy J.
; APPLICANT: Taylor, Robert
; APPLICANT: Erile, Douglas
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING
; TITLE OF INVENTION: INFECTIONS USING ANALOGUES OF INDOLICIDIN
; NUMBER OF SEQUENCES: 90
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/915,314
; FILING DATE: 20-AUG-1997
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 6180604tenburg Ph.D., Carol
; REGISTRATION NUMBER: 39,317
; REFERENCE/DOCKET NUMBER: 660081.405
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; US-08-915-314-29

Query Match 100.0%; Score 99; DB 3; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.1e-07;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPWKPMPWRR 13

Db 1 ILPMKMPWMPWRR 13

RESULT 5

US-09-230-180-30

Sequence 30, Application US/09230180

Patent No. 6183992

GENERAL INFORMATION:

APPLICANT: Kim, Sun-Chang

APPLICANT: Lee, Jae-Hyun

APPLICANT: Kang, Min-Hyung

APPLICANT: Kim, Jeong-Hyun

APPLICANT: Hong, Seung-Suh

APPLICANT: Lee, Hyun-Soo

APPLICANT: Samyang Genex Corporation

APPLICANT: Korea Advanced Institute of Science and Technology

TITLE OF INVENTION: METHOD FOR MASS PRODUCTION OF

FILE REFERENCE: 6181/0F135

CURRENT APPLICATION NUMBER: US/09/230,180

CURRENT FILING DATE: 1999-03-10

PRIOR APPLICATION NUMBER: PCT/KR98/00132

PRIOR FILING DATE: 1998-05-28

PRIOR APPLICATION NUMBER: KR 13372/1998

PRIOR FILING DATE: 1998-04-09

PRIOR APPLICATION NUMBER: KR 21312/1997

PRIOR FILING DATE: 1997-05-28

NUMBER OF SEQ ID NOS: 36

SOFTWARE: FastSeq for Windows Version 3.0

SEQ ID NO 30

LENGTH: 13

TYPE: PRT

ORGANISM: Bos taurus

US-09-230-180-30

Query Match

Best Local Similarity 100.0%; Score 99; DB 3; Length 13;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPWMPWRR 13

Db 1 ILPMKMPWMPWRR 13

RESULT 6

US-08-702-054B-16

Sequence 16, Application US/08702054B

Patent No. 6191254

GENERAL INFORMATION:

APPLICANT: Falls, Timothy J.

APPLICANT: Hancock, Robert E. W.

APPLICANT: Gough, Monisha

TITLE OF INVENTION: ANTIMICROBIAL CATIONIC PEPTIDES

TITLE OF INVENTION: AND METHODS OF SCREENING FOR THE SAME

NUMBER OF SEQUENCES: 44

CORRESPONDENCE ADDRESS:

ADDRESSEE: Fish & Richardson P.C.

STREET: 4225 Executive Square, Suite 1400

CITY: La Jolla

STATE: CA

COUNTRY: USA

ZIP: 92037

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: Windows 95

SOFTWARE: FastSeq for Windows Version 2.0b

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/702,054B

FILING DATE: 23-AUG-1996

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/002,687

FILING DATE: 23-AUG-1995

ATTORNEY/AGENT INFORMATION:

NAME: Haile, Lisa A.

REGISTRATION NUMBER: 38,347

REFERENCE/DOCKET NUMBER: 07420/013001

TELECOMMUNICATION INFORMATION:

TELEPHONE: 619/678-5090

TELEFAX: 619/678-5099

INFORMATION FOR SEQ ID NO: 16:

SEQUENCE CHARACTERISTICS:

LENGTH: 13 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-08-702-054B-16

Query Match

Best Local Similarity 100.0%; Score 99; DB 3; Length 13;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPWMPWRR 13

Db 1 ILPMKMPWMPWRR 13

RESULT 7

US-09-076-227-1

Sequence 1, Application US/09076227

Patent No. 6303575

GENERAL INFORMATION:

APPLICANT: Selsted, Michael E.

TITLE OF INVENTION: Indolicidin Analogs and Methods of Using Same

FILE REFERENCE: P-UC 3049

CURRENT APPLICATION NUMBER: US/09/076,227

CURRENT FILING DATE: 1998-05-12

NUMBER OF SEQ ID NOS: 37

SOFTWARE: PatentIn Ver. 2.0

SEQ ID NO 1

LENGTH: 13

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: Synthetic

FEATURE:

NAME/KEY: MOD_RES

LOCATION: (13)

OTHER INFORMATION: AMIDATION

US-09-076-227-1

Query Match

Best Local Similarity 100.0%; Score 99; DB 4; Length 13;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPWMPWRR 13

Db 1 ILPMKMPWMPWRR 13

RESULT 8

US-09-099-631A-1

Sequence 1, Application US/09099631A

Patent No. 6444645

GENERAL INFORMATION:

APPLICANT: Selsted, Michael E.

APPLICANT: Osapay, Klara

TITLE OF INVENTION: Crosslink-Stabilized Indolicidin Analogs

FILE REFERENCE: P-UC 3050

CURRENT APPLICATION NUMBER: US/09/099,631A

CURRENT FILING DATE: 1998-06-18

NUMBER OF SEQ ID NOS: 13

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 1

LENGTH: 13

```
; TYPE: PRT
; ORGANISM: Bos taurus
; FEATURE:
; NAME/KEY: MOD.RES
; LOCATION: (13)
; OTHER INFORMATION: AMIDATION
US-09-099-631A-1

Query Match
Best Local Similarity 100.0%; Score 99; DB 4; Length 13;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13
Db 1 ILPMKMPMPWRR 13

RESULT 9
US-09-099-631A-3
; Sequence 3, Application US/09099631A
; Patent No. 6444645
; GENERAL INFORMATION:
; APPLICANT: Selsted, Michael E.
; APPLICANT: Osapay, Klara
; TITLE OF INVENTION: Crosslink-Stabilized Indolicidin Analogs
; FILE REFERENCE: P-UC 3050
; CURRENT APPLICATION NUMBER: US/09/099,631A
; CURRENT FILING DATE: 1998-06-18
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: Patentln Ver. 2.1
; SEQ ID NO 3
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: MOD.RES
; LOCATION: (13)
; OTHER INFORMATION: AMIDATION
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Construct
US-09-099-631A-3

Query Match
Best Local Similarity 100.0%; Score 99; DB 4; Length 13;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13
Db 1 ILPMKMPMPWRR 13

RESULT 10
US-09-318-195A-2
; Sequence 2, Application US/09318195A
; Patent No. 6482799
; GENERAL INFORMATION:
; APPLICANT: Tuse, Daniel
; APPLICANT: Mortelmans, Kristien
; APPLICANT: Hokama, Leslie A.
; APPLICANT: Chapoy, Larry L.
; APPLICANT: Quinn, Michael H.
; APPLICANT: Large Scale Biology Corporation
; TITLE OF INVENTION: Self-Preserving Multipurpose Ophthalmic Solutions
; TITLE OF INVENTION: Incorporating a Polypeptide Antimicrobial
; FILE REFERENCE: 017942-001400S
; CURRENT APPLICATION NUMBER: US/09/318,195A
; CURRENT FILING DATE: 1999-05-25
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: Patentln Ver. 2.1
; SEQ ID NO 2
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Indolicidin
; OTHER INFORMATION: analog Indol-12-R13-R-OH
US-09-318-195A-2

Query Match
Best Local Similarity 100.0%; Score 99; DB 4; Length 13;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13
Db 1 ILPMKMPMPWRR 13

RESULT 11
US-09-030-619-98
; Sequence 98, Application US/09030619B
; Patent No. 6503881
; GENERAL INFORMATION:
; APPLICANT: Krieger, Timothy J.
; APPLICANT: Taylor, Robert
; APPLICANT: Erfle, Douglas
; APPLICANT: Fraser, Janet R.
; APPLICANT: West, Michael H.P.
; APPLICANT: McNicol, Patricia J.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING
; TITLE OF INVENTION: INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION
; TITLE OF INVENTION: WITH ANTIBIOTICS
; FILE REFERENCE: 660081.406
; CURRENT APPLICATION NUMBER: US/09/030,619B
; CURRENT FILING DATE: 1998-02-25
; NUMBER OF SEQ ID NOS: 232
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 98
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cationic Peptide Analogue
US-09-030-619-98

Query Match
Best Local Similarity 100.0%; Score 99; DB 4; Length 13;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13
Db 1 ILPMKMPMPWRR 13

RESULT 12
US-09-030-619-204
; Sequence 204, Application US/09030619B
; Patent No. 6503881
; GENERAL INFORMATION:
; APPLICANT: Krieger, Timothy J.
; APPLICANT: Taylor, Robert
; APPLICANT: Erfle, Douglas
; APPLICANT: Fraser, Janet R.
; APPLICANT: West, Michael H.P.
; APPLICANT: McNicol, Patricia J.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING
; TITLE OF INVENTION: INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION
; TITLE OF INVENTION: WITH ANTIBIOTICS
; FILE REFERENCE: 660081.406
; CURRENT APPLICATION NUMBER: US/09/030,619B
; CURRENT FILING DATE: 1998-02-25
; NUMBER OF SEQ ID NOS: 232
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 204
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Bos taurus
```

US-09-030-619-204

Query Match

Best Local Similarity 100.0%; Score 99; DB 4; Length 13;
Pred. No. 1.1e-07;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13

Db 1 ILPMKMPMPWRR 13

RESULT 13

US-09-416-481A-1

Sequence 1, Application US/09416481A

Patent No. 6524585

GENERAL INFORMATION:

APPLICANT: Selsted, Michael E.

TITLE OF INVENTION: Indolizidin Analogs and Methods of Using Same

FILE REFERENCE: P-UC 3794

CURRENT APPLICATION NUMBER: US/09/416,481A

PRIOR FILING DATE: 1999-10-12

PRIOR APPLICATION NUMBER: US 09/076,227

NUMBER OF SEQ ID NOS: 39

SOFTWARE: PatentIn Ver. 2.0

SEQ ID NO 1

LENGTH: 13

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: Synthetic

OTHER INFORMATION: construct

FEATURE:

NAME/KEY: MOD_RES

LOCATION: (13)

OTHER INFORMATION: AMIDATION

US-09-416-481A-1

Query Match

Best Local Similarity 100.0%; Score 99; DB 4; Length 13;
Pred. No. 1.1e-07;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13

Db 1 ILPMKMPMPWRR 13

RESULT 14

US-09-667-486-29

Sequence 29, Application US/09667486

Patent No. 6538106

GENERAL INFORMATION:

APPLICANT: Fraser, Janet R.

West, Michael H.P.

Krieger, Timothy J.

Taylor, Robert

Erfe, Douglas

TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING

INFECTIONS USING ANALOGUES OF INDOLIZIDIN

NUMBER OF SEQUENCES: 90

CORRESPONDENCE ADDRESS:

ADDRESSEE: SEED and BERRY LLP

STREET: 6300 Columbia Center, 701 Fifth Avenue

CITY: Seattle

STATE: Washington

COUNTRY: USA

ZIP: 98104

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/667,486

FILING DATE: 22-Sep-2000

CLASSIFICATION: <Unknown>

PRIORITY APPLICATION DATA:

APPLICATION NUMBER: US/08/915,314

FILING DATE: 20-AUG-1997

ATTORNEY/AGENT INFORMATION:

NAME: No. 6538106tenburg Ph.D., Carol

REGISTRATION NUMBER: 39,317

REFERENCE/DOCKET NUMBER: 660081.405

TELEPHONE: (206) 622-4900

TELEFAX: (206) 682-6031

INFORMATION FOR SEQ ID NO: 29:

SEQUENCE CHARACTERISTICS:

LENGTH: 13 amino acids

TYPE: amino acid

STRANDEDNESS: <unknown>

TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 29:

US-09-667-486-29

Query Match

Best Local Similarity 100.0%; Score 99; DB 4; Length 13;
Pred. No. 1.1e-07;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13

Db 1 ILPMKMPMPWRR 13

RESULT 15

US-09-076-227-24

Sequence 24, Application US/09076227

Patent No. 6303575

GENERAL INFORMATION:

APPLICANT: Selsted, Michael E.

TITLE OF INVENTION: Indolizidin Analogs and Methods of Using Same

FILE REFERENCE: P-UC 3049

CURRENT APPLICATION NUMBER: US/09/076,227

PRIOR FILING DATE: 1998-05-12

NUMBER OF SEQ ID NOS: 37

SOFTWARE: PatentIn Ver. 2.0

SEQ ID NO 24

LENGTH: 14

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:

NAME/KEY: MOD_RES

LOCATION: (14)

OTHER INFORMATION: Xaa is homoserine (Hse).

OTHER INFORMATION: Description of Artificial Sequence: Synthetic

OTHER INFORMATION: construct

US-09-076-227-24

Query Match

Best Local Similarity 100.0%; Score 99; DB 4; Length 14;
Pred. No. 1.2e-07;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13

Db 1 ILPMKMPMPWRR 13

Search completed: October 2, 2003, 10:05:20
Job time : 26 secs

HIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 10:04:03 : Search time 65 Seconds
(without alignments)
31.643 Million cell updates/sec

Title: US-09-444-281-85
Perfect score: 99
Sequence: 1 ILPMKMPWMPMR 13

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 587654 seqs, 158212981 residues

Total number of hits satisfying chosen parameters: 587654

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

Published Applications_AA:*

- 1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep:*
- 2: /cgn2_6/ptodata/2/pubpaa/PC7_NEW_PUB.pep:*
- 3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep:*
- 4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep:*
- 5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep:*
- 6: /cgn2_6/ptodata/2/pubpaa/PC7US_PUBCOMB.pep:*
- 7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep:*
- 8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep:*
- 9: /cgn2_6/ptodata/2/pubpaa/US09_PUBCOMB.pep:*
- 10: /cgn2_6/ptodata/2/pubpaa/US09B_PUBCOMB.pep:*
- 11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep:*
- 12: /cgn2_6/ptodata/2/pubpaa/US09A_NEW_PUB.pep:*
- 13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep:*
- 14: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pep:*
- 15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep:*
- 16: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep:*
- 17: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep:*
- 18: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	99	100.0	13	9 US-09-030-619-98	Sequence 98, Appl
2	99	100.0	13	9 US-09-030-619-204	Sequence 204, App
3	99	100.0	13	9 US-09-917-340-13	Sequence 13, Appl
4	99	100.0	13	11 US-09-988-792-5	Sequence 5, Appl
5	99	100.0	13	11 US-09-820-053A-42	Sequence 42, Appl
6	99	100.0	13	11 US-09-820-053A-57	Sequence 57, Appl
7	99	100.0	13	12 US-10-229-368-3	Sequence 3, Appl
8	99	100.0	13	12 US-10-229-368-4	Sequence 4, Appl
9	99	100.0	13	12 US-10-225-087-3	Sequence 3, Appl
10	99	100.0	13	12 US-10-225-087-4	Sequence 4, Appl
11	99	100.0	13	15 US-10-109-171-42	Sequence 42, Appl
12	99	100.0	13	15 US-10-109-171-57	Sequence 57, Appl
13	99	100.0	13	16 US-10-252-773-2	Sequence 2, Appl
14	99	100.0	19	9 US-09-909-652-5	Sequence 5, Appl
15	81	81.8	9	9 US-09-030-619-40	Sequence 40, Appl

16	81	81.8	12	12	US-10-229-368-17	Sequence 17, Appl
17	81	81.8	12	12	US-10-225-087-17	Sequence 17, Appl
18	75.5	76.3	15	9	US-09-030-619-39	Sequence 39, Appl
19	75.5	76.3	15	12	US-10-229-368-16	Sequence 16, Appl
20	75.5	76.3	15	12	US-10-225-087-16	Sequence 16, Appl
21	75	75.8	28	9	US-09-030-619-50	Sequence 50, Appl
22	75	75.8	28	9	US-09-030-619-104	Sequence 104, App
23	75	75.8	28	12	US-10-229-368-33	Sequence 33, Appl
24	75	75.8	28	12	US-10-225-087-12	Sequence 32, Appl
25	73.5	74.2	13	9	US-09-030-619-107	Sequence 107, Appl
26	73.5	74.2	13	12	US-10-229-368-40	Sequence 40, Appl
27	73.5	74.2	13	12	US-10-225-087-37	Sequence 37, Appl
28	73	73.7	12	9	US-09-030-619-43	Sequence 43, Appl
29	73	73.7	12	9	US-09-030-619-67	Sequence 67, Appl
30	73	73.7	12	9	US-09-030-619-73	Sequence 73, Appl
31	73	73.7	12	9	US-09-030-619-112	Sequence 112, App
32	73	73.7	12	12	US-10-229-368-20	Sequence 20, Appl
33	73	73.7	12	12	US-10-229-368-41	Sequence 41, Appl
34	73	73.7	12	12	US-10-229-368-82	Sequence 82, Appl
35	73	73.7	12	12	US-10-229-368-87	Sequence 87, Appl
36	73	73.7	12	12	US-10-225-087-20	Sequence 20, Appl
37	73	73.7	12	12	US-10-225-087-38	Sequence 38, Appl
38	73	73.7	12	12	US-10-225-087-72	Sequence 72, Appl
39	73	73.7	12	12	US-10-225-087-77	Sequence 77, Appl
40	73	73.7	13	9	US-09-030-619-53	Sequence 53, Appl
41	73	73.7	13	9	US-09-030-619-95	Sequence 95, Appl
42	73	73.7	13	9	US-09-030-619-99	Sequence 99, Appl
43	73	73.7	13	9	US-09-030-619-109	Sequence 109, App
44	73	73.7	13	12	US-10-229-368-5	Sequence 5, Appl
45	73	73.7	13	12	US-10-229-368-6	Sequence 6, Appl

ALIGNMENTS

RESULT 1
US-09-030-619-98
Sequence 98, Application US/09030619B
Patent No. US20020035061A1
GENERAL INFORMATION:
APPLICANT: Krueger, Timothy J.
APPLICANT: Taylor, Robert
APPLICANT: Erle, Douglas
APPLICANT: Fraser, Janet R.
APPLICANT: West, Michael H.P.
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING
TITLE OF INVENTION: INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION
FILE REFERENCE: 660081.406
CURRENT APPLICATION NUMBER: US/09/030,619B
CURRENT FILING DATE: 1998-02-25
NUMBER OF SEQ ID NOS: 232
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 98
LENGTH: 13
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Cationic Peptide Analogue
US-09-030-619-98

Query Match 100.0% Score 99: DB 9: Length 13:
Best Local Similarity 100.0% Pred No. 3.6e-05:
Matches 13: Conservative 0: Mismatches 0: Indels 0: Gaps 0:

QY 1 ILPMKMPWMPMR 13
|||||
Db 1 ILPMKMPWMPMR 13

RESULT 2
US-09-030-619-204

```
; Sequence 204, Application US/09030619B
; Patent No. US20020035061A1
; GENERAL INFORMATION:
; APPLICANT: Krieger, Timothy J.
; APPLICANT: Taylor, Robert
; APPLICANT: Erfile, Douglas
; APPLICANT: Eraser, Janet R.
; APPLICANT: West, Michael H.P.
; APPLICANT: McNicol, Patricia J.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING
; TITLE OF INVENTION: INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION
; FILE REFERENCE: 660081.406
; CURRENT APPLICATION NUMBER: US/09/030,619B
; CURRENT FILING DATE: 1998-02-25
; NUMBER OF SEQ ID NOS: 232
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 204
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Bos taurus
US-09-030-619-204
```

```
Query Match          100.0%; Score 99; DB 9; Length 13;
Best Local Similarity 100.0%; Pred. No. 3.6e-05;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 ILPWKMPWMPWRR 13
        |||
Db      1 ILPWKMPWMPWRR 13
```

```
RESULT 3
US-09-917-340-13
; Sequence 13, Application US/09917340
; Patent No. US20020090369A1
; GENERAL INFORMATION:
; APPLICANT: Murphy, Christopher J.
; APPLICANT: McNulty, Jonathan F.
; APPLICANT: Reid, Ted W.
; TITLE OF INVENTION: Transplant Media
; FILE REFERENCE: TPLANT-06468
; CURRENT APPLICATION NUMBER: US/09/917,340
; CURRENT FILING DATE: 2001-07-29
; PRIOR APPLICATION NUMBER: 60/221,632
; PRIOR FILING DATE: 2000-07-28
; PRIOR APPLICATION NUMBER: 60/249,602
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/290,932
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 96
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 13
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Bos taurus
US-09-917-340-13
```

```
Query Match          100.0%; Score 99; DB 9; Length 13;
Best Local Similarity 100.0%; Pred. No. 3.6e-05;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 ILPWKMPWMPWRR 13
        |||
Db      1 ILPWKMPWMPWRR 13
```

```
RESULT 4
US-09-988-792-5
; Sequence 5, Application US/09988792
; Publication No. US20030032599A1
; GENERAL INFORMATION:
; APPLICANT: Lipkowski, Andrezej W
```

```
; APPLICANT: Carr, Daniel B
; TITLE OF INVENTION: NOVEL ANTIMICROBIAL COMPOUNDS
; FILE REFERENCE: 18475-025
; CURRENT APPLICATION NUMBER: US/09/988,792
; CURRENT FILING DATE: 2001-11-20
; PRIOR APPLICATION NUMBER: 60/252,369
; PRIOR FILING DATE: 2000-11-21
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-988-792-5
```

```
Query Match          100.0%; Score 99; DB 11; Length 13;
Best Local Similarity 100.0%; Pred. No. 3.6e-05;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 ILPWKMPWMPWRR 13
        |||
Db      1 ILPWKMPWMPWRR 13
```

```
RESULT 5
US-09-820-053A-42
; Sequence 42, Application US/09820053A
; Publication No. US20030083243A1
; GENERAL INFORMATION:
; APPLICANT: Owen, Donald R.
; TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES
; FILE REFERENCE: HELX027
; CURRENT APPLICATION NUMBER: US/09/820,053A
; CURRENT FILING DATE: 2001-03-28
; NUMBER OF SEQ ID NOS: 165
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 42
; LENGTH: 13
; TYPE: PRT
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: SYNTHETIC SEQUENCE
; NAME/KEY: MOD.RES
; LOCATION: (13)
; OTHER INFORMATION: AMIDATION
US-09-820-053A-42
```

```
Query Match          100.0%; Score 99; DB 11; Length 13;
Best Local Similarity 100.0%; Pred. No. 3.6e-05;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 ILPWKMPWMPWRR 13
        |||
Db      1 ILPWKMPWMPWRR 13
```

```
RESULT 6
US-09-820-053A-57
; Sequence 57, Application US/09820053A
; Publication No. US20030083243A1
; GENERAL INFORMATION:
; APPLICANT: Owen, Donald R.
; TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES
; FILE REFERENCE: HELX027
; CURRENT APPLICATION NUMBER: US/09/820,053A
; CURRENT FILING DATE: 2001-03-28
; NUMBER OF SEQ ID NOS: 165
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 57
; LENGTH: 13
; TYPE: PRT
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
```

OTHER INFORMATION: SYNTHETIC SEQUENCE
US-09-820-053A-57

Query Match 100.0%; Score 99; DB 11; Length 13;
Best Local Similarity 100.0%; Pred. No. 3.6e-05;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKPMWPMWR 13
DB 1 ILPMKPMWPMWR 13

RESULT 7
US-10-229-368-3

; Sequence 3, Application US/10229368
; Publication No. US20030148945A1
; GENERAL INFORMATION:
; APPLICANT: MCNICOL, Patricia J.
; APPLICANT: Pawlak, Sonia K.
; APPLICANT: Rubinchik, Evelina
; APPLICANT: Cameron, Dale
; APPLICANT: Guarina, Maria Marta
; TITLE OF INVENTION: ANTIMICROBIAL AND ANTI-INFLAMMATORY
; FILE REFERENCE: 660081.418
; CURRENT APPLICATION NUMBER: US/10/229,368
; CURRENT FILING DATE: 2002-08-26
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Indolcidin peptide analogs
US-10-229-368-3

Query Match 100.0%; Score 99; DB 12; Length 13;
Best Local Similarity 100.0%; Pred. No. 3.6e-05;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKPMWPMWR 13
DB 1 ILPMKPMWPMWR 13

RESULT 8
US-10-229-368-4

; Sequence 4, Application US/10229368
; Publication No. US20030148945A1
; GENERAL INFORMATION:
; APPLICANT: MCNICOL, Patricia J.
; APPLICANT: Pawlak, Sonia K.
; APPLICANT: Rubinchik, Evelina
; APPLICANT: Cameron, Dale
; APPLICANT: Guarina, Maria Marta
; TITLE OF INVENTION: ANTIMICROBIAL AND ANTI-INFLAMMATORY
; FILE REFERENCE: 660081.418
; CURRENT APPLICATION NUMBER: US/10/229,368
; CURRENT FILING DATE: 2002-08-26
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Indolcidin peptide analogs
US-10-229-368-4

Query Match 100.0%; Score 99; DB 12; Length 13;
Best Local Similarity 100.0%; Pred. No. 3.6e-05;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKPMWPMWR 13
DB 1 ILPMKPMWPMWR 13

RESULT 9
US-10-225-087-3

; Sequence 3, Application US/10225087
; Publication No. US20030171281A1
; GENERAL INFORMATION:
; APPLICANT: Krieger, Timothy J.
; APPLICANT: MCNICOL, Patricia J.
; APPLICANT: Fraser, Janet R.
; TITLE OF INVENTION: ANTIMICROBIAL CATIONIC PEPTIDES AND
; FILE REFERENCE: 660081.417
; CURRENT APPLICATION NUMBER: US/10/225,087
; CURRENT FILING DATE: 2003-01-10
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Indolcidin analog
US-10-225-087-3

Query Match 100.0%; Score 99; DB 12; Length 13;
Best Local Similarity 100.0%; Pred. No. 3.6e-05;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKPMWPMWR 13
DB 1 ILPMKPMWPMWR 13

RESULT 10
US-10-225-087-4

; Sequence 4, Application US/10225087
; Publication No. US20030171281A1
; GENERAL INFORMATION:
; APPLICANT: Krieger, Timothy J.
; APPLICANT: MCNICOL, Patricia J.
; APPLICANT: Fraser, Janet R.
; TITLE OF INVENTION: ANTIMICROBIAL CATIONIC PEPTIDES AND
; FILE REFERENCE: 660081.417
; CURRENT APPLICATION NUMBER: US/10/225,087
; CURRENT FILING DATE: 2003-01-10
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Indolcidin analog
US-10-225-087-4

Query Match 100.0%; Score 99; DB 12; Length 13;
Best Local Similarity 100.0%; Pred. No. 3.6e-05;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKPMWPMWR 13
DB 1 ILPMKPMWPMWR 13

RESULT 11
US-10-109-171-42

; Sequence 42, Application US/10109171
; Publication No. US20030109452A1
; GENERAL INFORMATION:
; APPLICANT: Owen, Donald R.
; TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES AND METHODS FOR THEIR USE
; FILE REFERENCE: HELX028
; CURRENT APPLICATION NUMBER: US/10/109,171
; CURRENT FILING DATE: 2002-03-28
; NUMBER OF SEQ ID NOS: 165
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 42
; LENGTH: 13
; TYPE: PRT
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: SYNTHETIC SEQUENCE
; NAME/KEY: MOD_RES
; LOCATION: (13)
; OTHER INFORMATION: AMIDATION
US-10-109-171-42

Query Match 100.0%; Score 99; DB 15; Length 13;
Best Local Similarity 100.0%; Pred. No. 3.6e-05;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13
| | | | | | | | | | | | | | |
DB 1 ILPMKMPMPWRR 13

RESULT 12
US-10-109-171-57
; Sequence 57, Application US/10109171
; Publication No. US20030109452A1
; GENERAL INFORMATION:
; APPLICANT: Owen, Donald R.
; TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES AND METHODS FOR THEIR USE
; FILE REFERENCE: HELX028
; CURRENT APPLICATION NUMBER: US/10/109,171
; CURRENT FILING DATE: 2002-03-28
; NUMBER OF SEQ ID NOS: 165
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 57
; LENGTH: 13
; TYPE: PRT
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: SYNTHETIC SEQUENCE
US-10-109-171-57

Query Match 100.0%; Score 99; DB 15; Length 13;
Best Local Similarity 100.0%; Pred. No. 3.6e-05;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13
| | | | | | | | | | | | | | |
DB 1 ILPMKMPMPWRR 13

RESULT 13
US-10-252-773-2
; Sequence 2, Application US/10252773
; Publication No. US2003013183A1
; GENERAL INFORMATION:
; APPLICANT: EVERETT, NICHOLAS P.
; APPLICANT: LI, QUNINGSHUN
; APPLICANT: LAWRENCE, CHRISTOPHER
; APPLICANT: DAVIES, MAELOR H.
; TITLE OF INVENTION: PEPTIDES WITH ENHANCED STABILITY TO PROTEASE
; FILE REFERENCE: INTERLINK 3.0-003
; CURRENT APPLICATION NUMBER: US/10/252,773
; CURRENT FILING DATE: 2002-09-23

; PRIOR APPLICATION NUMBER: 60/106,373
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106,573
; PRIOR FILING DATE: 1998-11-02
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: antimicrobial peptide
US-10-252-773-2

Query Match 100.0%; Score 99; DB 16; Length 13;
Best Local Similarity 100.0%; Pred. No. 3.6e-05;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13
| | | | | | | | | | | | | | |
DB 1 ILPMKMPMPWRR 13

RESULT 14
US-09-909-652-5
; Sequence 5, Application US/09909652
; Patent No. US20020025537A1
; GENERAL INFORMATION:
; APPLICANT: Kairos Scientific, Inc.
; APPLICANT: Bylina, Edward J.
; APPLICANT: Coleman, William J.
; APPLICANT: Youvan, Douglas C.
; TITLE OF INVENTION: HIGH-THROUGHPUT METHODS FOR GENERATING
; TITLE OF INVENTION: AND SCREENING COMPOUNDS THAT AFFECT CELL VIABILITY
; FILE REFERENCE: 22346-7001
; CURRENT APPLICATION NUMBER: US/09/909,652
; CURRENT FILING DATE: 2001-10-15
; PRIOR APPLICATION NUMBER: US 60/219,179
; PRIOR FILING DATE: 2000-07-19
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Ubiquitin indolicidin fusion protein fragment
US-09-909-652-5

Query Match 100.0%; Score 99; DB 9; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.8e-05;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13
| | | | | | | | | | | | | | |
DB 7 ILPMKMPMPWRR 19

RESULT 15
US-09-030-619-40
; Sequence 40, Application US/09030619B
; Patent No. US20020035061A1
; GENERAL INFORMATION:
; APPLICANT: Krieger, Timothy J.
; APPLICANT: Taylor, Robert
; APPLICANT: Erfile, Douglas
; APPLICANT: Fraser, Janet R.
; APPLICANT: West, Michael H.P.
; APPLICANT: McNicol, Patricia J.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING
; TITLE OF INVENTION: INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION
; TITLE OF INVENTION: WITH ANTIBIOTICS

; FILE REFERENCE: 660081.406
; CURRENT APPLICATION NUMBER: US/09/030,619B
; CURRENT FILING DATE: 1998-02-25
; NUMBER OF SEQ ID NOS: 232
; SOFTWARE: FASTSEQ for Windows Version 3.0
; SEQ ID NO 40
; LENGTH: 12
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Indolicidin Analogue
US-09-030-619-40

Query Match 81.8%; Score 81; DB 9; Length 12;
Best Local Similarity 90.0%; Pred No. 0.0033;
Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 4 WKPMWPMWR 13
1:|||||||
Db 2 WRMPWPMWR 11

Search completed: October 2, 2003, 10:12:53
Job time : 66 secs

THIS PAGE BLANK (USPTO)